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Abstract 
The diagnosis of mixed genotype hepatitis C virus (HCV) infection is rare and information 
on incidence in the UK, where genotypes 1a and 3 are the most prevalent, is sparse.  
Considerable variations in the efficacies of direct-acting antivirals (DAAs) for the HCV 
genotypes have been documented and the ability of DAAs to treat mixed genotype HCV 
infections remains unclear, with the possibility that genotype switching may occur.  
In order to estimate the prevalence of mixed genotype 1a/3 infections in Scotland, a cohort 
of 512 samples was compiled and then screened using a genotype-specific nested PCR 
assay. Mixed genotype 1a/3 infections were found in 3.8% of samples tested, with a 
significantly higher prevalence rate of 6.7% (p<0.05) observed in individuals diagnosed 
with genotype 3 infections than genotype 1a (0.8%). An analysis of the samples using 
genotypic-specific qPCR assays found that in two-thirds of samples tested, the minor strain 
contributed <1% of the total viral load. The potential of deep sequencing methods for the 
diagnosis of mixed genotype infections was assessed using two pan-genotypic PCR assays 
compatible with the Illumina MiSeq platform that were developed targeting the E1-E2 and 
NS5B regions of the virus. The E1-E2 assay detected 75% of the mixed genotype 
infections, proving to be more sensitive than the NS5B assay which identified only 25% of 
the mixed infections. Studies of sequence data and linked patient records also identified 
significantly more neurological disorders in genotype 3 patients. Evidence of distinctive 
dinucleotide expression within the genotypes was also uncovered. Taken together these 
findings raise interesting questions about the evolutionary history of the virus and indicate 
that there is still more to understand about the different genotypes.  
In an era where clinical medicine is frequently more personalised, the development of 
diagnostic methods for HCV providing increased patient stratification is increasingly 
important. This project has shown that sequence-based genotyping methods can be highly 
discriminatory and informative, and their use should be encouraged in diagnostic 
laboratories. Mixed genotype infections were challenging to identify and current deep 
sequencing methods were not as sensitive or cost-effective as Sanger-based approaches in 
this study. More research is needed to evaluate the clinical prognosis of patients with 
mixed genotype infection and to develop clinical guidelines on their treatment.  
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1 Chapter 1: Introduction 
 
1.1 Hepatitis C virus 
1.1.1 The discovery of the hepatitis C virus 
Awareness of a transmissible hepatitis, distinct from both hepatitis A virus (HAV) and 
hepatitis B virus (HBV) dates back to the mid-1970s (Prince et al., 1974). Later studies, 
including a prospective cohort of multiply-infused heart transplant patients in 1975 (Alter 
et al., 1975) and a back-dated study re-analysing blood donated in the 1950s (Hoofnagle et 
al., 1977) identified a number of transfused samples that were serologically negative for 
both HAV and HBV but were icterogenic when transfused into patients. Among 
individuals developing post-transfusion hepatitis, approximately 10% were shown to be 
serologically negative for HAV and HBV, implying there was an alternative cause (Aach 
et al., 1981). The causative agent was designated non-A non-B hepatitis (NANBH) and a 
natural history of NANBH infection was defined (Purcell, Alter and Dienstag, 1976). 
Distinct histological findings were described for the liver and transmission from infected 
sera was demonstrated in a chimpanzee animal model (Hollinger et al., 1978; Tabor et al., 
1978). In addition to well-described iatrogenic transmissions (Alter et al., 1975)(Hoofnagle 
et al., 1977), outbreaks of NANBH were also identified occurring intermittently within the 
community (Holland and Alter, 1981).  
NANBH was demonstrated to be infectious when transfused from both acute and 
chronically infected individuals, implying that the causative pathogen was able to establish 
a chronic carrier state and remained infectious throughout the duration of the infection 
(Alter et al., 1978). Treatment of infected sera with chloroform prior to inoculation was 
sufficient to prevent NANBH transmission and implicated a lipid-soluble pathogen 
(Feinstone et al., 1983). Filtration of infected sera from chimpanzees through 
polycarbonate membranes of various sizes indicated that the causative agent was likely to 
be 30-60nm in diameter, suggesting that a small enveloped virus was the most likely 
causative agent of NANBH (He et al., 1987). Despite accumulating evidence implicating a 
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viral causative agent for NANBH, researchers struggled to identify any antigen, antibody 
or nucleic acid linked to the disease or to propagate an NANBH virus via cell culture for 
more than a decade after initial identification.  
A cDNA clone of the virus was eventually isolated from chimpanzees infected with human 
NANBH positive sera by Michael Houghton (Chiron Corporation) and Daniel Bradley 
(CDC) and their pioneering work was published in 1989 (Choo et al., 1989). 
Immunological assays based on the detection of anti-NANBH using a small yeast-
expressed recombinant part of the NANBH genome were developed in 1989 and were used 
demonstrate conclusively that the virus detected was the causative agent associated with 
NANBH (Kuo et al., 1989). The virus was named hepatitis C virus shortly afterwards and 
was established to be distantly related to other known flaviviruses and pestiviruses (Miller 
and Purcell, 1990). In the years following these discoveries, HCV was demonstrated to be 
the cause of most community acquired NAHBH in the developed world (Choo et al., 1990) 
and was linked to large numbers of hepatocellular carcinoma cases worldwide (Colombo et 
al., 1989). 
1.1.2 Classification of the hepatitis C virus 
Within the Baltimore Classification System (Baltimore, 1971), HCV is classified as group 
IV, alongside other viruses with positive sense single-stranded RNA genomes. Group IV is 
the largest group of RNA viruses, including 30 distinct families. All viruses within the 
group are able to replicate in the cytoplasm and are able to interact directly with ribosomes 
in the cell to trigger protein synthesis.  
Taxonomically, on the basis of its genomic structure, HCV is classified as a hepacivirus, 
within the Flaviviridae family (Lindenbach and Rice, 2007). The family is split into 4 
genera, flaviviruses, pestiviruses, pegiviruses and hepaciviruses (figure 1-1). This family of 
viruses are all small, enveloped, positive-sense, single-stranded RNA viruses that share 
similar replication strategies and common morphological and genomic features. All the 
Flaviviridae replicate in the cytoplasm and their genomes range in size from 9.6-12kb 
(Lindenbach and Rice, 2007). The viral proteins are translated directly from their RNA 
genomes as long polyproteins which are cleaved by both host and viral proteases 
(Lindenbach and Rice, 2007). The viral capsids are made from a single core protein (C) 
and the viruses encode 2-3 membrane-bound proteins that constitute the envelope 
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(Lindenbach and Rice, 2007). The viruses exhibit a diverse range of biological properties 
and are able to infect a wide range of both vertebrate and invertebrate hosts via a range of 
different transmission routes (Lindenbach and Rice, 2007). There are a number of 
important medically and veterinary pathogens within the family.  
 
Figure 1-1 The Flaviviridae 
A maximum likelihood phylogenetic tree of full-length reference Flaviviridae sequences showing the major 
genera within the group, flavivirus, pestivirus, pegivirus and hepacivirus. Viruses in the tree include Tick-
Borne Encephalitis Virus (TBEV), Yellow Fever Virus (YFV), West Nile Virus (WNV), Japanese 
Encephalitis Virus (JEV) and Dengue Viruses (DV-). Bootstrap values ≥70% after 1000 replicates are shown. 
 
Our understanding of the evolutionary origins of HCV is still incomplete  and our 
knowledge of viruses closely related to HCV is still expanding with the recent 
identification of numerous rodent, equine, bovine and canine hepacivirus homologs of 
HCV (Kapoor et al., 2011, 2013; Lyons et al., 2012; Corman et al., 2015). Many of these 
viruses do not appear to cause significant disease in their hosts and may prove to be useful 
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animal models for HCV work. The recent discovery of a novel human virus, human 
hepegivirus 1 (HHpgV-1), detected in the blood serum of four blood product transfusion 
recipients, suggests that there may yet be more to discover within this group of viruses 
(Kapoor et al., 2015).   
1.1.3 Genomic structure  
The HCV genome encodes 10 proteins in a large, single open reading frame (ORF). During 
viral replication, the virus is translated as a polyprotein of around 3000 amino acids which 
is post-translationally cleaved into 10 distinct viral proteins (Okamoto et al., 1991). The 
ORF is flanked at both the 5’ and 3’ ends by highly conserved untranslated regions (UTR). 
The viral genes can be broadly grouped into structural and non-structural genes and are 
shown in figure 1-2 (Selby et al., 1993). The structural genes are core (C), envelope 
proteins 1 and 2 (E1 and E2) and the p7 ion channel (P7). The non-structural genes 
outnumber the structural genes and they encode a transmembrane protein (NS2), a viral 
serine protease (NS3), an NS3 co-factor (NS4A), a hydrophobic protein (NS4B), a 
phosphoprotein (NS5A) and an RNA-dependant RNA-polymerase (RdRp) (NS5B). The 
non-structural proteins are largely involved in facilitating viral replication within infected 
cells. 
 
Figure 1-2; Organisation of the HCV genome 
Schematic diagram of the HCV genomic organisation with nucleotide coordinates of gene products based on 
H77 (accession reference NC_004102) 
 
The HCV 5’ UTR is a highly conserved region of the virus and has been shown to have 
similarity to the 5’UTRs of GBV-B and pestiviruses (Choo et al., 1991). Along with the 
first 12-30 nucleotides of the core region, folding of the RNA in the 5’UTR gives rise to a 
complex secondary structure, forming an internal ribosome entry site (IRES). The resulting 
IRES is capable of initiating cap-independent translation within cells, playing a key role in 
the early stages of HCV polyprotein translation (Honda et al., 1999). The 3’UTR at the 
opposite end of the HCV genome has several features, notably a long poly U/UC tract and 
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a highly conserved 98 nucleotide sequence at its 3’ terminal end. Stem-loop structures 
formed by the region have been shown to interact with the encoded RdRp and play a role 
in the initiation of RNA replication (Friebe and Bartenschlager, 2002). 
Post-translational cleavage of the structural proteins from the polyproteins is thought to be 
mediated by host proteases (Lohmann, Koch and Bartenschlager, 1996). The HCV core 
protein is an RNA-binding protein that forms the viral capsid. Cleavage from the 
polyprotein and assembly into viral capsid are both thought to occur at the cytoplasmic 
face of the endoplasmic reticulum (ER). The protein has been shown to have additional 
roles influencing transcriptional events, apoptotic pathways, cellular transformation, 
immune presentation and lipid metabolism (McLauchlan, 2000). Core, along with the viral 
genome forms the nucleocapsid which is surrounded by a host-derived lipid envelope 
(Lindenbach and Rice, 2007). Embedded within the envelope are two envelope 
glycoproteins, E1 and E2, both of which are type I transmembrane glycoproteins 
(Lindenbach and Rice, 2007). They have been shown to assemble as noncovalent 
heterodimers and are crucial mediators of viral entry, facilitating numerous steps in the 
attachment, entry and fusion processes (Cocquerel et al., 2003). Until recently, E2 was 
thought to be a class II fusion protein but recently published structural studies of its core 
region suggest a novel globular structure (Kong et al., 2013; Khan et al., 2014). The E2 
protein contains two hypervariable regions within it, HVR-1 and HVR-2, and HVR-1 is 
thought to be the major target for anti-HCV neutralising antibodies during infection (Kato 
et al., 1992).  
P7 is a small polypeptide, belonging to the viroporin family of proteins. The protein is an 
integral membrane protein and it is thought to form hexameric and heptameric ring 
structures, conferring cation channel functions (Steinmann and Pietschmann, 2010). These 
channels are most likely to function as calcium ion channels and, whilst not essential for 
RNA replication, mutations in the protein have been shown to be detrimental to the 
production of infectious viruses implicating a probable role for the protein in the assembly 
and egress of viral particles (Steinmann and Pietschmann, 2010; Chandler et al., 2012). 
NS2, along with the terminal region of NS3, forms a zinc-dependant metalloprotease 
(NS2-3) which is required for the cleavage of NS2 and NS3 (Grakoui et al., 1993). The 
protein is also thought to mediate processes associated with virus assembly, through a 
complex series of interactions with the other HCV proteins (Jirasko et al., 2010). The NS3 
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protein has multiple functions and is comprised of an N-terminal serine proteinase region 
and a C-terminal helicase/NTPase domain. NS4A is an important co-factor for NS3, and 
NS3-4A functions as a serine proteinase, post –translationally cleaving all non-structural 
protein products, apart from NS2/NS3 (Bartenschlager, 1999). The proteinase is a popular 
target for therapeutics and numerous protease inhibitors have been developed and licenced 
for the treatment of HCV (Clark, Peter and Nelson, 2013). The NS3 helicase-NTPase is 
thought to be involved in RNA binding and the unwinding of RNA secondary structure. A 
role facilitating translocation along the RNA strand during RNA replication has been 
hypothesized (Levin, Gurjar and Patel, 2005).  
The role of NS4B remains to be fully characterised although it is thought to be involved in 
the formation of replication complexes. The protein is usually closely associated with 
membranes and it is believed to initiate the formation of the membranous web, a 
conformational change to local membrane vesicles that generates a scaffold for the 
formation of replication complexes (Gouttenoire et al., 2009). NS5A is a phosphoprotein 
that is thought to play a central role in the regulation of HCV replication. The protein 
appears to be closely associated with lipid-rich regions of intracellular membranes and it 
has been hypothesized that changes to the level of NS5A phosphorylation provide a 
regulatory switch between replication and assembly (Tellinghuisen, Foss and Treadaway, 
2008). The protein is also thought to be a determinant of interferon sensitivity, possibly via 
protein kinase R inhibition (Gale et al., 1997). NS5B functions as an RNA-dependant RNA 
polymerase and it plays a key role in viral replication, synthesizing negative-stranded 
templates from the positively-stranded genome and vice versa. The protein has been shown 
to lack proof-reading activity and consequently, HCV replication is highly error-prone 
(Steinhauer, Domingo and Holland, 1992). The protein is essential for HCV replication 
and is a major target for the design of anti-viral therapeutics.       
 
1.1.4 The hepatitis C virus lifecycle 
The HCV lifecycle is generally divided into 3 stages comprising of attachment and entry, 
translation and replication and budding and release. Initial transmission of the virus is 
usually via parenteral routes, resulting in the release of infectious virions into the 
bloodstream. Whilst circulating within the bloodstream, HCV virions are thought to 
associate with low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) 
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(André et al., 2002). Viruses are trafficked in the bloodstream towards the liver where 
infection is established within hepatocytes. Initial exposure to the hepatocytes occurs after 
crossing the sinusoidal epithelia and viral interaction at the basolateral surface is mediated 
by HCV envelope proteins E1 and E2. Initial interactions are believed to occur with the 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) 
and the liver/lymph node-specific intracellular adhesion molecule-3 grabbing integrin (L-
SIGN), both of which are understood to play a central role in the tissue tropism of HCV 
(Gardner et al., 2003; Lozach et al., 2003). Evidence suggesting binding to low-density 
lipoprotein receptors (LDL-R) and heparan sulfate proteoglycans has also been published 
(Wünschmann et al., 2000; Barth et al., 2003). These initial binding steps are then thought 
to trigger a coordinated series of interactions with specific viral entry factors, eventually 
resulting in the release of the HCV genome into the cytosol (figure 1-3). E2 has been 
shown to mediate attachment to the tetraspanin CD81 and the scavenger receptor B1 (SR-
B1) (Pileri et al., 1998; Scarselli et al., 2002). Studies have indicated that CD81 may be 
involved in priming the viral envelope for pH-dependent membrane fusion (Sharma et al., 
2011). Interactions with these proteins then facilitate the transfer of the HCV virons onto 
the tight junction proteins claudin-1 (CLN-1) and occludin (OCN). CD81 and OCN have 
been shown to be key determinants of HCV’s human-specific tropism (Ploss et al., 2009; 
Bitzegeio et al., 2010). Eventual uptake of the virus into the cytosol is thought to occur via 
clathrin-mediated endocytosis and release of the viral genome is dependent on a low pH. 
Once within hepatocytes, HCV has also been shown to be capable of cell to cell spread in 
in vitro systems, suggesting that cell to cell transmission may  also occur in vivo, 
contributing to the establishment of infectious foci throughout the liver during infection 
(Timpe et al., 2008). 
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Figure 1-3; Entry of the HCV virus into hepatocytes 
Figure adapted from a figure in an MRes thesis submitted by AL McNaughton (2012) (McNaughton, 2012). 
  
Once the viral genome has been uncoated and released into the cytoplasm, the next phase 
of the lifecycle is translation and replication. As a positive-sense single-stranded RNA 
virus, the HCV genome is able to interact directly with host proteins and can be processed 
in a similar way to mRNA, resulting in the rapid production of viral products. The IRES 
contained within the 5’UTR facilitates the interaction of the viral genome with host cell 
translation complexes (Friebe et al., 2001). The genome is then translated as a single ORF 
into a long polyprotein which is then cleaved by both host and viral-encoded proteases. 
The cleaved protein products are associated with membranes originating from the 
endoplasmic reticulum. In order to replicate the viral genome, HCV induces the formation 
of the membranous web, a complex rearrangement of the intracellular membranes enabling 
the formation of HCV replication complexes (Egger et al., 2002). Comprised of NS3-4A, 
NS4B, NS5A and NS5B, these replication complexes produce positive-stranded HCV 
genomes from negative-sense intermediates. The complexes also function to generate 
negative-sense anti-genomes to function as templates for the production of positive-sense 
genomes although these are usually produced in relatively low quantities relative to the 
positive-sense genomes (Craggs et al., 2001). These positive-sense genomes are used to 
produce increased quantities of viral proteins, allowing a dramatic increase in the 
replicative rate of the virus.   
The final phase of the HCV lifecycle is the assembly and release of new HCV virions, 
enabling a continuation of the infection process. The process of HCV assembly and release 
has proven difficult to study however and our understanding of the process remains 
limited. During the process, core, E1, E2, p7 and HCV genomes must be brought together 
and packaged in a regulated manner to produce infectious virions. Recent work has 
identified domains in NS5A as key regulatory mediators of this process (Zayas et al., 
2016). Roles for p7 and NS2 contributing to the mediation of the assembly process have 
also been described (Popescu et al., 2011).  Cytosolic lipid droplets are thought to have a 
major function in the process and are associated with trafficking the viral core proteins 
from the endoplasmic reticulum to the site of assembly. Depletion of apolipoproteins, in 
particular, apoE, has been shown to restrict the production of viral progeny, implying that 
they are key viral infectivity factors (Jiang and Luo, 2009).  
 Determination of the HCV lifecycle has proved challenging as progress in the field has 
been restricted by the lack of permissive cell culture systems or easily accessible animal 
models. Much of our current understanding has therefore developed from the use of 
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surrogate systems allowing the modelling of aspects of the viral lifecycle. Early 
characterisation of the replicative process within hepatocytes relied heavily on the use of 
sub-genomic replicons, fragments of the HCV genome that are able to self-replicate within 
hepatoma cell lines (Lohmann et al., 1999; Blight, Kolykhalov and Rice, 2000). Infectious 
culture systems (HCVcc) have also been developed from the genotype 2 JFH-1 strain, 
isolated from a patient in Japan and have been widely used to study all aspects of the viral 
lifecycle (Wakita et al., 2005). Chimeric variants of the JFH-1 HCVcc system have been 
refined to enable the study of other genotypes but considerable variation in the replicative 
capacity of the chimeras is frequently observed, meaning they often cannot be directly 
compared (Pietschmann et al., 2006). Pseudoparticle systems (HCVpp), using the gag and 
pol retroviral genes to form particles expressing the HCV glycoproteins E1 and E2 on their 
surface, have also been used to examine the viral entry process (Bartosch, Dubuisson and 
Cosset, 2003). Recent work by Saeed et al., (2015) has demonstrated that the addition of 
SEC14L2 makes hepatoma cell lines permissive for the replication of multiple HCV 
genotypes, enabling the propagation of clinical isolates within in vitro systems (Saeed et 
al., 2015). It is anticipated that this novel system will provide powerful new tools to study 
the infection process within and facilitate the in vitro drug resistance testing of patient-
derived isolates for those responding poorly to treatment.  
 
1.2 The genotypes & epidemiology of the hepatitis C 
virus 
1.2.1 The hepatitis C virus genotypes 
Currently, the hepatitis C viruses are classified into 7 distinct genotypes (1 to 7) on the 
basis of their nucleotide sequence (Smith et al., 2014). The HCV genotypes show 
considerable diversity and may exhibit as much as 25-30% difference between each other 
at the nucleotide level (P. Simmonds  et al., 1993). After genotypic classification, HCV 
viruses are further classified into 67 distinct subtypes which may show up to 15% 
nucleotide sequence heterogeneity (figure 1-4).  A standardised system for the 
classification of HCV genotypes was proposed by Simmonds et al., in 2005 requiring 
phylogenetic analysis based on the core/E1, NS5B and complete genome sequences 
(Simmonds et al., 2005). The proposed classification system has since been adopted by the 
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International Committee on Taxonomy of Viruses and is used to this day (Smith et al., 
2014).    
There is a large range of subtype diversity among the different genotypes with genotypes 4 
and 6 being divided into 17 and 24 viral subtypes respectively (Smith et al., 2014). 
Conversely, genotypes 5 and 7 are restricted to a single subtype each, possibly a result of a 
lack of sequences and/or geographical restriction of these genotypes (Smith et al., 2014). A 
particularly high diversity within genotypes 1, 2 and 4 is observed in Africa and a similar, 
high divergence within genotypes 3 and 6 is found throughout Asia, suggesting that these 
particular viral genotypes have a long history of transmission within these regions (Tokita 
et al., 1994; Jeannel et al., 1998). Between the different genotypes, there are also 
documented differences in clinical associations (Zein, 2000), immune responses (M. W. 
Robinson et al., 2015), treatment outcomes (Zein, 2000) and geographical prevalence 
(Gower et al., 2014).  
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Figure 1-4; The phylogeny of the HCV genotypes 
A maximum-likelihood phylogenetic tree of full-length HCV reference sequences as available from the Los 
Alamos HCV database (Kuiken et al., 2004). Some of the most common subtypes, 1a, 1b, 2b, 3a, 4a and 4d 
have been highlighted. Well-defined geographical and transmission associations are indicated for the 
genotypes. Bootstrap values ≥70% after 1000 replicates are shown. 
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The highest prevalence rates are observed in Africa, particularly in Egypt and the 
Cameroon (both >10%) (Hajarizadeh, Grebely and Dore, 2013).  Approximately 50% of 
individuals infected with HCV are estimated to reside in Asia where large populations in 
China, India, Pakistan and Indonesia mean that despite low-to-mid level prevalence rates,  
high numbers of HCV-infected individuals (>9 million) are present in these countries 
(Hajarizadeh, Grebely and Dore, 2013). Genotype 1 is generally assumed to be the most 
prevalent genotype globally, infecting an estimated 46.2% of the total infected 
population(Gower et al., 2014; Messina et al., 2015). It should however be noted that 
genotype 1 viruses are most frequently diagnosed in the Americas and Europe where a 
disproportionately high number of studies also originate from (Messina et al., 2015) and it 
is therefore probable that prevalence rates for other genotypes are underestimated.      
1.2.2 Transmission of the hepatitis C virus 
Humans are the single host species for HCV and the virus is thought to have a long 
evolutionary history with humans, likely dating back several thousand years (Simmonds, 
2004). The majority of contemporary HCV transmissions occur via parenteral exposure 
with the most common transmission routes linked to the use of unclean needles during 
recreational drug use, medical procedures and tattooing (World Health Organisation, 
2015). Prior to the introduction of blood-borne viral (BBV) testing, blood and blood 
product transfusions were significant risk factors for HCV infection. Other, less frequently 
reported transmission routes include vertical transmission from mother to child, sexual 
transmission and needle stick injuries.  
There is a significant disparity between the most common HCV transmission routes in high 
and low resource nations. In high resource nations, sterilization of medical equipment is 
highly standardised and donated blood samples are screened according to rigorous 
guidelines. The majority of new HCV infections occurring are therefore in individuals with 
a history of injecting drug use (Razali et al., 2007; Cornberg et al., 2011; Williams et al., 
2011). In middle and low-income nations, external quality control schemes for the testing 
of donated blood are in place in 82% and 53% of nations respectively and as of 2011, there 
were still an estimated 39 countries that are unable to screen donated blood for transfusion-
transmissible infections (World Health Organization, 2011). Whilst transmissions will still 
occur via recreational drug use in these nations, the prevalence of HCV acquired through 
unsafe medical procedures is likely to be significantly higher.    
14 
 
Changes in global migration and the development of parenteral medical procedures are 
thought to have contributed to the increased spread of HCV from endemic regions to 
industrialised nations during the mid-1900s. Several studies, including work by 
McNaughton et al., have inferred an exponential growth in genotype 1a and 3a infected 
populations occurring in the 1940s (Pybus et al., 2005; Mcnaughton et al., 2015).  It is 
likely that the population mixing and increased use of blood transfusions during WWII 
played a pivotal role in the global dissemination of HCV. Since WWII the increasing 
availability of hypodermic syringes has led to a significant HCV epidemic among injecting 
drug users (Trepo and Pradat, 1999; Drucker, Alcabes and Marx, 2001; Aceijas and 
Rhodes, 2007). Widespread re-use of hypodermic syringes during vaccination initiatives 
has also contributed significantly to the spread of HCV, particularly in Egypt where an 
anti-schistosomiasis campaign in the 1960s led to millions becoming infected with HCV 
(Frank et al., 2000). 
Sexual transmission of HCV is thought to be relatively rare and studies have shown that 
rates of infection among long-term co-habiting heterosexual couples are low (Terrault et 
al., 2013). A number of factors have however been found to increase the likelihood of 
sexual transmission of HCV including co-infection with HIV and engaging in risky sex 
practices. Studies have shown that changes to gut-associated lymphoid tissue in the early 
phases of HIV infection can lead to the depletion of CD4+ cells in the gut. It is thought 
probable that HIV-induced changes to mucosal immunity may also be facilitating the 
sexual transmission of HCV (Guadalupe et al., 2006; Kim and Chung, 2009). Since 2000, 
it has become clear that HIV-positive men who have sex with men (MSM) are particularly 
at risk of contracting HCV via sexual routes and numerous large outbreaks within this 
population have been documented (Gotz et al., 2005; Urbanus et al., 2009; Laar et al., 
2013). Several mono-phyletic clusters of gt4d viruses transmitting across Europe have 
been linked to transmission networks in HIV-infected MSM, suggesting this genotype is 
relatively adept at sexual transmission (Serpaggi et al., 2006; van de Laar et al., 2007; 
Vogel et al., 2010; Thomson, Smith and Klenerman, 2011).   
 
1.2.3 Hepatitis C virus in the UK 
Within the UK an estimated 214,000 individuals are thought to be infected with chronic 
HCV (Public Health England, 2015). The distribution of HCV infections across the UK 
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varies significantly with the estimated prevalence in Scotland (0.7%) being almost twice 
the estimated prevalence in England (0.4%) (Public Health England, 2015). Urban centres 
are also disproportionately affected, with high levels of infection reported in  London, the 
North West and the Greater Glasgow region (Hutchinson et al., 2002; Harris et al., 2012). 
The prevalence of HCV is also known to vary significantly between different ethnic groups 
throughout the UK with relatively high numbers of Asian, British Asian and Eastern 
European individuals testing positive for HCV currently (Harris et al., 2012; Public Health 
England, 2015). HCV genotypes 1a and 3 are the most frequently diagnosed throughout 
the UK, being responsible for an estimated 90% of infections (Public Health England, 
2015). Both genotypes are strongly associated with transmission by IDU, the most 
commonly recorded risk factor for HCV in the UK. Evidence suggests that IDU is 
currently declining within the UK and that increasing numbers of injecting drug users are 
enrolling in drug treatment programs (National Treatment Agency for Substance Misuse, 
2010). Awareness of the disease among primary healthcare providers has also improved 
considerably and HCV testing rates have dramatically improved in all regions of the UK 
over the past 5 years (Public Health England, 2015). Despite these developments, hospital 
admissions for HCV-associated end-stage liver disease and hepatocellular carcinomas have 
tripled within the UK over the past decade, and the number of deaths from HCV has 
doubled (Public Health England, 2015).  
Since the introduction of screening for HCV in donor blood in 1990, transmission of HCV 
by infected blood or blood products has been virtually eliminated and is generally observed 
in older individuals or those who have received treatment abroad. In all regions of the UK, 
injecting drug use remains the major risk factor for HCV infection and is associated with 
an estimated 70-90.6% of infections (Public Health England, 2015).  Numerous studies 
have indicated that there is a heterogeneous gender prevalence of HCV within the UK with 
males accounting for 60-70% of the infected population (Mohsen, et al., 2001; Public 
Health England, 2015). Asian and British Asian individuals contribute a significant 
proportion of the individuals (approaching 50%) who are HCV positive with no previous 
history of injecting drug use suggesting that treatment abroad may be contributing to the 
transmission of HCV in these groups (Harris et al., 2012). Other genotypes frequently 
diagnosed within the UK include gt2 and gt1b although these are generally observed in 
older individuals with a history of a blood transfusion prior to 1980. 
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1.3 Infection with the hepatitis C virus 
1.3.1 Disease progression 
Today, HCV is recognised as a global problem, infecting an estimated 130-170 million 
individuals worldwide (Lavanchy, 2009, 2011; Hajarizadeh, Grebely and Dore, 2013). 
Infection with HCV can be broadly split into acute and chronic phases. In 15-40% 
individuals, infection with HCV is acute, with the infection lasting up to 6-12 months 
before being naturally cleared by the host (Westbrook and Dusheiko, 2014). Acute HCV 
infection is often asymptomatic and causes few issues for the host. Patients are rarely 
sufficiently ill (often describing relatively non-specific ‘flu-like’ symptoms) to consider 
seeking medical attention and as a result, cases of acute HCV are usually only detected in 
those attending clinics and treatment centres for alternative reasons (Cox et al., 2005). In 
the 60-85% individuals who do not clear HCV, progression towards chronic HCV 
infection occurs after the acute infection phase, with the virus likely to persist for the 
lifetime of the host unless treated. The virus can cause significant damage to the liver and 
consequently is a major source of morbidity and mortality, killing more than 350,000 
people annually (WHO and World Health Organization, 2012). 
Acute HCV is characterised by detectable viral loads in the blood 2-14 days post exposure 
and the subsequent elevation of ALT and AST levels, indicating increased liver stress (Cox 
et al., 2005; Glynn et al., 2005). After initial infection, there is an increase in HCV viral 
load followed by a plateau phase, usually occurring 45-68 days post infection (Glynn et al., 
2005). After the plateau phase, the viral load decreases and either spontaneous clearance or 
progression to chronic disease ensues. Antibody to the virus is typically detected 20-150 
days after infection (Cox et al., 2005; Glynn et al., 2005; Page-Shafer et al., 2008). 
Numerous prognostic indicators for viral clearance during acute infection have been 
identified in the literature including, infection with a gt1 virus, female gender and 
favourable host genetics inducing broad and neutralising antibody responses (Takaki et al., 
2000; Harris et al., 2007; Page et al., 2009; Lemon, 2010). Polymorphisms in the IL28B 
gene, particularly for the CC genotype at rs12979860, have been strongly associated with 
viral clearance during acute HCV (Thomas et al., 2009; Tillmann et al., 2010).    
In those who fail to clear the virus during the acute phase, a persistent chronic infection is 
established. Symptoms of chronic HCV are generally mild and non-specific, with anorexia, 
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nausea and right-upper quadrant pain commonly reported (Zaltron et al., 2012). Increased 
ALT levels are frequently observed but there is considerable variation, and a poor 
correlation is observed between ALT levels and disease severity (Alberti et al., 1992; 
Barrera et al., 1995; Massard et al., 2006). Fluctuations in the viral load to the magnitude 
of 0.5log are often observed throughout chronic infection and thought to have little clinical 
significance (Ito et al., 2004; Barreiro et al., 2013). Chronic HCV is usually a slowly 
progressing disease with persistent infection resulting in hepatic inflammation, often 
resulting in fibrotic scarring over time. In an estimated 10-20% of individuals with HCV, 
cirrhosis develops after 20-30 years (Thein et al., 2008; Westbrook and Dusheiko, 2014). 
The development of cirrhosis has been shown to be highly variable however with estimates 
ranging considerably with study methodology and population sampling (Thein et al., 
2008). Progression to cirrhosis is a multi-factorial process and numerous risk factors have 
been associated with an increased risk and accelerated rate of fibrotic progression 
including male gender, age >40 years, excessive alcohol intake, immunosuppression, 
diabetes and co-infection with HIV or HBV (T Poynard, Bedossa and Opolon, 1997; 
Ramos Paesa et al., 1998; Minola et al., 2002; Gaeta et al., 2003; Ratziu et al., 2003; 
Hutchinson, Bird and Goldberg, 2005). Hepatocellular carcinoma (HCC) is estimated to 
occur in 2-3% of individuals infected with HCV after 30 years (Grebely and Dore, 2011). 
Individuals with cirrhosis have an increased risk of developing HCC with studies 
indicating that annually 1-3% of cirrhotic individuals will develop HCC (El-Serag and 
Rudolph, 2007). A higher prevalence of HCC has also been associated with age >55 years, 
male gender and an excessive alcohol intake (Fattovich et al., 2004).    
1.3.2 Immunity to hepatitis C 
In up to 80% of individuals infected with HCV, the immune system is unable to effectively 
clear the virus and progression towards chronic infection occurs. Once chronic infection is 
established, patients are likely to carry the virus for the rest of their lifetime, unless 
treatment is successful. This makes HCV unusual as it is one of the few RNA viruses to 
establish chronic infection in immunocompetent hosts. The diversity observed between the 
HCV genotypes and their ability to rapidly mutate mean that heterologous protective 
immunity is difficult to generate and requires the specific targeting of conserved regions. 
Recent work has identified genetic components of the host immune system as being critical 
determinants in the outcome of acute HCV infection. Individuals carrying the human 
leukocyte antigen (HLA) B27 and several short nucleotide polymorphisms of the IFN-λ3 
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allele have been found to mount vigorous anti-HCV responses and have a significantly 
higher chance of clearing the virus during the acute phase of infection (Neumann-Haefelin 
et al., 2006, 2011; Mancuso et al., 2014; Moqueet et al., 2015).   
Initial infection with HCV is characterised by a phase of rapid viral replication which 
stimulates the innate immune system (figure 1-5). Specific viral features including the 
IRES, the 3’UTR poly U/UC tract and dsRNA replication intermediates are recognised by 
the pattern recognition receptors protein kinase R (PKR), toll-like receptor 3 (TLR-3) and 
retinoic acid-inducible gene I (RIG-I) (Horner and Gale, 2013). PKR and RIG-I activation 
initiate signal cascades mediated by mitochondrial anti-viral signalling protein (MAVS), 
triggering interferon-β (IFN- β) synthesis and the production of tumour necrosis factor-α 
(TNF- α) and CXCL10. TLR-3 signalling is cascaded by Toll/IL-1 receptor domain-
containing adaptor (TRIF), also resulting in the induction of IFN- β. HCV has been shown 
however to abrogate IFN induction by NS3-4A mediated cleavage of MAVS and TRIF 
(Foy et al., 2003; Li et al., 2005). Phagocyctic uptake of HCV RNA by Kupffer cells and 
dendritic cells in the intrahepatic environment has been shown to stimulate the synthesis of 
IFN-α , IFN-β and interleukin-1β (Il-1β), providing additional pathways for immune 
activation (Takahashi et al., 2010; Negash et al., 2013). IFN signalling via the JAK-STAT 
pathway also results in the induction of the interferon stimulated genes (ISGs). Distinct 
ISG profiles have been attributed to different HCV genotypes, indicating significant 
disparity in the host-pathogen interactions which occur for each genotype (M. Robinson et 
al., 2015; M. W. Robinson et al., 2015). 
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Figure 1-5; Intrinsic immune responses against HCV in hepatocytes 
Specific HCV RNA structures recognized by pattern recognition receptors and the immune signalling 
cascades activated. Dotted lines indicate pathways that have been demonstrated to be activated in other 
hepatic infections but have not yet been confirmed for HCV. Abbreviations not discussed elsewhere include 
MAM, mitochondria-associated endoplasmic reticulum membrane; TRAF3, TNF receptor-associated factor; 
TBK1, TANK-binding kinase 1; AP-1, activator protein-1. Image published by Park and Rehermann, 2014 
(Park and Rehermann, 2014). 
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Following HCV infection, activation of the adaptive immune response is delayed by 
around 8-12 weeks, regardless of whether or not chronic infection eventually establishes 
(Park and Rehermann, 2014). Individuals clearing their HCV infection have been shown to 
generate broad-acting CD4+ T cell responses early in the infection process. Responses are 
characterised by strong T cell proliferation and synthesis of IL-2, TNF-α and IFN-λ, and 
appear to be critical determinants of viral clearance (Missale et al., 1996; Smyk-Pearson et 
al., 2008). Among those developing chronic infection, the CD4+ T cell responses are 
typically poorly targeted and weaker with T cell exhaustion frequently observed (Gerlach 
et al., 2005). Vigorous CD8+ T cell responses targeting a broad range of epitopes with 
strong IFN-ɣ production have also been shown to be crucial in the resolution of acute HCV 
(Lechner et al., 2000; Thimme et al., 2001). CD8+ T cell responses by contrast are 
typically restricted in the acute phase of infection in individuals developing chronic HCV 
with viral mutations in the targeted epitope regions able to rapidly outpace the CD8+ T cell 
response (Park and Rehermann, 2014).  
In chimpanzee models, secondary challenge with HCV after an initial clearance of a 
primary HCV infection identified a rapid production of HCV-specific T cell responses, 
resulting in a faster clearance of the secondary infection (Bassett et al., 2001; Nascimbeni 
et al., 2003). Studies with people who inject drugs (PWID) have also found that rates of 
HCV infection are lower among individuals re-infected with HCV following viral 
clearance than in those previously unexposed to the virus (Mehta et al., 2002; Grebely et 
al., 2006). Whilst these studies do imply that protective immunity may be generated in 
some cases, other studies have documented multiple HCV infection at rates of 23.3-25% 
suggesting it is frequently ineffective (Herring et al., 2004; van de Laar et al., 2009; Pham 
et al., 2010). Studies have also suggested that protective immunity may diminish over time 
and among those clearing the virus, loss of memory T cells frequently occurs, indicating 
that re-infection is possible if re-exposed (Gerlach et al., 1999).  
1.3.3 Diagnosis of the hepatitis C virus 
Acute HCV infection is rarely noticed by the patient and the disease often remains 
asymptomatic for a number of years. Consequently, infections are usually detected many 
years later, either incidentally when screening for other conditions or after the patient has 
eventually developed symptoms suggesting chronic liver disease may be an issue (World 
Health Organisation, 2015). Diagnostic tests for HCV can be broadly grouped into those 
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indirectly detecting the virus and those directly identifying the presence of a virus. Indirect 
assays are serological and rely on the detection of a HCV-specific antibody response. In 
HCV testing, sandwich enzyme immunoassays (EIA) are the most frequently used 
antibody test in clinical settings, indicating the presence of an immune response against 
HCV by the detection of anti-HCV IgG (Kamili et al., 2012). Direct testing relies on the 
detection of a specific viral marker, usually viral antigen or viral RNA. Antigen testing 
uses specific detection methods, often involving fluorescently tagged antibodies, to detect 
the presence of a viral product. In HCV testing, core antigen assays are frequently used for 
this purpose as it is an easily detectable and relatively conserved antigen (Hosseini-
Moghaddam et al., 2012).  Detection of HCV RNA in the serum has also been shown to be 
a predictive biomarker for viral replication within the host (Yun et al., 1993; Marin et al., 
1994). The most widely-used assays are line probe assays (LiPA) and real-time 
quantitative PCR (qPCR) assays. Both assays rely on amplification of the viral genomic 
material and then the detection of a specific nucleotide sequence, often with a fluorescently 
tagged probe.  
In the UK, diagnostic testing for HCV is offered in a range of different clinical settings 
including GP surgeries, sexual health clinics and drug treatment facilities. Standard 
diagnostic testing in the UK requires two tests, an antibody test and a PCR test (NHS, 
2004). Two tests are used as antibody responses can take 2-8 weeks to develop in 
individuals after the acute phase of HCV infection and are considered poor biomarkers for 
acute HCV infection. In contrast, viral RNA can be detected 1-3 weeks after initial 
infection (Chevaliez, 2011). As a result, patients in the early stages of HCV infection may 
be antibody negative but PCR positive. The majority of commercially available assays 
target the 5’UTR or core regions of the virus (Cobb, Heilek and Vilchez, 2014). These 
regions of the virus are relatively well-conserved due to significant secondary structure and 
tests targeting these regions can be used to confirm the presence of multiple HCV 
genotypes.  qPCR assays also have applications in the quantitative measurement of viral 
load in the serum which can be useful for the monitoring of treatment responses (Cobb, 
Heilek and Vilchez, 2014). Reliably differentiating between acute and chronic HCV is 
often difficult as the presence of IgM (generally considered a biomarker of acute 
infections) is highly variable during acute HCV and remains elevated in many individuals 
with chronic HCV (Farci et al., 1992; Kao et al., 1997). Chronic HCV is often indicated by 
a review of the patient history, indicating no recent exposure to risk factors, or progressive 
liver disease.   
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Clinically, the determination of HCV genotype is an important prognostic indicator as 
HCV genotype is influential when considering the most appropriate therapy for patients as 
numerous treatments are known to have genotype-specific efficacies (Manns, Wedemeyer 
and Cornberg, 2006; Gottwein et al., 2011). Distinct inflammatory gene transcription 
profiles in the liver have also been described for genotypes 1 and 3 (Robinson et al., 2015) 
and higher rates of steatosis, cirrhosis and HCC have been linked with gt3 infection 
(Leandro et al., 2006; Kanwal et al., 2014). Genotyping assays need to target regions of the 
virus that have inter-genotypic variation but are relatively well conserved at the genotype 
level. The ‘gold standard’ approach involves sequencing the NS5B region of the virus and 
phylogenetic analysis of the sequence alongside reference sequences (Richter, 2002). 
Clinically however, this is expensive and time consuming and therefore alternative 
approaches using LiPA assays and genotype-specific qPCR assays are used (González et 
al., 2013). Whilst the use of such assays is generally considered satisfactory, limitations 
including intermediate results in approximately 5% of samples, a lack of differentiation for 
many of the HCV subtypes and an inability to resolve mixed genotype HCV reactions have 
been widely documented (Chevaliez et al., 2009; Larrat et al., 2013; Cobb, Heilek and 
Vilchez, 2014).   
1.3.4 Treatment of hepatitis C  
 Until 2011, treatment options for HCV were limited to a 48-week treatment of pegylated 
interferon alpha (PEG-IFN-α) and ribavirin. The drugs were difficult to tolerate, causing 
numerous side effects and sustained virologic response (SVR) rates were relatively low 
with 40-60% individuals clearing the virus as a result of treatment (Manns, Wedemeyer 
and Cornberg, 2006). Response rates were generally more favourable among younger 
patients, Caucasians and individuals infected with genotypes 2 or 3 (McHutchison et al., 
2000; Manns et al., 2001; Andriulli et al., 2008; Rodriguez-Torres et al., 2009). 
Individuals with a favourable IL28B polymorphism also had improved responses to 
therapy (Li et al., 2011). In 2011 however, the first of a new range of direct-acting anti-
virals (DAA) specifically targeting HCV were licensed for clinical use. The first drugs to 
be approved, Telaprevir and Boceprevir, were NS3-4A protease inhibitors, functioning by 
effectively restricting the viral capacity for post-translational cleavage (Gao et al., 2010; 
Hofmann and Zeuzem, 2011). When used in conjunction with PEG-IFN-α and ribavirin, 
the new treatments increased the SVR rate to 59-75% (Sarrazin et al., 2012), vastly 
improving on previous treatment rates.  
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Since the licensing of the first DAAs in 2011, 3 additional classes of DAA have been 
licensed, second generation NS3-NS4A protease inhibitors have been developed 
(Simeprevir) and numerous other treatments are in late stage clinical trials. The new 
classes of DAA include RNA-dependent RNA polymerase (RdRp) inhibitors, nucleoside 
analogues targeting NS5B such as Sofosbuvir and NS5A inhibitors including Daclatasvir 
and Ledipasvir (Pawlotsky, 2014). Potential new classes of therapies include cyclophilin 
inhibitors and miRNA 122 antagonists (Pawlotsky, 2014). Similar to approaches used with 
highly active anti-retroviral therapies (HAART), the expansion in treatment options has 
enabled the use of dual and triple therapies targeting multiple aspects of the viral lifecycle. 
These new treatments have largely been successful, offering IFN-free regimens with 
improved tolerance and SVR rates upwards of 90% frequently for patients (Pawlotsky, 
2014). Many of the drugs are highly efficacious against gt1 and gt4 viruses (table 1-1) with 
therapeutic options for other genotypes being limited either due to less favourable cure 
rates or, in the case of genotypes 5 and 6, the drugs have not been widely tested and there 
remains a lack of data (Pawlotsky et al., 2016). Gt3 strains are currently the most difficult 
to cure with the new DAA regimens and there remains limited treatment options for 
individuals infected with this genotype (Foster et al., 2011; Moreno et al., 2012; Goossens 
and Negro, 2014; EASL, 2015). Treatments have been shown to be effective in patients 
previously failing pegylated IFN-α and ribavirin therapies and in individuals with cirrhotic 
liver disease with longer treatment regimens (12 or 24 week depending on the treatment) 
generally being recommended in such cases (Pawlotsky et al., 2016). Additionally, many 
of the new drugs come at a prohibitive financial cost, making them difficult to access for 
the majority of people requiring treatment, particularly in resource-poor regions. For 
example, in the early access programme, designed to enable early access to the new DAA 
treatments for 500 urgent cases in the UK, the cost per treatment was upwards of £30,000 
(NHS England, 2014).    
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Table 1-1; IFN-free treatment combinations for the HCV genotypes 
Table detailing the IFN-free treatment options for HCV genotypes 1-6 as detailed in the EASL 
Recommendations on Treatment of Hepatitis, 2016 (Pawlotsky et al., 2016). The listed treatments are 
suitable for both HCV and HCV/HIV co-infected patients with chronic HCV without cirrhosis. Treatments 
suitable for treatment-naïve patients and patients who failed on a treatment based on pegylated IFN-α and 
ribavirin (treatment-experienced patients). 
 
Numerous studies have documented the presence of naturally-occurring resistant variants 
to DAA treatments (Kuntzen et al., 2008; Fonseca-Coronado et al., 2012; Wang et al., 
2013). Many of the variants described are the result of non-synonymous single nucleotide 
polymorphisms (SNPs) that confer changes to DAA binding or interaction sites. The 
majority of documented SNPs are estimated to have a low prevalence of 0.1-3.5% (Chen et 
al., 2016). Higher prevalence rates of several SNPs have been documented however, many 
of which have been found to have strong genotypic associations. Notable examples in the 
NS3 region conferring resistance to Simeprevir include Q80K, which has been found in 
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37.6% of gt1a strains and S122R, which was detected in 45.1% gt2 strains (Chen et al., 
2016).  In the NS5A region, the Q30R variant associated with resistance to Daclatasvir and 
Ledipasvir has been found in 29.2%  gt3 sequences and 55.3% of gt4 strains (Chen et al., 
2016). Y93H, conferring resistance to Daclatasvir and Ledipasvir has also been widely 
documented in gt1 strains (Lontok et al., 2015). The strong genotypic associations 
documented indicate that barriers to resistance may be low in some genotypes, even if the 
resistant variants are not present in strains prior to the initiation of treatment. A lack of 
studies and available sequences for in silico analysis are however limiting our knowledge 
of the topic in non-gt1 viruses (Sarrazin, 2016). It has been suggested that the use of dual 
therapies, targeting multiple regions of the virus lifecycle simultaneously in a similar way 
to highly active anti-retroviral therapies, may be effective at mitigating some of these risks 
(Chayama et al., 2012; Gutierrez, Lawitz and Poordad, 2015).  Recent treatment guidelines 
have indicated that resistance profiling should be explored subsequent to virological 
breakthrough or treatment relapse (EASL, 2015). 
 
1.4 Sequencing 
1.4.1 History of PCR & sequencing 
The discovery of the structure of DNA by Watson and Crick in 1953 and an understanding  
importance of the DNA sequence paved the way for the subsequent development of DNA 
sequencing techniques (Watson and Crick, 1953). Early sequencing methods were 
extremely time consuming, requiring the use of both electrophoresis and chromatography 
techniques to identify nucleotides. Technological constraints meant the method was only 
suitable for very short DNA fragments but they did enable the sequencing of short operator 
motifs from the E. coli lac operon among others (Gilbert and Maxam, 1973). In 1975, 
Sanger developed a new method of sequencing, relying on electrophoresis to separate 
DNA fragments by length and the use of radio-labelled nucleotides (Sanger and Coulson, 
1975). The method was a significant improvement upon previous techniques and enabled 
the sequencing of the bacteriophage φX174 genome in 1978, the first instance of full-
genome sequencing in history (Sanger et al., 1978). Sanger also pioneered ‘dideoxy’ 
chain-termination sequencing (also known as Sanger sequencing), significantly increasing 
the length of DNA fragments that could be accurately sequenced (figure 1-6) (Sanger, 
Nicklen and Coulson, 1977).   
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Figure 1-6; Dideoxy chain termination sequencing 
An illustration of dideoxy chain termination sequencing and a typical chromatogram read out. Chain 
terminating nucleotides lacking a 3’-OH group are incorporated onto DNA fragments during replication with 
a DNA polymerase. Fragments are separated by length using gel electrophoresis and the dideoxynucleotides 
are labelled with fluorescent dye, enabling identification of the nucleotide at the chain end and subsequent 
construction of the sequence. 
 
Dideoxy chain termination sequencing revolutionised sequencing and the study of DNA. 
Progress was made extending the length of fragments that could be sequenced and the 
technique became more accessible. The generation of increasing amounts of sequence data 
lead to the development of Genbank by the National Institute for Health in 1982 (Bilofsky 
and Burks, 1988). Genbank was established as a central repository for sequences and the 
researchers working with them, making the data generated highly accessible. Shortly after 
the establishment of Genbank, programs such as FASTA and BLAST were developed, 
enabling rapid comparisons between sequences and increasing the feasibility of many 
previously complex tasks (Pearson and Lipman, 1988; Altschul et al., 1990).  
The development of PCR by Kray Mullis in the early 1980s  was another technique that 
revolutionised biomedical research (Mullis et al., 1986). The PCR technique was 
developed to enable the rapid amplification of a specific DNA region from relatively low 
amounts of template. The method is based on a series of denaturation, primer annealing 
and extension steps which utilise repetitive thermo-cycling to generate new copies of a 
DNA template. Crucial to the evolution of the PCR technique was the discovery in 1976 of 
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the Taq polymerase (Chien, Edgar and Trela, 1976).  The Taq polymerase is a DNA 
polymerase isolated from Thermus aquaticus, a thermophilic bacterial species that lives at 
temperatures of 50-80°C. The enzymatic activity of the Taq polymerase consequently 
functions well at high temperatures and this particular property was harnessed to enable the 
thermo-cycling of reactions during PCR. Selective targeting of the reaction to a specific 
region is accomplished by changing the primer sequences. The basic steps included in a 
PCR protocol which would typically be repeated for 20-40 cycles are listed below -  
Denaturation – DNA molecule split into two template strands.  
Annealing – primers are bound to the template strands of DNA. 
Extension – the polymerase enzyme extends the sequence using nucleotides. 
 
Automation of both thermo-cycling and sequencing techniques meant that increasingly 
larger volumes of work were possible and numerous variants of the technique have 
subsequently emerged. Methods enabling the conversion of RNA into complementary 
(c)DNA using a reverse transcriptase encoded by retroviruses (RT-PCR) were developed 
(Baltimore, 1970; Temin and Mizutani, 1970). RT-PCR has numerous applications in 
molecular biology including transcriptomics and the study of RNA viruses. Methods 
allowing the quantification of DNA (qPCR) during the amplification process have also 
been refined, using DNA probes with a reporter attached. As PCR-based amplification of 
the target occurs, probes binding specifically to the amplicon anneal and the amount of 
DNA present can be estimated by measuring the concentration of the reporter molecule. 
qPCR has had numerous applications including the measurement of gene expression, viral 
load quantification and pharmacological response monitoring.  
1.4.2 Development of deep sequencing technologies 
The development of capillary-based sequencing methods, using replaceable 
polyacrylamide matrices was a pivotal development, vastly improving  the speed, 
resolution and separation efficiency of previous sequencing methods (Swerdlow and 
Gesteland, 1990; Pariat et al., 1993). Building on this, the use of innovative chemistries 
has been harnessed to facilitate the rapid, low cost production of large amounts of data 
enabling the massively parallel sequencing of millions of reads. There are a number of 
platforms currently available, all using slightly different methods but the two market 
leaders have been 454 pyrosequencing and Illumina sequencing, using flow-cell 
technology.  
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454 pyrosequencing, developed by the European Molecular Biology Laboratory (EMBL), 
became the first commercially available deep sequencing platform in 2005 (Margulies et 
al., 2005). During the process, fragmented single-stranded DNA is attached onto beads 
which then undergo emulsion-based PCR amplification. The beads are separated into 
wells, immobilised and nucleotides are repeatedly washed over them. Nucleotides binding 
to the template strands induce a light signal that is nucleotide specific. The reaction 
intensity is relative to the number of bound nucleotides and the emissions are recorded as a 
flowgram. Relatively long read lengths of 400-1000bp are possible with this platform.  
In 2006 the first Illumina deep sequencing platform also became available, using bridge-
based amplification within flow cells (Bennett et al., 2005). In Illumina-based sequencing, 
adapters are ligated onto fragments of DNA which are then amplified using PCR (figure 1-
7). The fragments are then immobilised into clusters on a flow cell coated in 
oligonucleotides that are complementary to the adapters on the sequences. The unattached 
end then binds to adapters that act as primers on the flow cell, creating a ‘bridge’. PCR is 
then initiated, the clusters are amplified and sequencing by synthesis occurs. Reversible 
terminator nucleotides, labelled with nucleotide-specific fluorescent dyes are used, 
allowing the detection of each nucleotide incorporated onto the sequence. This platform 
was originally limited by a short read length of 2 x 50-75bp but improvements have meant 
that the paired-end sequencing of up to 2 x 300bp sequences is now possible.      
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Figure 1-7; Illumina sequencing 
Illumina sequencing process showing (A) the immobilisation of fragments onto flow cell using adapter 
sequences and the initiation of bridge-based amplification and (B) the generation of clusters for sequencing 
by synthesis. Figure taken from Goodwin et al., (2016)(Goodwin, McPherson and McCombie, 2016). 
 
Since the introduction of commercially-available deep sequencing, there has been an 
exponential growth in the submissions of whole genome sequences to Genbank. Deep 
sequencing technologies are driving an ‘omics’ rather than a gene-centric approach to 
research in many areas of biology and whole genome sequencing is an increasingly 
affordable option for many studies. In virology, the technology offers opportunities to 
analyse highly diverse and rapidly evolving populations on a fine scale. New, third-
generation sequencing platforms seeking to overcome the limitations of read length and 
accuracy are also in development. Among the most promising platforms are Helicos single 
molecule sequencing and Pacific Bio, designed to sequence reads of up to 10,000bp in 
length and offering the potential for the full genome sequencing of RNA and small DNA 
viruses  (Korlach et al., 2010; Thompson and Steinmann, 2010).   
1.4.3 Applications of deep sequencing 
Developments in the field of genetics have contributed towards improvements in clinical 
diagnostics. PCR, qPCR and multiplex PCRs are routinely used in clinical laboratories 
across the world to detect infections, screen donated blood and measure viral loads. Deep 
sequencing technologies have made the rapid sequencing of large numbers of sequences 
affordable and their use is becoming increasingly common within research laboratories 
across the world. In the near future, more advanced chemistries and the development of 
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improved analytical techniques offer the potential for the integration of deep sequencing 
into routine testing protocols in diagnostic laboratories.   
Deep sequencing has enabled culture-independent virus discovery using de novo sequence 
reconstruction techniques, often referred to as meta-genomic approaches. Reconstructed 
viral sequences isolated from samples can be compared with databases of known 
pathogens to look for similarity. If no matches are found, the genomic structure can be 
analysed and used to search for genera-specific patterns. This approach can be used in 
cases where the aetiological agent is unknown and, although a relatively high viral load is 
required for robust results, the method is much quicker than previously available protocols. 
It has been used to identify Astrovirus VA1/HMO-C in immunocompromised patients with 
encephalitis (Brown et al., 2015), novel human papilloma viruses causing respiratory 
disease (Mokili et al., 2013) and a new Rhabdovirus associated with haemorrhagic fever in 
the Congo (Grard et al., 2012), among other examples. Meta-genomic techniques are 
frequently used in conjunction with target enrichment strategies which use custom-
designed oligonucleotide probes bound to beads to selectively capture and isolate genomic 
fragments, increasing the concentration of the genomic material of interest (Linnarsson, 
2010). The technique can also be used to selectively remove human genomic material from 
samples, increasing the sequencing sensitivity for low viral load samples. Metagenomics 
and target enrichment have applications in microbiome and virome analysis, enabling an 
improved understanding of the microbial diversity present within organisms. The human 
microbiome and its role in health and disease has now been widely studied, unravelling the 
complex functional roles of the microbial communities within us (Cho and Blaser, 2012; 
Delwart, 2013). For low-viral load samples and low-variant minor strain detection, 
amplicon-based deep sequencing has also been used. In order to generate amplicons for 
sequencing, prior knowledge of the region of interest is required and the amplicon length is 
constrained by the read length of the platform used. Advantages of the approach include an 
increased sensitivity and depth for the region of interest relative to metagenomics 
approaches (Lefterova et al., 2015). Studies have used the technique successfully to detect 
drug resistant minor stains in HIV- (Simen et al., 2009) and HCV-infected patients 
(Abdelrahman et al., 2015).      
 The large amounts of data generated by deep sequencing allow analysis of complex 
microbial and viral populations, including quasispecies. Within the clinic, this technology 
has been successfully used to detect pre-existing drug-resistant minority variants of HIV 
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and HCV, informing on treatment plans for patients (Svarovskaia et al., 2012; Shao et al., 
2013). Deep sequencing provides a useful tool for monitoring intra-host population 
dynamics, allowing the monitoring of disease progression and improving the 
understanding of the interaction between host and immune system. Deep sequencing also 
offers the potential to analyse virus transmission dynamics on a fine scale. In complex 
epidemiological studies, the genomic region sequenced and the analytical methods used 
can all impact on the eventual conclusions drawn (Campo et al., 2015). Deep sequencing 
methods allow whole viral genome sequencing and the detection of minority variants, 
significantly improving resolution of the linkages within the transmission network. During 
the recent Ebola outbreak in West Africa, a portable deep sequencing kit allowed a real-
time analysis of the outbreak, informing public health bodies on the effectiveness of 
control measures (Carroll et al., 2015).  
 In other fields, the deep sequencing revolution has meant that the full sequencing of the 
human genome is now relatively affordable. Projects such as the 100,000 genomes project 
have been established to enable genome-wide association studies for rare disease causing 
variants  (Siva, 2015). Transcriptome analysis has been used to develop our knowledge of 
disease progression and identify novel therapeutic targets (Craig et al., 2013). In oncology, 
deep sequencing has highlighted the heterogeneous nature of many tumours, improving our 
understanding of the disease and its progression (Bedard et al., 2013). Whole genome and 
transcriptome sequencing have been used to rapidly identify clinically-informative 
mutations in cancerous tumours, with patient treatment being tailored to the findings 
(Roychowdhury et al., 2012). This personalised approach to oncology has the potential to 
improve our understanding of disease-associated biomarkers, enabling early intervention 
and preventative treatment in many cases.  
Numerous barriers remain however before the technology can be successfully utilised in 
the clinic. High throughput sequencing methods are also notoriously error-prone currently, 
with each specific platform having particular constraints associated with it and protocols 
for the platforms are technically demanding. Contamination during library preparation 
from reagents and the laboratory environment is common and can severely impact the 
interpretation of the resulting data. The large amounts of data produced by high-throughput 
sequencing methods pose a problem, and there has been a significant acceleration in the 
amount of data produced in recent years. Increasingly expensive storage solutions are 
required to facilitate the current pace of data generation. In many cases, the biologically 
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and clinically relevant information may be hidden by large amounts of false positives and 
noise. Frequently, the development of custom pipelines by specialist bioinformaticians is 
required to analyse the data accurately and this again adds a significant cost to the analysis. 
Laboratories often lack individuals with a bioinformatic skillset, making it difficult to 
analyse the data accurately. There are ethical debates surrounding the use and ownership of 
the genetic data gathered which remain to be addressed. It is also possible that incidental 
findings which are clinically relevant may be uncovered during deep sequencing and this 
can present a challenging ethical dilemma for scientists. Understanding the limitations of 
these technologies and controlling for them accurately will be a vital part of adapting them 
for use in the clinic.   
 
 
1.5 Mixed hepatitis C virus infections 
1.5.1 Mixed infections 
The failure of individuals infected with HCV to develop protective immunity means that 
patients can be infected with multiple HCV viruses, leading to mixed HCV infections. 
These infections have been documented at the genotype, sub-genotype and strain level. 
Mixed genotype HCV infections are largely grouped into two different infection processes, 
co-infection and superinfection (Blackard and Sherman, 2007). Co-infections occur when 
an individual is infected simultaneously with two or more different HCV viruses (figure 1-
8). Superinfection occurs when a secondary HCV infection occurs in the background of an 
already present HCV infection. The two types of infection are difficult to distinguish 
clinically, largely due to the lack of routine serial screening of at-risk individuals. Many 
tests used in the clinical setting lack the sensitivity and specificity required for the 
diagnosis of mixed infection, therefore these infections are rarely detected (Cunningham et 
al., 2015). Indirect evidence of mixed genotype HCV infections can be observed in reports 
of inter-genotypic recombinant HCV strains that have been detected (Du et al., 2012; 
Hedskog et al., 2014). Whilst recombination is thought to be a rare occurrence due to the 
replication strategy of the virus, the detection of recombinants does point to the 
simultaneous presence of two viruses in an individual.  
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Figure 1-8; Re-infection, co-infection and superinfection 
Illustration highlighting the differences between re-infection, co-infection and superinfection with HCV. 
Figure adapted from Blackard et al., (2007) (Blackard and Sherman, 2007).  
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As mixed infections are rarely detected clinically and cohorts of them are challenging to 
curate for longitudinal studies, information on the clinical outcomes of those with mixed 
infections is sparse. The numbers of mixed infection positive patients identified in studies 
are also frequently too low to obtain meaningful statistical power (table 1-2) (Cunningham 
et al., 2015). The natural history of mixed genotype HCV infection is poorly understood 
and it is unclear if such infections are transient or if both strains are able to persist 
throughout the lifetime of the host. Previous work on the dynamics of superinfecting HCV 
strains in patients undergoing liver graft surgery found that mixed infections are usually 
quick to resolve and that in all cases studied (n=6) the virus with the greatest diversity 
went on to become the dominant virus strain (Ramirez et al., 2010).  
 
1.5.2 The prevalence of mixed infection  
Mixed genotype HCV infections have been reported in the literature previously and there 
have been numerous studies to assess their prevalence across numerous geographical 
regions. A large amount of variation is observed in the prevalence rates of mixed infection 
reported in these studies with estimates of between 1.0-25.3% being reported (Sereno, 
Perinelli and Laghi, 2009; Pham et al., 2010). Taking an average of the studies identified, 
the average prevalence of mixed HCV infections was estimated to be 9.1 ± 0.07%. 
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Table 1-2; Published studies on the prevalence of mixed HCV infections 
Selected publications highlighting the significant variation among mixed HCV infection prevalence estimates. PWID denotes people who inject drugs. ND indicates the dominant 
genotype was not declared in the study. Where appropriate, reinfections have been excluded from the mixed HCV prevalence rates reported in the studies.  
Study 
Number 
tested 
Testing 
method 
HCV region 
targeted 
Demographic information 
HCV genotypes detected in 
mixed infections 
Dominant genotype 
Mixed HCV 
prevalence 
(Lau et al., 1996) 107 LiPA 5’UTR USA, chronic HCV patients 1a,1b,2a,2b, 3a, 4* ND 3.7% 
(Giannini et al., 1999) 213 N-PCR/RFLP Core Italy, chronic liver disease 1a,1b,2 * ND 10.80% 
(Natov et al., 1999) 224 RFLP 5’UTR US, renal patients 1a,1b,2a,2b,3a,4 † ND 10% 
(Blatt et al., 2000) 6807 LiPA 5’UTR USA, not selective 1,2,3,4,5,6 ND 4% 
(Stamenkovic et al., 2000) 117 N-PCR/LiPA Core Siberia, chronic HCV 1a,1b,2,3,4 * ND 9.1% 
(White et al., 2000) 38 HMA 5’UTR Australia, PWID 1a,1a,2a,2b,3a ND 8% 
(Schröter et al., 2003) 600 N-PCR 5’UTR Germany, not selective 1a,1b,2a,2b,3a,4a ND 2.20% 
(Singh, Malhotra and Sarin, 2004) 36 LiPA 5’UTR India, chronic HCV 1a,1b,2,2b,3a,3b,4a,4e,5a † ND 11.10% 
(van Asten and Prins, 2004) 126 N-PCR Core  Europe, PWID 1b,3a,4 ND 5% 
(Herring et al., 2004) 12 N-PCR E1-E2 US, acutely infected 1a,1b,3a * ND 25% 
(Bowden et al., 2005) 138 LiPA/HMA 5’UTR Australia, PWID 1a,3a,6 ND 3.6% 
(Tsatsralt-Od et al., 2005) 27 PCR 5’UTR Mongolia, liver disease 1a,1b,2a,2b,3a ND 6.60% 
(Buckton et al., 2006) 44 RFLP/N-PCR 5’UTR UK, PWID 1a,1b,2,3a † 1a (71%) 9% 
(Buckton et al., 2006) 37 RFLP/N-PCR 5’UTR UK, haemophiliacs 1a,1b,2,3a,5 † 1b (50%), 3a (50%) 19% 
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Study 
Number 
tested 
Testing 
method 
HCV region 
targeted 
Demographic information 
HCV genotypes detected in 
mixed infections 
Dominant genotype 
Mixed HCV 
prevalence 
(Li et al., 2008) 374 N-PCR/HMA Core & E1-E2 US, PWID 1a,1b,2a,2b,3a ND 7.50% 
(Micalessi et al., 2008) 98 LiPA 5’UTR Belgium, PWID 3,4 ND 1% 
(Yun et al., 2008) 107 LiPA 5’UTR Korea, PWID 1a,2a,2c * ND 5% 
(Ayesh et al., 2009) 92 Real-time PCR 5’UTR Gaza strip, chronic HCV 1,4 ND 7.6% 
(Sereno, Perinelli and Laghi, 2009) 200 LiPA 5’UTR Italy, PWID 1b,3a ND 1% 
(van de Laar et al., 2009) 59 N-PCR NS5B Amsterdam, PWID 1a,1b, 2a, 2b,3a.4a,4d * † ND 23.80% 
(Pham et al., 2010) 87 Real-time PCR Core Australia, PWID in prison 1a,1b,2a,2b,3a  1a (33%), 3a (38%) 25.30% 
(Butt et al., 2011) 22,125 PCR 5’UTR & Core Pakistan, nationwide survey 1a,1b,1c,2a,2b,3a,3b,4,6a * ND 5.50% 
(Du et al., 2012) 164 N-PCR E2 & NS5B China, PWID & non-PWID 1a,3a,3b * ND 1.20% 
(Grebely, Pham, et al., 2012) 163 Real-time PCR E1-E2 Australia, treatment cohort 1a,1b,2a,2b,3a * 3a (67%) 16.50% 
(Hairul Aini et al., 2012) 40 N-PCR 5’UTR & NS5B Malaysia, haemophiliacs 1,3,4 ND 12.50% 
(McNaughton et al., 2014) 47 N-PCR E1-E2 UK, PWID 1a, 3a 3a (100%) 10.6% 
(Gowin et al., 2016) 1159 LiPA 5’UTR Poland, Chronic HCV 1a,1b,3a,4a * ND 2.2% 
Testing methods: HMA – Heteroduplex mobility assay, RFLP – Restriction fragment length polymorphism, LiPA – Line probe assay, N-PCR – Nested PCR 
HCV genotypes detected: *Indicates inter-genotype infections were detected, †Indicates subjects infected with ≥3 genotypes detected 
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Studies also indicated that mixed HCV infections can be found globally and that a wide 
range of genotypes are involved.  The greatest prevalence rates were associated with 
studies sampling from incarcerated, IDU and haemophiliac populations. Among 
incarcerated populations, exposure rates can be extremely high, caused by a combination 
of widespread drug use and tattooing and a poor availability of clean needles (Hellard, 
Hocking and Crofts, 2004; Hellard, Aitken and Hocking, 2007). Prior to the introduction of 
testing for HCV in 1990, haemophiliacs were at particular risk for multiple exposures as 
the clotting factor transfusions required to treat the disease were produced using 
components from multiple donations. Improved testing protocols and increased awareness 
of this issue has drastically reduced transmission risks in this group of patients. The high 
variability in mixed infection prevalence rates is likely due to differences in the study 
design, populations sampled and the detection methods used. Studies also showed 
discrepancies in the level of classification used with some examining mixed infections at a 
genotype level and others investigating at the sub-genotype or strain level. Studies of 
acutely-infected individuals also tended to report relatively high rates of mixed HCV 
infection. A recent study using Bayesian modelling methodologies has suggested that 
mixed genotype infections may be occurring more frequently than previously thought 
during the acute infection phase with unobserved rapid spontaneous clearance of 
superinfecting strains (Sacks-Davis et al., 2015). This implies that these infections are 
relatively common but that by the time most individuals are diagnosed after chronic HCV 
has established, these mixed infections have resolved, leaving a single dominant strain.  
1.5.3 Clinical consequences of mixed infection 
As mixed genotype HCV infections are rarely detected in the clinical setting, data on the 
clinical implications of these infections is sparse and the impact of such mixed infections 
on disease progression, treatment outcome and quasispecies evolution is poorly 
understood. Numerous reports of partially resolved mixed infections and minor strain 
outgrowth during the treatment of mixed HCV infections have been documented (Schröter 
et al., 2003; Grebely, Pham, et al., 2012; Abdelrahman et al., 2015). Given that many of 
the new DAAs for HCV have genotype-specific efficacies, our lab group at the Centre for 
Virus Research in Glasgow has highlighted concerns that the treatment of mixed genotype 
infections with such regimens may only partially resolve infections and patients will 
appear to have switched genotype (McNaughton et al., 2014). Clinically such presentations 
may also lead clinicians treating individuals with HCV to suspect patients have been re-
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exposed to HCV and this may lead to distrust between the clinicians and patients, which 
may also be detrimental to recovery. 
There has been suggestions in the literature that having mixed HCV infections can lead to 
increased liver damage relative to individuals infected with a single virus (Kao et al., 1994; 
Widell et al., 1995). Studies that documented super-infections found that infection with a 
secondary HCV virus is frequently accompanied by a transient elevation in alanine 
transaminase (ALT) levels, suggesting damage to the liver may occur (Widell et al., 1995; 
Kao et al., 1996; Grebely, Pham, et al., 2012). Some studies have also suggested that 
mixed infection is a relatively transient process with one virus rapidly becoming dominant 
and the other clearing (Laskus et al., 2001; Fan et al., 2003). Work by Toyoda et al. (1998) 
also identified increased quasispecies diversity among individuals with mixed infections 
relative to those with a single-strain infection, implicating differences in the immune 
response to mono- and multiple infections (Toyoda et al., 1998).    
The presence of multiple HCV strains within an individual also indicates that viral 
recombination is a possibility. Whilst recombination among HCV viruses is thought to be 
rare, there have been several strains reported in the literature, involving recombinants 
derived from multiple different HCV genotypes (Lee et al., 2010; Du et al., 2012; Hedskog 
et al., 2014). It is also probable that detection of recombination is underestimated as few 
diagnostic protocols analyse multiple regions of the HCV genome. In the reported studies, 
break points frequently occur at the NS2-NS3 junction although they have also been 
mapped within the structural genes (Cristina and Colina, 2006; González-Candelas, López-
Labrador and Bracho, 2011). Several naturally occurring genetic polymorphisms 
conferring resistance to DAA have been reported and there is the potential for previously 
sensitive viruses to acquire resistance via recombination (Bartels et al., 2008; Lopez-
Labrador, Moya and Gonzalez-Candelas, 2008). With the expanded use of DAA 
treatments, HCV viruses are likely to be forced down alternative evolutionary pathways 
and it is possible that increases in the numbers of treatment-resistant recombinant strains 
may be observed in the future.      
1.5.4 Superinfection exclusion 
Reports of recombinant HCV strains contrast with previous studies indicating that HCV is 
capable of excluding secondary strains from infecting an already-infected hepatocyte, a 
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process referred to as super-infection exclusion (Schaller et al., 2007; Tscherne et al., 
2007). Super-infection exclusion in hepatocyte-derived cells has been demonstrated in 
vitro for HCV and Webster et al. (2013) published evidence that the process occurs within 
the hepatocyte during RNA replication (Webster et al., 2013). Data from the study 
indicated that different viral replicons were likely to be confined within separate 
replication complexes within the hepatocytes and that mitotic cell division was a key step 
in the exclusion process, possibly due to resulting disruption of the membranous web 
(Webster et al., 2013). Relatively minor mutations occurring at NS5A C2447R and within 
the poly U/UC tract have however been shown to overcome these replicative constraints 
and enable the replication of multiple HCV strains within the same hepatocyte (Webster, 
Ott and Greene, 2013). Work by Evans et al. (2004) also found that the presence of a fit, 
stably replicating HCV strain can impair the replication capacity of a secondary, less fit 
strain (Evans, Rice and Goff, 2004). Other studies have suggested that the down-regulation 
of CLDN1 and occludin observed after HCV infection functions to block superinfection of 
secondary strains (Liu et al., 2008).  
Whilst evidence of superinfection exclusion has been demonstrated in vitro, evidence is 
hard to obtain in vivo. Nonetheless, studies on super infection exclusion raise interesting 
questions on the viral population structure within individuals with mixed infections. HCV 
has been shown to form distinct foci within the liver of infected individuals (Stiffler, 
Nguyen, J. a Sohn, et al., 2009). Within the context of mixed infections it is not clear 
whether the different HCV genotypes would form distinct foci or if multiple genotypes or 
strains would be present within the same foci. The identification of recombinant strains 
suggests that, at least at some point, more than one strain must be present within the same 
cell, otherwise these recombinants could not have arisen. It may be the case that exclusion 
of closely related virus strains is possible but that at the genotype level, competition 
between the viruses present is more complex. Studies have also hypothesized that 
superinfection exclusion may provide a mechanism for the survival of less-fit viral strains, 
ensuring the propagation of a large pool of variants within infected hosts (Tscherne et al., 
2007).  
1.5.5 Co-infections with other pathogens 
 In the majority of individuals infected with HCV a chronic infection establishes which is 
able to persist throughout the lifetime of the host. As a consequence of this, any infections 
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which occur subsequent to the original HCV infection occur in the context of an 
established infection. Interactions can occur between these co-infecting pathogens but the 
implications of this are poorly understood. Numerous viruses, including HIV and HBV, 
share similar transmission routes with HCV and as a result, these infections are common in 
individuals with HCV. As a result, healthcare professionals routinely screen patients for 
multiple blood-borne viruses (BBVs).      
The presence of HIV in individuals infected with HCV has been reported to be associated 
with higher HCV viral loads, a rapid progression of liver disease and poor responses to 
treatment (Eyster et al., 1994; Merchante et al., 2006; Hua et al., 2013; Lo Re et al., 2014). 
Even in patients with well-controlled HIV and good CD4+ T cell counts, liver disease 
outcomes for HIV-HCV co-infected patients still remain poor (Lo Re et al., 2014). 
Numerous pathogenic mechanisms of HIV which may be influencing the course of HCV 
infection have been identified including the promotion of fibrogenesis, the induction of 
hepatocyte apoptosis and the attenuation of CD8+ T cells responses (Kim et al., 2005; Lin 
et al., 2008; Babu et al., 2009). HIV-HCV co-infection is a particular problem among 
MSMs and in sub-Saharan Africa where HCV is becoming a leading cause of death among 
the HIV-positive population (Rao et al., 2016).   
Co-infections of HCV with other icterogenic viruses including hepatitis A virus (HAV), 
hepatitis B virus (HBV) and hepatitis E virus (HEV) have all been reported in the literature 
(Devalle et al., 2003; Tsatsralt-Od et al., 2005; Bayram et al., 2007). HBV shares a 
common parenteral transmission route with HCV whereas both HAV and HEV are 
transmitted by enteric routes. HCV and HBV co-infection has been associated with the 
development of fulminant hepatitis and increased rates of cirrhosis and HCC (Benvegnu et 
al., 1994; Wu et al., 1994; Zarski et al., 1998; Chiaramonte et al., 1999). Replicative 
interference has also been documented between HCV and HBV with evidence suggesting 
HCV has a strong inhibitory effect on HBV replication (Jardi et al., 2001). Studies of co-
infection with HAV have reported increased cases of jaundice, fulminant hepatitis and 
increased mortality rates (Vento et al., 1998; Devalle et al., 2003). In contrast to this, other 
studies have observed increased rates of spontaneous clearance of HCV subsequent to 
HAV infection and it has been hypothesized that HAV may suppress HCV replication 
(Deterding et al., 2006; Cacopardo, Nunnari and Nigro, 2009). Cases of spontaneous 
clearance of HCV following co-infection with HBV have also been documented (Kong et 
al., 2014; Yu et al., 2014; Bulteel et al., 2016). It may be that HAV or HBV superinfection 
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induces a powerful immune response within the liver resulting in the spontaneous 
clearance of HCV. 
Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1), a multifunctional viral 
protein associated with extrachromosomal replication, has been shown to upregulate the 
rate of HCV replication in vitro by heterologous transactivation (Y Sugawara et al., 1999). 
Given that EBV has been shown to infect the liver and  EBNA1 is frequently detected in 
HCC, this does suggest a possible role for EBV in the development of liver disease during 
HCV infection (Markin, 1994; Yasuhiko Sugawara et al., 1999). Co-infection with 
cytolomegavirus (CMV), a closely related virus to EBV, has also been correlated with poor 
treatment outcomes and increased rates of fibrosis among individuals with HCV (Bader el-
Din et al., 2011). Studies have also indicated that co-infection with non-viral pathogens, 
including schistosomiasis and Helicobacter pylori, may lead to increased liver disease 
(Kamal et al., 2006; Esmat et al., 2012).   
1.6 Intra-host diversity of hepatitis C 
1.6.1 Hepatitis C virus evolution within the host 
The majority of mutations occurring in the HCV genome originate from errors made by the 
NS5B RdRp during replication as the protein lacks a proof-reading mechanism. The RdRp 
encoded by HCV is particularly error prone and the virus is estimated to make at least one 
error every time the genome is copied (Guedj et al., 2010). The high error rate of the RdRp 
has been found to be a crucial virulence factor for HCV with increases or decreases to the 
RdRp error rate proving detrimental to the pathogenicity of the virus. This error-prone 
replication combined with the relatively fast replication rate of the virus, which is 
estimated to produce around 10
12
 virions per day, generates a highly diverse population of 
viruses within infected individuals (Neumann et al., 1998). Selection within the population 
occurs as a result of extrinsic factors including the host immune system and treatment with 
anti-virals and the intrinsic functional constraints of viral gene products that limit the 
tolerance for mutations (Lohmann et al., 2001). Antigenic variation within intra-host 
populations have been noted to be relatively convergent in contrast to the extreme 
divergence observed at the genetic level suggesting that whilst the viruses explore a large 
amount of sequence space, functional limitations are highly restrictive in vivo (Campo et 
al., 2012).      
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Divergent intra-host evolutionary rates have been identified within the genotype 1 viruses, 
with gt1a viruses evolving at a faster rate than gt1b viruses (Gray et al., 2011). Differences 
have also been noted in the rate of evolution of genotypes 2 and 5 relative to the other 
genotypes, possibly arising as a result of unusual epidemiologic trajectories (Salemi and 
Vandamme, 2002). Genotypic differences in the rate of evolution among HCV viruses are 
likely to be conferred by adaptation of the viruses to transmission within specific 
communities. Gray et al., have hypothesized that faster rates of evolution would be 
selected for within populations with high rates of transmission, such as PWID (Gray et al., 
2011). Likewise, among populations where individuals are infected for a long period of 
time prior to transmission into a new host, there would be less selection for rapidly 
evolving viruses. This suggests that within individuals with mixed genotype infections, 
viruses of different genotypes would evolve at varying rates. A study by Culasso et al., 
following a patient infected with gt1a, gt2a and gt3 over a 13-year period, found that the 
three viral lineages followed distinctly different evolutionary trajectories (Culasso et al., 
2014). This suggests that within the same host, under the same selective pressures, the 
different HCV genotypes have the potential to diversify along divergent evolutionary 
pathways and the clinical implications of this for the patient remain unclear.           
Differences in the rate of evolution observed within HCV viruses from intra-host and 
among-host datasets have been observed with an increased evolutionary rate present in 
intra-host studies (Gray et al., 2011). Successful infection following transmission between 
hosts requires viral adaptation to a new environment and it is likely that host-specific 
adaptations conferring fitness in one individual may not be useful in other individuals. 
Studies have identified transmission-associated bottleneck events for HCV, implying that 
initial infection is established with a limited number of viral strains (Ou et al., 2011; Wilke 
et al., 2012). Ou et al. (2011) also identified a second population decline, occurring during 
the acute phase roughly 100 days post infection (Ou et al., 2011). The second decline 
appeared pivotal in the disease progression with diversity remaining restricted from this 
point among those clearing the virus and new variants emerging in those developing 
chronic HCV (Ou et al., 2011). 
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1.6.2 Evolution across the hepatitis C genome 
 
The tolerance for mutations within HCV viruses varies considerably across the genome, 
resulting in an uneven distribution of variation throughout the different viral products.  A 
study by Gray et al. (2011) looking at gt1 viruses found that whilst the majority of the 
genome evolved at a relatively constant rate, evolution within the E1-E2 region occurred at 
a much faster rate (Gray et al., 2011). Pairwise distances between and within different 
genotypes along the genome are reflective of variation in these evolutionary rates (figure 
1-9). Untranslated regions of the genome which have been shown to have complex 
secondary structure are highly conserved among HCV viruses with the 5’UTR showing up 
90% homology between the different genotypes (Bukh, Purcell and Miller, 1992). 
Structural conservation within the 5’UTR is linked to its role in the formation of the IRES, 
a region noted for its extensive secondary structure, which plays a central role in the 
initiation of CAP-independent translation (Honda, Brown and Lemon, 1996). The core 
region of the virus (nucleotides 342-915) is also well conserved relative to other viral 
regions and again, RNA secondary structures have been identified within this region 
(Tuplin, Evans and Simmonds, 2004; Mauger et al., 2015).  
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Figure 1-9; Within and between genotype diversity of HCV 
p-distance scans of full-length HCV genomes comparing within and between genotype diversity, generated 
from 150 bp windows across the genome using SSE software (Simmonds, 2012). A schematic diagram of the 
HCV genome is shown underneath (adapted from figure 1-2).  
 
The most divergent regions of the HCV genome are located within the envelope genes (E1 
and E2) and NS5A (figure 1-9). Whilst a large amount of inter-genotypic NS2 diversity is 
also observed, this is largely between genotypes and the within- genotype diversity in the 
region is considerably lower. The V3 region located within NS5A is near to the interferon 
sensitivity-determining region and studies have correlated mutations in V3 with interferon 
resistance and poor treatment outcomes (Puig-Basagoiti et al., 2005; Yuan et al., 2010). 
Numerous B-cell and T-cell epitopes have been identified in NS5A, suggesting the region 
is under considerable immune selection (Zhang et al., 1994; Dou et al., 2002). Researchers 
have suggested that the high diversity observed in the V3 region is a result of different 
genotypic adaptations to the evasion of intracellular host defences (Simmonds, 2004). 
Within E2 there are two highly variable regions, HVR-1 and HVR-2. Antibody, CD4+ and 
CD8+ T cell epitopes have all been identified within the HVR-1 region, suggesting 
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diversity within the region is largely driven by immune-mediated pressure (Shirai et al., 
1999; Farci, 2000; Sarobe et al., 2006). Numerous studies have also correlated high intra-
host variation of HVR-1 sequences with increased likelihood of progression to chronic 
disease (Farci, 2000; Chen and Wang, 2005; Thomson et al., 2011). Likewise restricted 
intra-host diversity has been associated with increased rates of spontaneous clearance 
during acute HCV (Farci, 2000; Thomson et al., 2011). A putative role for HVR-2 
mediating the structural stability of the E1-E2 heterodimer has been proposed (McCaffrey 
et al., 2011).  
These observed differences in variability have important implications in the design of 
studies involving sequence analysis and genotyping. The high rates of evolution within the 
E1-E2 region mean that whilst the region is useful for intra-host studies, the large number 
of mutations within the region make epidemiological inference at the population level 
difficult (Goncalves Rossi, Escobar-Gutierrez and Rahal, 2016). Highly conserved regions 
such as the 5’UTR and core show little discrimination between sub-genotypes and evolve 
slowly over time making them unsuitable for evolutionary studies. Detection of the 5’UTR 
and core regions are however useful biomarkers indicating the presence of an active HCV 
infection and are widely used in diagnostic laboratories to diagnose infection and for 
genotyping.  
1.6.3 Quasispecies   
Rates of evolution of HCV within an infected individual are estimated to be 10
-2
 to 10
-3
 
substitutions per site per year, placing HCV amongst the fastest mutating RNA viruses 
(Domingo, 2007; Lutchman et al., 2007). Consequently, the viral population in individuals 
infected with HCV is composed of many closely related but genetically heterologous 
variants and is often referred to as a quasispecies (Holland, De La Torre and Steinhauer, 
1992; Bukh, Miller and Purcell, 1995). Within a quasispecies, viral variants are linked 
within a mutational network and the diversity maintained within the population is a crucial 
survival mechanism, enabling the virus to rapidly adapt to dynamic environmental 
conditions. The high mutation rate of many RNA viruses is widely considered to be a key 
virulence factor for these pathogens, without which they would struggle to establish 
productive infections. Numerous studies have shown that increasing the fidelity of RNA 
virus polymerases can severely attenuate the pathogenicity of a viral population in vivo 
(Pfeiffer and Kirkegaard, 2005; Vignuzzi et al., 2006). In quasispecies theory, and contrary 
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to typical Darwinian models of evolution, selective pressures are thought to act on the 
population as a whole, rather than acting on individual variants within it and fitness within 
a quasispecies population is often considered in terms of ‘survival of the flattest’ rather 
than the more typical ‘survival of the fittest’ (Wilke et al., 2001). ‘Survival of the flattest’ 
describes a fitness model where, among rapidly producing viruses, it is considered 
advantageous to occupy a large amount of sequence space within a fitness landscape rather 
than be highly adapted (or ‘fit’) to a particular niche within the landscape. By exploring a 
large amount of sequence space, viruses are able to mitigate for their high mutation rates 
and remain highly adaptable to environmental changes, therefore maintaining their genetic 
robustness.   
In HCV, the highly heterogeneous nature of the quasispecies has been shown to have a 
vital role in viral persistence, disease progression and response to treatment (Domingo, 
Sheldon and Perales, 2012). Diversity within the population has been shown to be 
predictive of progression towards chronicity (Farci, 2000). During HIV co-infection where 
the immune response is impaired, HCV viral diversity is reduced, likely a consequence of 
the reduced selection for immune escape variants (Shuhart et al., 2006). This implies that 
the immune system is a strong selective factor for heterogeneity within the viral 
population. It is thought that the high mutation rate observed within HCV enables 
continual evasion from neutralising antibodies, providing an effective immune escape 
mechanism for the virus. Current understanding of the viral population structure supporting 
the observed diversity during HCV remains incomplete however. The majority of studies 
in the field characterise diversity based on samples collected from a select sub-set of the 
total viral population (often the blood serum), and evidence suggests that models based on 
such inference provide inadequate interpretations of intra-host viral evolution (Gray et al., 
2012). Within the liver HCV has been shown to replicate within discrete foci. Viral 
populations within the foci have been shown to be substantially divergent from the viral 
population circulating in the serum (Sobesky et al., 2007; Stiffler, Nguyen, J. A. Sohn, et 
al., 2009). An in vitro study by Leitch et al., has also indicated that discrete viral 
populations can be detected at the cellular level, implying that the networks underlying the 
diversity observed within the liver are complex (McWilliam Leitch and McLauchlan, 
2013). HCV has also been shown to compartmentalise during infection and genetically 
distinct viral populations have been isolated from numerous non-hepatic sites including 
peripheral blood mononucleocytes (PBMCs), lymphocytes and brain tissue (Laskus et al., 
2000, 2007; Radkowski et al., 2002; Roque-Afonso et al., 2005). Whilst the replicative 
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capacity of these viral sub-populations remains unclear, the detection of multiple viral 
reservoirs within HCV-infected individuals indicates the presence of a highly 
heterogeneous population structure capable of maintaining a complex quasispecies.  
1.7 Dinucleotide frequency & codon use bias 
1.7.1 Dinucleotide bias 
Compositional biases among the dinucleotide frequencies of vertebrate genomes were first 
noted in the 1960s (JOSSE, KAISER and KORNBERG, 1961; Russell et al., 1976). Since 
then, species-specific dinucleotide frequency signatures have been described for many 
organisms, suggesting that observed biases are reflective of the selective pressures placed 
upon organisms (Karlin et al., 1995; Karlin and Mrazek, 1997). Among the observations 
noted, TpA (or UpA in mRNA and RNA genomes )has been noted to be repressed in 
almost all organisms studied and CpG is frequently repressed in vertebrate genomes 
(Karlin et al., 1995). TpA dinucleotides are found within a number of key regulatory 
motifs including TATA box sequences and two of the three stop codons (Karlin and 
Ladunga, 1994). Repression of TpA in the genome is therefore thought to reduce the risk 
of inappropriate binding of transcriptional activators, maintaining the regulation of gene 
expression (Karlin and Ladunga, 1994; Karlin et al., 1995). UpA and UpU sequences in 
mRNA have been shown to be preferential targets for ribonucleases, particularly 
endonuclease L (Beutler et al., 1989). In transcriptionally active regions of the genome that 
are destined for expression within the cytosol via mRNA, TpA motifs are highly repressed, 
reducing the risk of degradation and extending the half-life of the mRNA. Avoidance of 
TpA dinucleotides therefore reduces the risk of nonsense mutations and increases the 
stability of RNA. Additionally TpA dinucleotides have the lowest thermodynamic stacking 
energy of all the dinucleotides, implying that the repression of TpA motifs may also 
function to facilitate an increase DNA stability (Breslauer et al., 1986).  
Within vertebrate genomes, CpG dinucleotides are frequently methylated, particularly in 
transcriptionally active regions. CpG methylation is thought to predispose the site to 
spontaneous deamination whereby the cytosine (C) residue is converted to a thymine (T) 
residue, resulting in point mutations across the genome (Bird, 1980).  As a result, CpG 
dinucleotides are depleted over time and replaced with TpG dinucleotides resulting in a 
marked suppression of CpG nucleotides among many vertebrate genomes (Karlin et al., 
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1995). Further suppression of CpG within the genome may also function to mitigate the 
risk of mutational damage to the genome. Among species that do not methylate their 
genomes, including insects and fungi, CpG repression is not observed (Karlin and Mrazek, 
1997). Many viruses,  and particularly RNA viruses with cytosolic replicative phases, have 
been observed to have similar dinucleotide biases to those of their hosts (Jenkins and 
Holmes, 2003; Greenbaum et al., 2008). Among dsRNA viruses, where replication occurs 
in discrete intracellular compartments isolating the dsRNA from the cytosol, CpG 
dinucleotides are generally not suppressed (figure 1-10) (Simmonds et al., 2013).  
Numerous studies have hypothesised that dinucleotide mimicry of the host occurs among 
viruses in order to avoid immune detection (Karlin, Doerfler and Cardon, 1994; Belalov 
and Lukashev, 2013; Cheng et al., 2013; Atkinson et al., 2014). Unmethylated CpG motifs 
have been found to be immunostimulatory and are recognised by toll-like receptor 9 (TLR-
9) (Uden and Raz, 2000; Weeratna et al., 2000). Work by Atkinson et al., has suggested 
that further, uncharacterised sensors associated with the PKR pathway may play an 
additional role in the detection of RNA with an abnormally high UpA or CpG content 
(Atkinson et al., 2014). Intriguingly, work on the 1918 pandemic influenza and the recent 
H5N1 strain has suggested that these viruses have a comparatively high CpG content 
relative to other strains. It has been hypothesised that this high CpG content may trigger 
stronger than usual innate immune reaction to these viruses, partially explaining the high 
mortality rate associated with these viruses (Chan et al., 2005; Kobasa et al., 2007; 
Greenbaum et al., 2008).  Studies have also suggested that the frequency of CpG and UpA 
dinucleotide pairs in the RNA genome may also influence the replicative capacity of the 
virus with  studies in Theiler’s murine encephalomyelitis virus (Atkinson et al., 2014) and 
other viruses (Karlin, Doerfler and Cardon, 1994) indicating that viruses with lower than 
expected CpG and UpA frequencies were able to replicate faster and to greater levels than 
other strains.  
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Figure 1-10; CpG expression in viruses infecting mammals and insects 
CpG observed amount/expected amount ratio (O/E) among viruses infecting (A) mammalian and (B) insect 
species. Viruses have been categorised according to their genome type: RNA+, positive sense single-stranded 
RNA; RNA-, negative sense single-stranded RNA; rtRNA, retrovirus; dsRNA, double-stranded RNA. 
Illustration published by Simmonds et al. (2013) (Simmonds et al., 2013). 
 
1.7.2 Codon Use Bias 
Shortly after the deciphering of the genetic code, it was realised that there was 
considerable redundancy within the system with 64 possible codons encoding just 20 
amino acids (Lagerkvist, 1978). Such redundancy enables multiple codons to encode the 
same amino acid with degeneracy frequently observed in the second and third codon 
positions (Lehmann and Libchaber, 2008). Codon use bias within genomes is thought to 
evolve as a result of the translational and mutational pressures placed upon them (Plotkin 
and Kudla, 2011). Among many viral species, similarities to the host codon bias has been 
demonstrated and the replacement of preferred codons with randomised alternatives  has 
been shown to severely attenuate viruses  (Zhou et al., 1999; Mueller et al., 2006; 
Greenbaum et al., 2008; Lobo et al., 2009; Belalov and Lukashev, 2013). Codon de-
optimisation has also been shown to be an effective method of generating attenuated 
strains for live viral vaccines (Baker, Nogales and Martinez-Sobrido, 2015; Cheng et al., 
2015; Diaz-San Segundo et al., 2015). It is unclear how exactly codon de-optimisation 
functions to reduce viral infectivity. Given that viruses are reliant upon host cell proteins in 
order to replicate, numerous studies have suggested that reductions in translational 
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efficiency play role in viral attenuation by codon de-optimisation (Karlin, Blaisdell and 
Schachtel, 1990; Mueller et al., 2006; Yang et al., 2013). Recent studies by Kunec and 
Osterrieder (2016) and Tulloch et al., (2014) have provided evidence that codon de-
optimised viral vaccines are effective because of inadvertent increases in CpG (and to a 
lesser extent UpA) dinucleotides that occur during de-optimisation, not because of changes 
to the codon bias (Tulloch et al., 2014; Kunec and Osterrieder, 2016). Kunec and 
Osterrieder (2016) also published evidence indicating that whilst viral dinucleotide 
frequency mimicked that of the host, the codon use bias frequently did not, appearing 
instead to be driven by the maintenance of the dinucleotide frequency (Kunec and 
Osterrieder, 2016).   
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1.8 Aims and objectives of the project 
Within the UK, the two most frequently diagnosed genotypes  are gt1a and gt3, each 
infecting around 45% of the total infected population (Public Health England, 2015). As 
both genotypes co-circulate and are transmitted within the IDU population in the UK it is 
likely that multiple genotype infections are occurring within this population. The only 
prevalence study within the UK to date identified mixed infections in 9% (4/44) of PWID 
(Buckton et al., 2006). Mixed genotype infections are rarely identified in the clinic as most 
currently employed diagnostic protocols only detect the major genotype present.  Many of 
the newly licensed DAA treatments have been documented to have genotype-specific 
efficacies that are particularly adept at treating gt1 infections but have poorer efficacies 
against gt3 infections (EASL, 2015). We have previously hypothesized that in regions such 
as the UK where non-gt1 viruses are highly prevalent, undiagnosed mixed genotype 
infections may respond poorly to some DAAs, possibly resulting in minor strain outgrowth 
and genotype switching (McNaughton et al., 2014). Given the recent increase in HCV 
treatment options, a larger study, encompassing a wider range of patients, may be 
informative for clinicians and researchers within the field. 
The aims for the project were, therefore –  
1) To screen a large cohort of gt1a and gt3 HCV positive patient samples in order to 
determine the mixed gt1a/gt3 infection prevalence within the UK population. This 
will be achieved by developing and optimising highly sensitive and specific PCR-
based methods that can be used for the detection of mixed gt1a/gt3 infection. 
Sanger-based sequencing will be used to perform phylogenetic characterisation of 
the mixed genotype infections identified within our cohort. 
2) To quantify the relative proportions of gt1a and gt3 present in samples with mixed 
infections. Genotype-specific qPCR assays for gt1a and gt3 will be developed for 
this purpose.  
3) To explore the potential of deep sequencing based methodologies for the diagnosis 
of mixed gt1a/gt3 infections in the clinic. In order to achieve this, pan-genotypic 
PCR-based assays compatible with the Illumina MiSeq platform will be developed 
targeting highly informative regions of the viral genome that can used for viral sub-
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typing. The efficacy of the deep sequencing approach for the identification of 
mixed genotype infections will be compared to the classical PCR method outlined 
in aim 1.  
4) To correlate viral sequence data in conjunction with linked clinical data to 
investigate differences between gt1a and gt3 viruses.  
5) As a part of a general comparative analysis of viral strains involved in mono and 
dual genotype HCV infections, we investigated dinucleotide frequencies and 
unexpectedly identified interesting variances in CpG expression. This led to an 
additional project aim to investigate dinucleotide frequencies and RSCU in HCV 
and related flaviviruses. This included an analysis of the genomes, genomic regions 
and temporal divergence of the of HCV and flavivirus host range.  
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2 Chapter 2: Materials & Methods  
2.1 Materials 
2.1.1 Chemicals 
Table 2-1; Chemicals  
Chemical Supplier 
Agarose Life Technologies 
Ampicillin Sigma-Aldrich 
Ethanol VWR International 
Glycerol Sigma-Aldrich 
Isopropanol VWR International 
SYBR safe – DNA gel stain 
Nucleic acid loading dye 
Life Technologies 
Life technologies 
Water, distilled  Filtered in-house 
Water, nuclease free  Qiagen 
 
 
2.1.2 Solutions 
Table 2-2; Solutions  
Solutions Components Supplier 
LB broth 2% tryptone, 0.5% yeast extract, 10mM 
NaCl, 2.5mM KCl,   
Thermo Scientific 
Luria-Bertani (LB) agar 
 
1% peptone, 0.5% yeast extract, 0.5% NaCl, 
1.2% agar 
Thermo Scientific 
RNA storage solution  1 mM sodium citrate, pH 6.4 (+⁄- 0.2) Life Technologies 
SPRI buffer 2.5 mNaCl, 20% PEG KAPA Biosystems 
Super Optimal Broth with 
Catabolite repression (SOC) 
10mM MgCl2,10mM MgSO4 20mM glucose Sigma Aldrich 
TAE (x50) 40 mM Tris-acetate, 1 mM EDTA, pH 8.3 
when diluted to x1 solution  
Life Technologies 
Tris buffer 10mM Tris, pH 8.5 Sigma Aldrich 
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2.1.3 Enzymes 
Table 2-3; Enzymes  
Enzyme Supplier 
KOD Polymerase 
RNAsin 
RNase H 
RNase OUT 
Proteinase K 
DNase I 
Illustra Exostar 
End repair enzyme 
A-tailing enzyme 
Merck Millipore 
Life Technologies 
Life Technologies 
Life Technologies 
Sigma-Aldrich 
Life Technologies 
Jencons 
KAPA Biosystems 
KAPA Biosystems 
Mung bean nuclease New England Biolabs (NEB) 
Platinum Taq Polymerase Life technologies 
SuperScript III Reverse Transcriptase Life Technologies 
T4 Ligase Thermo Scientific 
T7 Transcriptase Promega 
Xba1 restriction enzyme Promega 
 
2.1.4 Kits 
Table 2-4; Kits  
Kit Manufacturer 
Ampure XP DNA beads Agencourt 
CloneJET PCR cloning kit Thermo Scientific 
High Sensitivity D1000 ScreenTape, reagents and ladder Agilent technologies 
Illumina Mi Seq V3 300bp paired end kit Illumina 
KAPA HiFi PCR kit KAPA Biosystems 
KAPA Library Preparation kit KAPA Biosystems 
KOD Hotstart PCR kit Merck Millipore 
Mini-prep kit Qiagen 
NEBNext® Multiplex Oligos for Illumina® (Index Primers Set 1) New England Biosciences 
Platinum Taq PCR kit Life Technologies 
QIAamp Viral RNA Mini Kit Qiagen 
Qubit dsDNA high sensitivity assay kit Thermo Scientific 
RNeasy mini kit Qiagen 
SuperScript III reverse transcription kit Life Technologies 
T7 RiboMAX Express Large Scale RNA Production System Promega 
TaqMan® Fast Advanced Master Mix Life Technologies 
 
2.1.5 Primers and probes 
Primers and probes used for nested PCRs and qPCR reactions (table 2-5, primers A-H and 
table 2-8) were sourced from Eurofins and were manufactured using a desalting 
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purification. Primers used for deep sequencing (table 2-5, primers I-L) were PAGE-
purified and obtained from Integrated DNA Technologies (IDT). Blunt-ended dsDNA 
fragments used to generate controls were ordered from and synthesized by Life 
Technologies. The numbering of the HCV primers and controls have been discussed based 
on the standardised numbering system suggested by Kuiken C et al., (2006) using H77 
(accession number AF009606) as a reference (Kuiken et al., 2006).  
 
2.1.5.1  PCR primers designed for this project 
The pan-genotypic primers (primers I-L, table 2-5) that were used to generate the 
amplicons for deep sequencing were modified by the addition of a phosphorothioate bond 
between the last two nucleotides at the 3’ end. This rendered the primers resistant to the 3’ 
to 5’ endonuclease activity of the KAPA HiFi proofreading enzyme.   
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Table 2-5; Primer sets 
Genotype 
specificity 
Region Ref 
Primer 
type 
Sequence (5’ → 3’) Tm (°C) GC (%) Length Position (H77) 
Primers for Sanger Sequencing 
Gt1a E1-E2 
A OS CAT ATA ACG GGY CAY CGC ATG G 54.8-58.6 50-59 22 1275-1296 
B IS ATG ATR ATG AAC TGG TCY CCY AC 51.7-57.1 39-52 23 1305-1327 
C IAS TYG TCC TYA AYA ACA CYA GRC C 49.2-58.6 36-59 22 1972-1951 
D OAS TGG TTY GGY TGY ACY TGG ATG AA 51.7-58.8 39-57 23 2008-1986 
Gt3a E1-E2 
E OS TTY CTY GTG GGR CAA GCC TTC A 53-58.6 45-59 22 1203-1224 
F IS TTY AGA CCY CGY CGC CAT CA 51.8-57.9 50-65 20 1227-1246 
G IAS CAG AYG TGT TCY TGC TGR AGT C 53-58.6 45-59 22 1993-1972 
H OAS CCT YTW CTG CCC CAC YGA CTG 56.3-60.2 57-67 21 2143-2123 
Primers for Deep Sequencing 
Pan-genotypic E1-E2 
I S GC NTG GGA YAT GAT GAT GAA YTG 51.7-57.1 39-52 23 1296-1318 
J AS GDG SGT ART GCC ARC ART ANG 50.5-60.2 43-67 21 1812-1792 
Pan-genotypic NS5B 
K S ATG AYA CCM GVT GYT TYG ACT C 49.2-58.6 36-59 22 8257-8278 
L AS TAY CTS GTC ATA GCY TCC GTG A 53-56.7 45-55 22 8636-8617 
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2.1.5.2 Primers used for deep sequencing 
Table 2-6; Dual indexing primer sets, New England Biolabs (NEB) 
NEB Index 
Sequence 
(5'→3') 
NEBNext i501 Primer TATAGCCT 
NEBNext i502 Primer ATAGAGGC 
NEBNext i503 Primer CCTATCCT 
NEBNext i504 Primer GGCTCTGA 
NEBNext i505 Primer AGGCGAAG 
NEBNext i506 Primer TAATCTTA 
NEBNext i507 Primer CAGGACGT 
NEBNext i508 Primer GTACTGAC 
NEBNext i701 Primer ATTACTCG 
NEBNext i702 Primer TCCGGAGA 
NEBNext i703 Primer CGCTCATT 
NEBNext i704 Primer GAGATTCC 
NEBNext i705 Primer ATTCAGAA 
NEBNext i706 Primer GAATTCGT 
NEBNext i707 Primer CTGAAGCT 
NEBNext i708 Primer TAATGCGC 
NEBNext i709 Primer CGGCTATG 
NEBNext i710 Primer TCCGCGAA 
NEBNext i711 Primer TCTCGCGC 
NEBNext i712 Primer AGCGATAG 
 
Table 2-7; Adapter sequences (NEB) 
NEB adapter sequence Sequence (5'→3') 
Adapter (read 1) AGATCGGAAGAGCACACGTCTGAACTCCAGTCA 
Adapter (read 2) AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT 
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2.1.5.3 Primers used for qPCR 
 
Table 2-8; Primer and probe sets used for qPCR.  
*Primers published by Jones et al., (2010) (Jones et al., 2010). All other primers were designed specifically for this study.    
Genotype Region Ref Primer type Sequence (5’ → 3’) Tm (°C) GC (%) Length Position (H77) 
Pan-
genotypic 
5’UTR 
A S (JFH-1 16)*  TCT GCG GAA CCG GTG AGT AC 55.9 60 20 333-352 
B AS (JFH-1 17)* GCA CTC GCA AGC GCC CTA TC 57.9 65 20 500-481 
C Probe FAMTM-AAA GGC CTT GTG GTA CTG-MGB 48 50 18 460-477 
GT1a NS5B 
D S CTG TCG AGC CGC AGG GCT C 59.7 74 19 8507-25 
E AS GCT CCA AGT CGT AYT CTG GYT GBG 57.9-62.0 50-63 20 8686-62 
F Probe 
FAMTM-CCT CCG TGA AGG CTC TCA GGY 
TCG CYG CG-MGB 
68.6-71.4 66-72 29 8625-597 
GT3a NS5B 
G S GGA ACC CGG ACT TYC TYG TCT G 56.7-60.4 55-64 22 8527-48 
H AS CTC AAG GTC RTA GGT RGG CTG YGG 57.1-62.4 54-67 23 8684-61 
I Probe 
FAMTM-CGA CGC CRT CAC TCT CRG CCA 
CCA CRA CYA G-MGB 
67-72.3 58-71 31 8589-559 
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2.1.5.4 Synthetic DNA oligonucleotides 
Table 2-9; Synthetic DNA oligonucleotides 
Accession number Genotype Region Position  Length 
AF009606 1a E1-E2 1128-2054 927 
AF009606 1a NS5B 8166-9137 972 
GQ356206 3a E1-E2 1167-2147 998 
GQ356206 3a NS5B 8217-9083 956 
 
2.1.6 Bacteria 
NEB 5-alpha competent E. coli cells (New England Biolabs) were used when required for 
the propagation of plasmids in cloning procedures.  
2.2 Patient cohort 
2.2.1 Ethics statement 
Ethical approval for the use of patient samples in this project was granted by the NHS 
Research Scotland Greater Glasgow and Clyde Biorepository, application number 89. 
Ethical approval for the project allowed concurrent collection of anonymised linked 
clinical data for patients diagnosed as HCV positive by WSSVC during the period August 
2013 to March 2014. The data was collected from the clinical portal system, providing data 
on patient contact with secondary care providers in the region. The information was 
anonymised by a University of Glasgow medical student, Harriet Mei Tan.  
2.2.2 Sample collection 
Sample collection for the project occurred in two phases. The initial phase, in 2011, 
involved the collection of samples from the West of Scotland Specialist Virology Centre 
(WSSVC) and the Lothian Specialist Virology Testing Centre (BBV Edinburgh). 25 gt1a 
and 25 gt3 HCV-positive serum samples were collected at each site from individuals with a 
history of injecting drug use. Between August 2013 and March 2014, an additional 411 
gt1a and gt3 samples were collected from the WSSVC to expand the screening for mixed 
genotype HCV infections. For the second collection, only HCV-positive serum samples 
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that had been recently genotyped and had >140μl remaining were collected for the cohort. 
All samples were genotyped prior to collection by the diagnostic laboratory using an in-
house method. The genotyping method in use at the WSSVC involved a multiplex q-PCR 
targeting the 5’UTR region with specific probes for gt1, gt2 and gt4/5 (see appendix, figure 
8-3 for result interpretation panel). Diagnosis of gt3 was based on the absence of a specific 
result for the other genotypes and a further assay was used to differentiate gt1a and gt1b 
strains. The WSSVC were informed of all samples that were identified as having a mixed 
infection. 
2.2.3 Statistical analyses 
Clinical data linked to samples obtained from patients with HCV was analysed using SPSS 
software (IBM analytics) in conjunction with Excel (Microsoft) and GraphPad Prism 
software (GraphPad Software, Inc.). Differences in the means and distributions of data 
comprising two groups were compared using the independent samples t-test function 
within the SPSS or GraphPad Prism. For data where there were three or more groups, the 
ANOVA analysis option was used to compare the means using the type III sums of squares 
method. The significance of differences in the distribution of categorical data was 
determined using Chi-squared tests. The univariable and multivariable analyses were both 
performed using SPSS software. For the univariable analysis, the dependent factors were 
age, gender, HCV genotype or liver disease and the co-morbidities were analysed as 
discrete fixed factors. Statistical significance for all analyses was determined with a cut-off 
of p <0.05 and values of p <0.1 were interpreted as tending towards significance.  
2.3 Methods 
2.3.1 Control transcripts 
Previous studies have shown that control RNA transcripts derived from synthetic dsDNA 
based on patient-isolated sequences can be used effectively as controls for PCR assay 
optimisation (Schwaiger and Cassinotti, 2003; Dierssen et al., 2008; McLeish et al., 2012). 
We developed a similar method to produce control RNA transcripts for HCV genotypes 1a 
and 3a for both the E1-E2 and NS5B regions. The method is outlined in figure 2-1. Blunt 
ended dsDNA fragments used to generate the controls were obtained from Life 
Technologies. Both the E1-E2 and NS5B controls were based on patient-derived sequences 
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with the gt1a controls based on H77 (accession number AF009606) and the gt3a controls 
based on 3a.GB.2005 (accession number GQ356206) (Kolykhalov et al., 1997; Humphreys 
et al., 2009). The criteria used for selection of the controls are discussed in chapter 4 
section 4.2.1. Transcript controls were used throughout the project for assay optimisation, 
relative quantification during qPCR and fidelity assessments.  
62 
 
 
 
Figure 2-1; Workflow developed for the production of control transcripts 
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2.3.1.1 Plasmid preparation 
Cloning was performed using the CloneJET PCR cloning kit using the method for fragments 
of 1kb or smaller. Blunt-ended DNA fragments were prepared by the addition of dH2O as 
indicated by the manufacturer. The DNA fragment (0.15 pmol) was added to 0.05 pmol 
pJET1.2 (blunt cloning vector) along with 10 μl reaction buffer, 1 μl T4 ligase and nuclease 
free water (up to 19 μl). The reaction mixture was briefly vortexed and then placed on ice for 
5 minutes (min) before being used directly for transformation.    
 
2.3.1.2 Cloning 
NEB 5-alpha competent E. coli cells were thawed on ice for 10 min. The transformation 
reaction was initiated by adding 1-5 µl of the ligation reaction (containing 1 pg-100 ng of 
plasmid DNA) to the cell mixture and gently flick mixing it. The mixture was placed on ice 
for 30 min and then heat shocked at exactly 42°C for 30 seconds in a water bath. Following 
incubation on ice for 5 min, 950µl of room temperature SOC media was added and the 
mixture incubated at 37°C in a shaking heat block set at 250 rpm for 60 min. The cells were 
thoroughly mixed during the preparation of 10-fold dilutions in SOC and 50-100 µl of each 
dilution was spread onto LB agar (+100 μg/ml Ampicillin) selection plates pre-warmed to 
30oC. The plates were then incubated at 30oC for 48 h or37ºC for 16 h. The lower incubation 
temperature was used when high fidelity copying of the clonal plasmid inserts was required.  
 
2.3.1.3 Mini-preps 
Bacterial colonies that had successfully grown on LB agar (+100 μg/ml Ampicillin) were 
picked and individually inoculated into 5ml aliquots of LB broth (+100μg/ml Ampicillin). 
They were grown overnight at 37°C for 16hrs. Plasmids were purified from 1.5ml aliquots of 
the inoculated broth using a column mini-prep kit. Bacterial cultures were centrifuged at 6800 
x g for 3 min and the supernatant discarded. The pellets were resuspended in 250 µl of pre-
prepared buffer P1, 250 µl of buffer P2 was added and the tube was inverted 4-6 times. A 
further 350 µl of buffer N3 was then added to the solution and the tube again inverted 4-6 
times. The mixture was centrifuged at 17,900 x g for 10 min, during which time a white pellet 
consisting of cell debris formed. The supernatant containing the plasmids was applied to a 
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QIAprep 2.0 spin column which was centrifuged for 1 min at full speed and the filtrate was 
discarded. The column was washed by the sequential addition of 500 ul of PB and 750 ul of 
buffer PE, centrifuging for 1 min and discarding the filtrate at each step. To remove any 
residual buffer, the column was centrifuged for 1 min to remove any residual buffer and then 
placed into a fresh Eppendorf. In order to elute the plasmids, 50 µl of buffer EB was added to 
the column and left to stand for 1 min. After being centrifuged for 1 min, the column was 
discarded and the plasmids contained in the filtrate were retained.     
 
2.3.1.4 Restriction digests 
The purified pJET1.2 plasmids were linearized by a restriction digest with Xba I (Promega). 
The plasmid construct (40 ul) was incubated with 5 µl Xba I and 5 µl Buffer D at 37
o
C for 2 
hours. 
 
2.3.1.5 Mung bean nuclease treatment 
Mung bean nuclease treatment was used to remove 5’ and 3’ overhangs from linearized 
plasmid constructs prior to transcription of the fragments into RNA. The reaction was set up 
by adding 5 µl of mung bean buffer (10x) to 2 µl of mung bean nuclease and 43 µl of sample. 
The mixture was then incubated for 1h at 30
o
C. Blunt-ended dsDNA fragments, ready to 
undergo transcription, were generated.  
 
2.3.1.6 T7 transcription 
The following reaction was set up using the T7 RiboMAX kit (Promega) in 1.5 ml 
eppendorfs; T7 RiboMAX 2x buffer (10 µl), linear DNA sample (2 µl), water (6 µl) and T7 
RiboMAX enzyme mix (2 µl). The contents were well mixed and incubated at 37
o
C for 1 
hour. After incubation, the samples were treated with 1 Unit of RNase-free DNase per µg of 
DNA and incubated for 15 min at 37
o
C to remove remaining DNA templates. 
2.3.1.7 Gel electrophoresis of RNA 
1.5% agarose gels were prepared by mixing 1.5 g of agar with 100 ml of TAE preparation. 
The mixture was heated until boiling and then left to cool to approximately 45oC. When 
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cooled, 10 µl of SYBR safe stain was added to the mixture prior to pouring into a gel cast 
with a comb. Once set, samples were mixed with a loading dye, loaded onto the gel and run 
along a current gradient. A ladder was run alongside the samples for size comparison. The 
gels were analysed by UV light on a transilluminator and a photograph was taken of the gel.  
2.3.1.8 RNA quantification 
The concentrations of synthetic RNA transcripts were quantified with a Nanodrop ND-1000 
spectrophotometer, which measures the optical density of nucleic acid samples at 260nm. A 
minimum of 3 readings/sample were taken and the average calculated. The Endmemo 
website (http://www.endmemo.com/bio/dnacopynum.php) was then used to convert the 
concentration (ng/µl) into transcript copy number (copies/µl).Stock controls consisting of 
suitable ten-fold serial dilutions of the RNA controls were made and stored at -80°C. The 
controls were aliquoted for single use and only thawed immediately prior to use to prevent 
degradation of RNA through freeze/thaw cycles.     
 
2.3.2 RNA extraction 
2.3.2.1 RNA extraction 
Viral RNA from samples was extracted using a QIAamp viral RNA mini kit. Lysis of the 
HCV virions was carried out under tightly controlled conditions in an enhanced bio-
containment facility. A 140 µl aliquot of patient sera was added to 560 µl of AVL buffer 
containing 5.6 µl of carrier RNA (supplied with the kit). The sample and buffer were 
vortexed briefly and the mixture was incubated at room temperature for 10 min. After briefly 
pulse centrifuging the samples, 560 µl of 100% ethanol was added and the samples were 
vortexed for 15 seconds. Following this, 630 µl of the solution was applied to a QIAmp mini 
column (in a 2 ml collection tube) which was then centrifuged at 6000 x g for 1 min. The 
filtrate in the collection tube was discarded and the column placed into a fresh collection 
tube. The remaining 630 µl of the sample was applied to the column and the centrifugation 
step repeated. The column was placed in a fresh collection tube and 500 µl of buffer AW1 
was applied before centrifuging at 6000 x g for 1 min. The filtrate was discarded and the 
column placed into a fresh collection tube. Following this, 500 µl of buffer AW2 was added 
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and the sample centrifuged at 20 000 x g for 3 min. The filtrate was then discarded; the 
column placed in a fresh centrifuge tube and the sample was spun at 20 000 x g for a further 1 
min. The column was then placed into an Eppendorf tube and 60 µl buffer AVE (elution 
buffer) applied to the columns. The samples were incubated at room temperature for 1 min 
before being centrifuged at 6 000 x g for 1 min. The columns were then discarded and the 
RNA was stored at -70ºC until required. 
2.3.2.2 cDNA synthesis  
Extracted RNA was transcribed into cDNA using SuperScript III reverse transcriptase as per 
manufacturer’s instructions. Initially, 10 µl RNA was mixed with 1.0 µl dNTPs, 0.08 µl 
random primers and 1.92 µl dH2O. The reaction mixture was incubated at 65°C for 5 min and 
then cooled on ice for 1 min. After this, a master mix comprising of 4.0 µl buffer, 1.0 µl 
SuperScript reverse transcriptase, 1.0 µl RNaseOUT and 1.0 µl DTT was prepared, 7 µl of 
which was added to the reaction cooled on ice, creating a total reaction volume of 20 µl. The 
reaction was then incubated at 25 °C for 5 min, 50 °C for 60 min and finally, 70 °C for 15 
min before being held indefinitely at 4 °C. RNaseOUT was used to selectively inhibit 
ribonucleases and reduce any possible RNA degradation. The cDNA libraries were stored at -
80ºC prior to testing.       
2.3.3 Screening of mixed infections 
2.3.3.1 Primer design 
Unless otherwise stated, primers were designed manually using alignments of reference 
sequences downloaded from the Los Alamos HCV database (Kuiken et al., 2005). The 
alignment included sequences for all 67 characterised sub-types of HCV (see table 10 for 
accession numbers). Alignments were supplemented with additional gt1a and gt3a sequences 
as required to ensure that the developed primers would be capable of identifying a diverse 
range of strains. The exact requirements of each primer set varied but in general, they were 
designed to be 18-24bp in length, have a GC content of 40-60% and a Tm of 55-60°C 
(although this varied depending on the enzyme used). Primer pairs were designed to have a 
similar Tm and designs indicating a strong likelihood of hairpin formation or primer 
dimerization were avoided. Degenerate positions were incorporated where appropriate to 
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accommodate strain variation between viral sequences. Primer properties were assessed using 
Oligo Calc (www.basic.northwestern.edu/biotools/OligoCalc).  
 
2.3.3.2 Nested PCR  
Sub-type specific nested PCR assays were developed and their annealing temperatures 
optimised to screen samples for the presence of mixed gt1a/gt3a infections. The first round 
PCR was performed using the Platinum Taq PCR System and the secondary PCR was carried 
out with the KOD Hot Start PCR system, both as per manufacturer’s instructions. Primers A-
D (table 2-5) were used to screen for genotype 1a strains and primers E-H (table 2-5) used to 
screen for genotype 3a strains. For the first round reaction, the following were mixed together 
in a total reaction volume of 20 µl; 0.4 µl DNTPs, 0.6 µl MgCl2, 2.0 µl buffer, 0.4 µl each of 
the sense and anti-sense primers (using 10μM working stocks), 2 µl cDNA, 0.08 µl platinum 
Taq and 14.12 µl dH2O. Cycling conditions were as follows: initial denaturation, 94°C for 2 
min and 40 cycles of 94°C for 30 seconds, 55°C (gt1a) or 56°C (gt3a) for 30 seconds and 
72°C for 1 min; the reaction was then held at 4°C. For the second round reaction, the 
following reaction mixture was prepared in a total volume of 20 µl; 2.0 µl DNTPs, 1.2 µl 
MgSO4, 2.0 µl buffer, 0.6 µl of both the sense and anti-sense primers, 1 µl from the first 
round reaction, 0.4 µl KOD Taq and 12.2 µl dH2O. Cycling condition were as follows: initial 
denaturation, 95°C for 2 min and 25 cycles of 95°C for 20 seconds, 55°C (gt1a) or 56°C 
(gt3a) for 10 seconds and 70°C for 15 seconds; the reaction was then held at 4°C. Products 
from the reactions were run on a 1.5% agarose gel to confirm the presence of a product of the 
expected size. All screening reactions had a positive control (an aliquot of 10
4
 copies/μl of 
the control transcript of the appropriate genotype) and a negative control (nuclease free 
water) that were amplified alongside the samples.  
2.3.3.3 Gel electrophoresis of DNA 
The  protocol for the electrophoresis of DNA was identical to that of the protocol for RNA 
gel electrophoresis (see section 2.3.1.6). 
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2.3.3.4 Sanger sequencing 
Samples for sequencing were treated with Illustra Exostar (Jencons) to remove excess 
primers and dNTPs from the solution prior to sequencing. A 2 µl aliquot of Illustra Exostar 
(prepared as instructed) was added to 5 µl of sample. The mixture was then incubated at 37°C 
for 15 min and 80°C for a further 15 min. If greater than 7 µl was required, two reactions 
were run and the samples pooled. Samples were prepared and pre-mixed with primers as 
required by Eurofins. Samples were sent to Eurofins for Sanger sequencing. All the 
sequenced amplicons were checked against alignments of  frequently used  laboratory strains 
to screen for contamination events.  
2.3.4 qPCR 
2.3.4.1 5’UTR 
A qPCR targeting the 5’UTR was used throughout the project to quantify the HCV viral load 
(primers A-C, table 8) (Jones et al., 2010). The qPCR was performed in 96-well plates with 
the TaqMan fast 7500 system using TaqMan fast reagents in accordance with the 
manufacturer’s instructions. Pre-prepared cDNA (section 2.3.2.2) was amplified for 40 cycles 
in a reaction that contained 2µl of cDNA, 900 nM of each primer, 250 nM of probe and 10 µl 
TaqMan fast master mix. The reaction volume was adjusted to 20 µl by the addition of dH2O. 
Cycling conditions were 95°C for 20 seconds and then 40 cycles of 95°C for 3 seconds and 
60°C for 30 seconds. A dilution series prepared from known concentrations of JFH-1 
replicon transcripts were used as controls for comparative quantification.   
2.3.4.2 NS5B 
 Genotype-specific primers and probes suitable for use with the TaqMan fast system (Life 
Sciences) were designed for HCV genotypes 1a and 3a (primers D-F and G-I, table 8). 
Reactions were set up in an identical manner to that described in section 2.3.4.1. Genotype-
specific controls derived from synthetic blunt-ended dsDNA were used for comparative 
quantification (see methods 2.3.1).    
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2.3.4.3 Deep sequencing 
A PCR-based Illumina deep sequencing approach targeting partial E1-E2 and NS5B regions 
of HCV was developed that was compatible with the Illumina MiSeq platform. Primers for 
the PCR were designed to work in conjunction with the V3 MiSeq reagent kit, allowing the 
sequencing of 2 x 300bp paired-end reads. An overview of the protocol used is shown in 
figure 2-2.  
 
 
Figure 2-2; Workflow developed for the deep sequencing protocol 
  
In order to limit the risk of contamination, samples were split into separate runs on the basis 
of their genotype. Samples with mixed genotype HCV infections were placed on the run of 
their major genotype as determined by qPCR. In cases where this information was not 
known, the genotype recorded by the diagnostic laboratory was presumed to be the major 
genotype in the sample. 
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2.3.4.4 PCR 
To generate amplicons for deep sequencing, samples underwent two separate PCR reactions 
using the E1-E2 (table 5, primers I-J) and NS5B (table 5, primers K-L) pan-genotypic 
primers. The KAPA HiFi PCR kit was used to generate the amplicons as per manufacturer’s 
instructions. The following reaction mixtures were prepared; 4 µl buffer, 0.6 µl DNTPs, 0.6 
µl of both the sense and the anti-sense primers, 0.4 µl KAPA HiFi enzyme, 4 µl cDNA and 
9.8 µl dH2O to create a total reaction volume of 20 µl. Cycling conditions were as follows: 
initial denaturation, 95°C for 3 min and 30 cycles of 95°C for 20 seconds, 61°C (gt1a) or 
64°C (gt3a) for 25 seconds and 72°C for 40 seconds, followed by a final extension at 72°C 
for 1 min. The reaction was then held at 4°C.  
2.3.4.5 Clean-up of amplicons 
Agencourt AMPure XP magnetic beads were used for the purification of amplicons after 
PCR reactions. AMPure XP beads exploit the negative charge of DNA and are able to 
reversibly bind to DNA at high concentrations of polyethene glycol (PEG) and salt. PCR 
reactions were diluted with Tris to a total volume of 50µl. Depending upon the size of 
products being selected, 1x – 1.4x volume of AMPure XP beads was then added. Smaller 
volumes of beads select for larger DNA fragments and the removal of primer-dimers was 
obtained by the use of 0.85x volume of beads. Samples were mixed well with the beads by 
pipetting and left to stand at room temperature for 10 min before being placed on a magnetic 
rack for 5 min. The supernatant was then removed and the beads were washed twice in 200 µl 
of 70% ethanol. The beads were left to air dry for 5-10 min and then resuspended in 8-15 µl 
Tris. Some in-house protocols have been developed whereby the beads are kept in the 
samples during enzymatic reactions to limit the DNA loss during preparation (Gavin Wilkie, 
CVR, unpublished). In cases where this protocol was used, solid-phase reversible 
immobilization (SPRI) buffer was used for the DNA clean-up in identical volumes to the 
beads.  
2.3.4.6 DNA quantification with Qubit 
The amount of DNA was quantified with the Qubit dsDNA High-Sensitivity (HS) kit as per 
manufacturer’s instructions. A working solution was prepared by adding HS reagent to buffer 
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in a 1:200 dilution. For each sample, 1-2 µl of PCR product was added to 198-199 µl of 
working solution and then vortex mixed. Samples were run on the Qubit against standards 
and DNA was quantified in ng/µl.   
2.3.4.7 Library preparation 
The protocol followed for the library preparation is an in-house protocol based on the 
instructions provided with the KAPA library preparation (for Illumina) kit and adapted for 
use by Gavin Wilkie (high-throughput sequencing facility manager, MRC-CVR).  
After production of the E1-E2 and NS5B amplicons with pan-genotypic primers, the DNA 
was purified using 1x AMPure XP magnetic beads and then quantified using Qubit. The E1-
E2 and NS5B amplicons for each sample were then combined in equimolar ratios. After 
mixing the amplicons, the volume was adjusted to 25 µl with Tris and the samples then 
underwent library preparation. The ends of the PCR fragments were repaired by adding 2 µl 
of end repair enzyme in 3µl of end repair buffer to 25 µl of sample. The reaction was 
incubated for 30 min at 20°C and then the volume was increased to 50 µl using 10 mM Tris. 
DNA was purified using 1x AMPure XP magnetic beads and the beads were retained within 
the samples after elution to minimise sample loss. Samples were eluted into 21 µl of 10 mM 
Tris. A single 3’ Adenosine residue was then added to each fragment in an A-tailing reaction 
by adding 21 µl of end-repaired DNA to 1.5 µl of A-tail enzyme in 2.5 µl of buffer and 
incubating at 30°C for 30 min. The volume was increased to 50 µl using 10 mM Tris and the 
DNA purified by adding 1x SPRI. Samples were eluted into 15 µl of 10 mM Tris and DNA 
concentration was quantified using Qubit.  
The amount of DNA present was then converted to pmols using the following equation  –  
 
𝑝𝑚𝑜𝑙𝑠 =  
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑁𝐴 (𝑛𝑔)
[𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑖𝑧𝑒 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡𝑠 (𝑘𝑏) × 660]
 
 
 
As the E1-E2 and NS5B fragments were mixed together in equimolar ratios, the size of the 
fragments was assumed to be the average of their two lengths. The average molecular weight 
of a nucleotide base is considered to be 660 g/mol. Based on the calculation, adapters were 
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then ligated onto the ends of the A-tailed DNA in a reaction with a 20:1 molar excess of 
adapters to DNA fragments. The amount of adapter required was calculated with a minimum 
of 0.5 µl and a maximum of 5 µl adapter being used. Following this, 14 µl of A-tailed DNA 
was added to 1 µl of ligase in 5 µl of buffer with 0.5-5 µl NEB adapter. The total reaction 
volume was adjusted to 25 µl using dH2O and incubated at 20°C for 1 hour. Each reaction 
was incubated for 15 min with 1 µl of USER enzyme at 37°C in order to remove unpaired 
uracil bases in the adapters and generate the free ends required for the indexing PCR reaction.  
The volume was adjusted to 50 µl and the DNA was purified using x0.85 volume SPRI. The 
samples were eluted into 15 µl Tris and each sample was assigned a unique combination of 
an i5 and i7 indexed primer for dual index tagging.  For the PCR reaction, 10 µl of DNA was 
added to 12.5 µl of 2x KAPA HiFi Hotstart ready mix with 1.25 µl of each assigned primer 
tag. The reaction then underwent PCR with the following cycling conditions; 95°C for 3 min 
and 12-16 cycles of 95°C for 20 seconds, 65°C 15 seconds and 72°C for 30 seconds, 
followed by a final extension at 72°C for 1 min. The reaction was then held at 4°C 
indefinitely. In the majority of cases, the PCR reactions were cycled 12 times and 16 cycles 
were used when the starting amount of DNA present was known to be low (based on Qubit 
quantification). After the PCR reaction, the volume was adjusted to 50µl, the DNA was 
purified with x0.85 volume of SPRI and the samples were eluted into 15 µl of Tris. Library 
concentrations were quantified by Qubit. 
2.3.4.8 TapeStation analysis 
Library preparations were analysed on TapeStation to assess the size of the products. A 2µl 
aliquot of sample was mixed with 2µl tape station buffer. Samples were then run on the 
TapeStation with a sizing ladder using a D1000 HS cassette (Aligent) for analysis. Using the 
library concentration obtained by Qubit and the size determined by TapeStation, the molarity 
of each library DNA was calculated with the following equation –  
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 (𝑛𝑀) =  [
𝐷𝑁𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔/µ𝑙)
[𝑝𝑒𝑎𝑘 𝑠𝑖𝑧𝑒 (𝑏𝑝) × 660]
]  × 1000000 
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Using the calculated molarity, samples were pooled together in equimolar ratios prior to 
running them on the MiSeq. Guidance calculating the aliquots required for equimolar pooling 
was provided by Gavin Wilkie.  
2.3.4.9 Deep sequencing 
Libraries were denatured prior to sequencing by treatment with freshly prepared 
0.2 M NaOH. DNA library pools were diluted to 4 nM and 5 µl of the pools was added to 5 
µl of 0.2 M NaOH. The mixture was vortexed, briefly centrifuged and then incubated for 5 
min at room temperature. 10 µl of the denatured DNA was then added to 990 µl of pre-
chilled hybridization buffer (provided with Illumina cartridges), resulting in a 20 pM 
denatured library in 1 mM NaOH. This mixture was then diluted further using the 
hybridization buffer to give 600µl of a desired final library concentration of between 6-20 
pM. This was then loaded onto the MiSeq cartridge, which in turn was loaded onto the MiSeq 
sequencer. As our runs were sequencing E1-E2 and NS5B amplicons, diversity among our 
samples was low. This lack of variation can cause issues with the interpretation of the 
sequencing data, and samples were therefore run at a relatively low cluster density with 5-
10% PhiX controls in order to compensate.  
2.4 Phylogenetic and sequence analysis techniques 
2.4.1 Alignments 
All analysed sequences were examined and aligned using the MUSCLE (v3.8) program 
embedded within Simmonics Sequence Editor (SSE) (Edgar, 2004; Simmonds, 2012).  
2.4.2 Maximum-likelihood analysis 
Maximum likelihood phylogenetic analyses were carried out on alignments using MEGA 5.0 
(Tamura et al., 2011). Bootstrap re-sampling with 1000 replicates was used to assess the 
statistical support for the branches within phylogenetic trees. Bootstrap values ≥70% were 
considered significant and indicated on the trees. When discussing sequences, position within 
the genome is always quoted relative to the HCV strain H77 (Kuiken et al., 2006). Reference 
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sequences for analysis were downloaded from either NCBI Genbank or the Los Alamos HCV 
Database (Kuiken et al., 2005; Benson et al., 2013). 
2.4.3 Deep-sequencing analysis 
Deep sequencing data from the Illumina MiSeq was analysed using an in-house Unix-based 
pipeline. Sequencing adapters were removed and low-quality reads were removed using Fast 
QC and Trim Galore! (Babraham Bioinformatics). High-quality paired-end reads then 
underwent a number of analyses for genotyping, quasispecies diversity and dinucleotide 
frequency.  
Genotyping of the deep sequencing reads was done using an in-house bioinformatics pipeline 
developed by Sreenu Vattipally (Research bioinformatician, CVR). The pipeline worked by 
bioinformatically excising deep sequencing reads into 37bp k-mers and comparing against 
pools of genotype-specific k-mers. An outline of the pipeline is shown in figure 2-3. Several 
thousand HCV sequences were used as reference sequences and bioinformatically chopped to 
generate the pools of unique genotype-specific k-mers. K-mer identity matching between the 
reference k-mers and the read k-mers had to be 100% to allow genotyping. Consensus 
sequences were generated from the genotype reads and compared with previously obtained 
sequences using maximum likelihood phylogenetic analysis.   
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Figure 2-3; K-mer bioinformatic analysis 
Outline of the K-mer bioinformatic analysis developed by Sreenu Vattipally and used to genotype the deep 
sequencing reads 
 
 
For other comparative sequence analyses, Tanoti was used (Vattipally, 2014). Tanoti was 
used to compare deep sequencing reads against reference genomes and Sanger sequences 
from previous work. Consensus sequences were generated from the Tanoti files and 
compared with previously obtained products sequenced by the Sanger method using 
maximum likelihood phylogenetic analysis (section 2.4.2).   
2.4.4 Diversity analysis 
The deep sequencing data was used to assess diversity present within the viral populations. 
The diversity analysis was carried out with assistance from Richard Orton (Research 
Associate, MRC-CVR) and Sreenu Vattipally. CD-Hit (http://www.bioinformatics.org/cd-
hit/) was used to perform a cluster-based analysis of the sequencing data (Li and Godzik, 
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2006; Fu et al., 2012) on a Linux-based system available at the Centre for Virus Reseach. 
Using a fasta format sequence database, the CD-Hit analysis functions by utilising a greedy 
incremental algorithm that takes the longest read in a dataset and compares all the other reads 
in the dataset to it (Fu et al., 2012). The sequences were initially sorted by length and the 
longest sequence was taken to represent the first cluster. Subsequent reads were compared to 
the longest read using a short word filtering algorithm. Reads that were above a user-defined 
threshold of similarity to the longest read were grouped into a cluster together. Reads that 
were not similar were taken as representative of new clusters and subsequent sequences were 
compared to all the clusters generated. Clusters with >500 reads associated were considered 
to be real variants. A threshold of 0.9 was selected for this study, meaning that each cluster 
detected was at least 10% divergent at the nucleotide level from the longest read and other 
clusters. The numbers of clusters of >500 and >1000 reads were recorded in order to gauge 
diversity present within the samples in this study.  It should be noted that for this analysis the 
reads from each sample were previously separated by genotype using Tanoti (Vattipally, 
2014) and that in samples with multiple genotypes detected within them, clustering analysis 
has been performed on each genotype separately. 
2.4.5 Dinucleotide frequency analysis 
The expected and observed ratios of CpG and UpA dinucleotide occurrences were calculated 
using a program within Simmonics Sequence Editor (Simmonds, 2012). The amount of each 
nucleotide (A, T, C or G) in a given sequence was counted and the expected frequency of 
each dinucleotide calculated based on these values. The observed frequency of dinucleotides 
was then calculated and used to calculate the ratio of observed:expected (O/E) for each of the 
dinucleotide pairs. 
𝑂: 𝐸 𝑅𝑎𝑡𝑖𝑜 =
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑖𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒𝑠 𝑖𝑛 𝑎 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒
𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑑𝑖𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒𝑠 𝑖𝑛 𝑎 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒
   
 Data was analysed using Excel (Microsoft) and SPSS software.    
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2.4.6 Relative synonymous codon usage 
The relative synonymous codon usage (RSCU) for coding sequences were calculated using a 
program within Simmonics Sequence Editor (Simmonds, 2012). Alignments were checked to 
ensure that they were in frame prior to calculating the RSCU. The RSCU was calculated by 
first counting the frequency of each amino acid. The relative frequency of each codon used 
was then recorded and the relative usage of each codon for its respective amino acid was 
calculated. Base composition and dinucleotide frequency bias were not taken into account 
during the analysis. Data was analysed using Excel (Microsoft) and SPSS software (IBM).  
2.4.7 Viral sequences used for analysis 
Viral sequences used for analyses throughout the project were downloaded from the Genbank 
(Benson et al., 2013) and Los Alamos databases (Kuiken et al., 2005). Details of the 
sequences and the analyses they were used in can be found in the appendix, table 8-1.   
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3 Chapter 3: Analysis of linked 
clinical data 
 
3.1 Introduction 
Chronic infection with HCV is associated with a highly variable clinical outcome with many 
individuals suffering from the progressive development of liver fibrosis, cirrhosis and HCC. 
Cirrhosis develops after 20-30 years in approximately 10-20% of individuals with HCV 
(Thein et al., 2008; Westbrook and Dusheiko, 2014)  and numerous risk factors have been 
linked with an increased risk of fibrotic progression including male gender, age >40 years, 
excessive alcohol intake, immunosuppression, diabetes and co-infection with HIV or HBV (T 
Poynard, Bedossa and Opolon, 1997; Ramos Paesa et al., 1998; Minola et al., 2002; Gaeta et 
al., 2003; Ratziu et al., 2003; Hutchinson, Bird and Goldberg, 2005). Extra-hepatic 
manifestations and co-morbidities are also frequently reported amongst patients infected with 
HCV and include a wide range of conditions, such as cryoglobulinemia, insulin resistance, 
immunological disorders, depression and gastrointestinal disorders (Louie et al., 2012; 
Cacoub et al., 2014). Whilst infection rates in many nations are currently in decline, the rates 
of HCV-related morbidity and mortality are increasing and are causing significant financial 
strain on health systems globally (Wong et al., 2000; Deuffic-Burban et al., 2012). Similar 
trends are seen in the UK including Scotland, where rates of HCV-related mortality have 
increased significantly in recent years (McDonald et al., 2010; Public Health England, 2015).  
 
The analysis of linked clinical data from patients with HCV is a valuable resource and can 
highlight trends in transmission, treatment and patient prognosis, suggesting where resources 
may be best focused. Previous studies have indicated that there are genotype-specific 
differences in the immune response to HCV  (Robinson et al., 2015) and that gt3 infection is 
associated with a more rapid progression towards cirrhosis and HCC relative to gt1 infection 
(Leandro et al., 2006; Kanwal et al., 2014). In this chapter, the data collected on the cohort 
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was analysed by genotype, to compare the clinical and demographic characteristics of 
patients infected with gt1a and gt3 infections. Further analysis looking at the gender and the 
severity of liver disease among patients in the cohort was also performed where appropriate, 
providing an insight into the demographics of individuals infected with HCV in the 
geographical region.   
 
3.1.1 Data collection 
During the period August 2013-march 2014, 1132 HCV positive samples were genotyped at 
the West of Scotland Specialist Virology Laboratory (WSSVC) based at the Glasgow Royal 
Infirmary. Generally, HCV positive patients in the region are genotyped shortly after initial 
diagnosis and prior to treatment. For this study, anonymised data was collected on postcode, 
age, and the viral genotype of the patients providing the 1132 samples. Over the period 
August 2013-march 2014, any sample that had been genotyped and had ≥140 μl serum 
available was also collected for the mixed gt1a/gt3 screening (chapter 4). A total of 205 gt1a 
samples and 206 gt3 samples were collected. An additional 48 gt1a and 47 gt3 samples 
collected as part of an earlier study were also screened for mixed gt1a/gt3 infection (chapter 
4). In addition to this, for a subset of 590 HCV-positive samples from patients living within 
the Greater Glasgow and Paisley postcode districts (PC) who underwent genotyping at the 
WSSVC between August 2013-march 2014, detailed data on co-morbidities, liver disease and 
viral load was collected regardless of whether or not a sample was collected concurrently. 
Enhanced data was only available for this subset of patients as ethical approval for the project 
was granted by the NHS Greater Glasgow & Clyde Biorepository and linked data for the 
remaining 542 patients was held by other health boards. Clinical data on the cohort was 
sourced from the clinical portal system, which provides data on patient contact with 
secondary care providers in the region and is considered a relatively robust source for data 
collection. 
 
3.2 Characteristics of the population sampled 
The WSSVC is a part of The Scottish National Blood Borne Virus Specialist Testing Service, 
providing specialist testing for blood borne viruses (BBV) in Scotland. Consequently, 
samples are sent to the WSSVC from throughout Scotland and the samples we collected are 
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reflective of this. Sampling from the Greater Glasgow region (including Motherwell and 
Paisley PC areas) is likely to be over-represented. Estimates of prevalence Scotland-wide 
have established that 39% of all HCV cases  are within the Greater Glasgow and Clyde 
regions (Codere et al., 2015) ; in our study, 51% of cases were sampled from this region 
(figure 1A). Greater Glasgow does however represent a significant proportion of the Scottish 
population and is known to have relatively high rates of IDU and HCV infection. Awareness 
of this issue is good among healthcare providers within the region and testing rates are likely 
to be high in the region as a result. This is reflected in the data with 42% of the samples 
collected coming from Glasgow PC areas. As the WSSVC is located within Glasgow, a 
prolonged retention of samples from the region relative to other samples may also have 
affected sampling. Additionally, Edinburgh has its own specialist BBV testing centre and 
samples were collected from there once, during the initial phase of sample collection for the 
project, and were not included in the linked clinical data collected. As a result, sampling from 
the Edinburgh PC area is likely under-represented within this cohort.   
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Figure 3-1; Regional prevalence of samples in the cohort  
 (A) Postcode (PC) regions of Scotland from where the 1132 samples were collected. (B) Regional prevalence of HCV genotypes diagnosed at the WSSVC. The numbers of 
samples from each region are overlaid on the chart. From these figures, it can be seen that samples and data from the Glasgow and Paisley PC areas comprise ~50% of the 
cohort.  
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Between July 2013 and March 2014, 42.3% of the samples tested at WSSVC (n=1132) were 
gt3, 41.8% were gt1a and 10.8% were diagnosed as having another genotype (figure 3-1, B). 
The sample was either insufficient or the viral load was too low to get an accurate result in 
5.1% of cases. No cases of gt5 or gt7 were diagnosed in the region during the sampling 
period. Genotypic distribution patterns were fairly consistent throughout the different PC 
regions of Scotland, with most of the regions having similar prevalence patterns to the overall 
prevalence rate. Exceptions were seen in regions with low sampling rates including, the Outer 
Hebrides (n=2), Kirkwall (n=2) and the Shetland Isles (n=2). The Aberdeen, Edinburgh, 
Falkirk and Inverness PC areas had considerably larger numbers of HCV infections that were 
not gt1a or gt3 than other regions. Aberdeen and Edinburgh PC areas are documented to have 
the highest rates of non-Scottish residents and both regions have strong international links.   
 
3.2.1 Characteristics of the Glasgow and Paisley PC area cohort 
 
Figure 3-2; Genotypes of HCV positive patients in the Glasgow and Paisley areas 
The genotypes of 590 HCV positive patients in the Glasgow and Paisley postcode districts, as determined by the 
WSSVC. NK includes samples where genotype was not known, due either to insufficient sample or sample not 
being tested. No gt5 or gt7 samples were detected within the cohort by the WSSVC.  
 
The most common HCV genotypes diagnosed within the Glasgow and Paisley PC area were 
genotype 1a (44%) and genotype 3 (43%) (figure 3-2).  All other genotypes were detected at 
relatively low frequency and the genotype in 4% of cases was not determined.  This is 
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comparable with the reported genotype prevalence observed across the UK, with genotypes 
1a and 3 being the most commonly reported, especially among populations with high 
numbers of IDUs (Public Health England, 2015). HCV infection was more common in males 
with 74.2% of the population we sampled being male. This is commonly seen among the 
HCV positive community, with IDU and risky behaviours generally being more common 
among males than females (Public Health England, 2015). 
 
Figure 3-3; Ages of HCV-infected individuals 
(A) Dot plot showing the distribution of ages of 1132 HCV-infected individuals by gender. (B) Dot plot 
showing the distribution of ages of HCV-infected individuals by HCV genotype (gt1a or gt3). 
 
The average age of individuals sampled was 42.6 ± 9.8 years, with a range of 7-82 years. 
97.3% of individuals in the study were aged between 18 and 60 years and the interquartile 
age of the cohort was 36-49 years. The range of ages observed was comparable between 
genders (p=0.85) with females having an average age of 41.9 ± 11.5 years and males having 
an average age of 42.8 ± 9.2 years. A greater proportion of females (p=0.02) were diagnosed 
under the age of 30 (15.1%) than males (8.7%), suggesting that females either are infected 
with HCV at a younger age or that they are more likely to seek medical treatment at an earlier 
stage than their male counterparts. The average age of individuals infected with genotype 1a 
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was 42.5 ± 8.8 years and this was similar (p=0.22) to the average age of those with genotype 
3 infections (42.4 ± 9.3 years).  
 
Figure 3-4; Risk factors for HCV infection 
The risk factors for HCV infection for 590 HCV positive patients in the Glasgow and Paisley postcode regions. 
Patients have been stratified by genotype and ‘other’ contains patients infected with gt1b, gt2, gt4 and gt6. 
 
Within the cohort, injecting drug use (IDU) was the major HCV risk factor for all genotypes, 
with 60-80% of patients recorded as having a history of IDU (figure 3-4). IDU was more 
common in individuals infected with gt1a or gt3 than in individuals infected with other 
genotypes of HCV. Other risk factors were infrequent, although sexual contact was identified 
as a potential route of transmission for 11.6% patients not infected with gt1a or gt3. A review 
of these patients (n=5) showed that they were infected with either gt1b (n=4) or gt6 (n=1). 
Among individuals not infected via IDU, the proportion of females in the cohort was 44.2%, 
18.4% higher than the overall female representation. In 20.3% of patients, the potential route 
of HCV transmission was either not recorded or unknown. Whilst in a number of cases, this 
has likely not been recorded or the patient may have omitted to acknowledge certain risky 
behaviours, for a large proportion of these individuals the route of HCV transmission will be 
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genuinely unknown. It is also worth noting that in patients where the risk factor is unknown, 
renal disorders are listed as a co-morbidity in 9% cases. This is almost double the frequency 
of renal disorders across the whole dataset (p = 0.08) and whilst infection from 
inappropriately sterilised dialysis machines is rare in the UK, it is possible that treatment 
abroad may have contributed to a number of these infections. It should however be noted that 
renal disease is relatively common among HCV positive patients, often associated with liver 
failure, cryoglobulinaemia and other co-morbidities (Perico et al., 2009) making it difficult to 
draw robust conclusions. The risk factor was listed as unknown for all individuals under the 
age of 20 in our cohort (n=3) and no individuals were listed as having contracted  HCV 
infection through either vertical transmission or via a blood transfusion, implying these are 
uncommon events within the UK. The average age of individuals whose risk factor for 
infection with HCV was IDU (n=373) was significantly younger (41.7 ± 8.2 yrs) than other 
individuals (n=139) in the study (45.1 ± 12.9 yrs) (p<0.01). When individuals with an 
unknown risk factor for HCV transmission were excluded from the analysis (n=96), the age 
of individuals was higher (47.1 ± 13.3 yrs) and the difference was still found to be significant 
(p<0.05). The range in ages was also less in those who had contracted HCV via IDU (22-71 
years) relative to other individuals in the cohort (7-82 years).  
Using either a Fibroscan result of ≥14 kPa (Coco et al., 2007) or ‘cirrhosis’ listed in the 
medical history of patients, 26.1% individuals in this study were found to have cirrhosis. 
Little difference was found in the rates of cirrhosis in females (21.4%) compared to males 
(27.7%) (p = 0.21). Patients with gt3 infections had higher rates of cirrhosis (30.2%) than 
those with gt1a infections (24.8%) (p = 0.06). Whilst neither of these findings are significant, 
there is a suggestion that gt3 infection may influence progression towards cirrhosis. Rates of 
fibrosis were also higher in male patients and in those with gt3 infections although Fibroscan 
has been shown to be less accurate at staging liver disease in patients with F1-F2 grading than 
it is at staging those with F3-F4 grading (Wong, 2013). Fibrotic staging by Fibroscan can also 
require adjusting in patients known to have an HIV-HCV co-infection and ≥12.5kPa is used 
as the cut-off for cirrhosis in these cases rather than >14kPa. Rates of known HIV-HCV co-
infections were low in our cohort (n=8) and no patients had Fibroscan results that required 
adjustment. Rates of cirrhosis were particularly high however with 4/8 HIV co-infected 
individuals having cirrhotic livers. This is consistent with previous studies showing that HIV 
co-infection with HCV leads to worse outcomes for patients (Sulkowski, 2001; Reiberger et 
al., 2010). 
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Within this cohort, 28.2% of patients had started treatment when the clinical data was 
collected, information on treatment status was not available for 7.5% patients and the 
remaining 64.3% patients had not been treated.  There was only a short duration however 
between collection of the samples and subsequent collection of the linked clinical data. 
Genotyping assays are usually only done at the point of initial diagnosis and many patients 
sampled here are therefore likely to be in the early stages of clinical referral.  This has likely 
contributed to the low treatment rates observed in this cohort. Of the patients that were 
treated, 10.9% had achieved SVR by the time of sampling and 50.2% of patients had not yet 
completed their therapy. Within the cohort, 30.9% individuals had failed to achieve an SVR, 
and this would be considered a good SVR rate for a cohort treated with PEG-IFN-α  (Manns, 
Wedemeyer and Cornberg, 2006). However, it is not known what this cohort was treated with 
and it is probable that a subset of patients within the cohort were treated with DAAs such as 
telaprevir or Boceprevir and this has contributed to the high SVR rate observed.  
  
3.3 Co-morbidities associated with hepatitis C infection 
Within the cohort, 18.7% of individuals infected with HCV had no other recorded factors 
affecting their health. Consequently, the majority of individuals infected with HCV have 
additional complications in addition to their HCV infection. Among the other 81.3% 
individuals with HCV, the average number of co-morbidities occurring per person was 1.69 
(± 1.38). Individuals most commonly had 1 single complication and the range was 0-7 co-
morbidities per person. Complications are likely to be a combination of pre-existing medical 
conditions and additional morbidities that have developed as a result of infection with HCV. 
The most common conditions recorded, affecting ≥10% of the population sampled were, 
psychiatric disorders (44.6%), trauma, stabbing or assaults (15%), excessive alcohol intake 
(30.8%), neurological disorders (10.3%) and gastrointestinal complications (14.6%). The 
high levels of psychiatric disorders, trauma, stabbings, assaults and excessive alcohol 
consumption are patterns of behaviour reported by many patients within this cohort and are 
suggestive of chaotic lifestyles, which are frequently associated with IDU. Conditions 
affecting the respiratory, circulatory, digestive and central nervous systems are all reported at 
rates >5% and rates of co-infecting pathogens including HIV (1.6%), HBV (0.8%) and TB 
(0.4%) were found to be low in this cohort.    
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Figure 3-5; Co-morbidities 
The frequencies of co-morbidities affecting HCV positive individuals in the cohort. 
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The rates of co-morbidities affecting the cohort were subsequently analysed after 
stratification by gender, liver disease severity, HCV genotype and age. Liver disease was 
defined as cirrhotic based on either a Fibroscan result of ≥14 kPa or ‘cirrhosis’ listed in the 
medical history of patients and patients without data recorded on liver disease were excluded 
from the analysis. Only individuals with either HCV gt1a or gt3 were included in the 
genotypic analysis and all other genotypes were excluded as numbers were low. For the age-
based stratification, 45 years of age was selected as a threshold for the analysis based on 
United Nations age classifications, representing the division between middle adulthood and 
older adulthood and the end of reproductive age in females (United Nations, 1982). 
Univariable and multivariable analyses were performed on the dataset and the results are 
presented in tables 3-1 and 3-2.  
In general, there was a good correlation between the univariate and multivariate analysis with 
the same co-morbidities being identified as significant in the majority of cases. In the 
univariate analysis, five significant differences were identified in the co-morbidities affecting 
male and female patients with HCV. Female patients were more likely to have psychiatric 
disorders, respiratory complications and, as would be expected, gynaecological conditions. 
Males were more likely to have been involved in a trauma, stabbing or assault and were 
almost twice as likely to have gastrointestinal complications. In the multivariable analysis, 
only three factors were found to be significant between male and female patients. Psychiatric 
disorders and gynaecological conditions were significantly more common among females 
infected with HCV whereas gastrointestinal conditions were more common in males with 
HCV. One male patient was identified with gynaecological complications and this is likely to 
be a mistake by the clinician filling out a sample collection form.  
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Table 3-1; Univariable analysis of the recorded co-morbidities 
Results of univariable analyses of the co-morbidities affecting individuals infected with HCV analysed by gender, severity of liver disease and HCV genotype. P values ≤0.05 
were considered statistically significant and have been highlighted. Values tending towards significance (between p>0.05 and p ≤0.1) have been underlined.  
 
 
Co-morbidity
M         
(n=438)
% F         (n=152) % p
Not 
Cirrhotic 
(n=379)
%
Cirrhotic 
(n=134)
% p Gt1a (n=249) % Gt3 (n=247) % p
No recorded co-morbidities 88 20.1 25 16.4 0.28 82 21.64 14 10.45 0.62 51 20.48 47 19.03 0.60
High alcohol consumption 134 30.6 42 27.6 0.96 100 26.39 58 43.28 <0.01 77 30.92 69 27.94 0.18
Obesity 10 2.3 6 3.9 0.16 9 2.37 6 4.48 0.49 9 3.61 5 2.02 0.37
Truama, stabbing or assault 73 16.7 17 11.2 0.02 57 15.04 20 14.93 0.35 37 14.86 41 16.60 0.49
Cancer 10 2.3 3 2.0 0.78 7 1.85 6 4.48 0.43 6 2.41 5 2.02 0.51
Cardiovascular disease or stroke 32 7.3 11 7.2 0.98 26 6.86 13 9.70 0.73 23 9.24 12 4.86 0.10
Diabetes 11 2.5 6 3.9 0.90 9 2.37 7 5.22 0.08 7 2.81 8 3.24 0.80
Dermatology 18 4.1 6 3.9 0.51 13 3.43 8 5.97 0.12 10 4.02 9 3.64 0.94
Endocrine 5 1.1 5 3.3 0.09 8 2.11 2 1.49 0.98 4 1.61 5 2.02 0.64
Gastrointestinal disorders 67 15.3 13 8.6 0.05 37 9.76 38 28.36 <0.01 28 11.24 34 13.77 0.24
Gynecological disorders 1 0.2 19 12.5 <0.01 12 3.17 3 2.24 0.49 6 2.41 5 2.02 0.89
Haematological 9 2.1 2 1.3 0.92 4 1.06 5 3.73 0.01 5 2.01 6 2.43 0.63
Hemochromatosis 4 0.9 2 1.3 0.53 3 0.79 3 2.24 0.19 3 1.20 1 0.40 0.36
Liver transplant 1 0.2 0 0.0 0.72 1 0.26 0 0.00 0.26 1 0.40 0 0.00 0.26
Neurological disorders 48 11.0 12 7.9 0.85 39 10.29 14 10.45 0.48 18 7.23 32 12.96 0.05
Orthopaedic 21 4.8 11 7.2 0.28 16 4.22 7 5.22 0.79 17 6.83 11 4.45 0.16
Psychiatric disorders 172 39.3 86 56.6 <0.01 164 43.27 65 48.51 0.31 108 43.37 110 44.53 0.90
Respiratory 35 8.0 21 13.8 0.17 35 9.23 13 9.70 0.75 22 8.84 20 8.10 0.90
Rheumatological 3 0.7 2 1.3 0.49 4 1.06 1 0.75 0.72 2 0.80 1 0.40 0.83
Urological or renal disorders 21 4.8 7 4.6 0.76 12 3.17 13 9.70 0.03 12 4.82 8 3.24 0.36
Vascular 24 5.5 11 7.2 0.74 17 4.49 14 10.45 0.01 12 4.82 20 8.10 0.14
HBV 4 0.9 0 0.0 0.59 2 0.53 2 1.49 0.43 3 1.20 1 0.40 0.49
HIV 8 1.8 1 0.7 0.55 4 1.06 4 2.99 0.49 5 2.01 2 0.81 0.37
TB 3 0.7 0 0.0 0.27 2 0.53 0 0.00 0.60 2 0.80 0 0.00 0.14
Gender Liver health Genotype
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Table 3-2; Multivariable analysis of the recorded co-morbidities  
Results of a multivariable analysis of the co-morbidities affecting individuals infected with HCV analysed by gender, severity of liver disease and HCV genotype. P values 
≤0.05 were considered statistically significant and have been highlighted. Values tending towards significance (between p>0.05 and p ≤0.1) have been underlined. 
Co-morbidity
M         
(n=438)
%
F         
(n=152)
% p
Not 
Cirrhotic 
(n=379)
%
Cirrhotic 
(n=134)
% p
Gt1a 
(n=249)
%
Gt3 
(n=247)
% p
No recorded co-morbidities 88 20.1 25 16.4 0.69 82 21.64 14 10.45 <0.01 51 20.48 47 19.03 0.97
High alcohol consumption 134 30.6 42 27.6 0.34 100 26.39 58 43.28 <0.01 77 30.92 69 27.94 0.31
Obesity 10 2.3 6 3.9 0.19 9 2.37 6 4.48 0.22 9 3.61 5 2.02 0.34
Truama, stabbing or assault 73 16.7 17 11.2 0.11 57 15.04 20 14.93 0.97 37 14.86 41 16.60 0.87
Cancer 10 2.3 3 2.0 0.84 7 1.85 6 4.48 0.10 6 2.41 5 2.02 0.69
Cardiovascular disease or stroke 32 7.3 11 7.2 0.99 26 6.86 13 9.70 0.29 23 9.24 12 4.86 0.10
Dermatology 18 4.1 6 3.9 0.85 13 3.43 8 5.97 0.20 10 4.02 9 3.64 0.53
Diabetes 11 2.5 6 3.9 0.60 9 2.37 7 5.22 0.10 7 2.81 8 3.24 0.66
Endocrine 5 1.1 5 3.3 0.07 8 2.11 2 1.49 0.66 4 1.61 5 2.02 0.80
Gastrointestinal disorders 67 15.3 13 8.6 0.04 37 9.76 38 28.36 <0.01 28 11.24 34 13.77 0.29
Gynecological disorders 1 0.2 19 12.5 <0.01 12 3.17 3 2.24 0.58 6 2.41 5 2.02 0.94
Haemachromatosis 4 0.9 2 1.3 0.66 3 0.79 3 2.24 0.18 3 1.20 1 0.40 0.29
Heamatological 9 2.1 2 1.3 0.32 4 1.06 5 3.73 0.04 5 2.01 6 2.43 0.67
Liver transplant 1 0.2 0 0.0 0.56 1 0.26 0 0.00 0.55 1 0.40 0 0.00 0.30
Neurological disorders 48 11.0 12 7.9 0.40 39 10.29 14 10.45 0.96 18 7.23 32 12.96 0.03
Orthopedic 21 4.8 11 7.2 0.30 16 4.22 7 5.22 0.63 17 6.83 11 4.45 0.90
Psychiatric disorders 172 39.3 86 56.6 <0.01 164 43.27 65 48.51 0.30 108 43.37 110 44.53 0.95
Respiratory 35 8.0 21 13.8 0.19 35 9.23 13 9.70 0.87 22 8.84 20 8.10 0.49
Rheumatological 3 0.7 2 1.3 0.46 4 1.06 1 0.75 0.75 2 0.80 1 0.40 0.53
Urological or renal disorders 21 4.8 7 4.6 0.52 12 3.17 13 9.70 <0.01 12 4.82 8 3.24 0.55
Vascular 24 5.5 11 7.2 0.65 17 4.49 14 10.45 0.01 12 4.82 20 8.10 0.12
HBV 4 0.9 0 0.0 0.24 2 0.53 2 1.49 0.28 3 1.20 1 0.40 0.29
HIV 8 1.8 1 0.7 0.40 4 1.06 4 2.99 0.12 5 2.01 2 0.81 0.22
TB 3 0.7 0 0.0 0.41 2 0.53 0 0.00 0.40 2 0.80 0 0.00 0.15
Gender Liver health Genotype
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Among individuals with cirrhotic livers the frequencies of excessive alcohol intake, 
gastrointestinal complications, urological and renal conditions, vascular complications and 
haematological disorders were all found to be more common in both the univariate and 
multivariate analysis. The majority of these complications may occur as a direct result of 
having poor liver function apart from excessive alcohol intake which is likely to be a 
causative association. The multivariate analysis additionally identified that having no other 
co-morbidities in addition to HCV infection was significantly more common in individuals 
without cirrhotic livers.  
After stratification by genotype, only a single co-morbidity was found to have a 
significantly different distribution between the two genotypes analysed within the cohort. 
Neurological disorders were found to be significantly more common in patients infected 
with gt3 (12.96%) in both the univariate and the multivariate analysis than in patients 
infected with gt1 (7.23%). The cohort was also analysed after stratification by age and this 
data is shown in the appendix, table 8-3. In the univariate analysis, older patients (≥45yrs 
old) were found to have significantly more complications associated with cardiovascular 
disease or stroke, cancer and gastrointestinal disorders. Additionally, in the multivariate 
analysis rheumatological and haematological disorders were also found to be significantly 
more common among individuals with HCV over the age of 45. Many of these disorders 
are more frequently observed in older populations and may not have occurred as a direct 
consequence of HCV infection.  
 
3.4 Liver disease and viral load 
HCV viral load is considered to be an important prognostic indicator and can be used as a 
marker of how effectively the virus is replicating within an infected individual. Studies 
have shown that patients with high viral loads (>800,000 IU/ml) may respond poorly to 
treatment (Zeuzem et al., 2006; Poordad et al., 2012). Significant drops in HCV viral load 
(>2logs) in the early phases of treatment are also considered indicative of a likely positive 
response to treatment and a high chance of achieving SVR (Trepo, 2000).  Viral load 
means and distributions were analysed in our cohort using t-tests for analyses of two 
groups and ANOVA when three or more groups were analysed. Data on viral load was 
available for all 1132 patients tested at the WSSVC during the period August 2013-March 
2014 (figure 3-6 A) and additional information on the severity of liver disease was 
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available for 590 patients form the Glasgow and Paisley postcode regions (figure 3-6 B and 
figure 3-7). All samples in the cohort had recently undergone genotyping at the WSSVC. 
Viral genotyping is usually preformed once, shortly after initial diagnosis and not 
commonly repeated. As a result, the majority of samples analysed subsequently should be 
pre-treatment viral loads. The results are shown in figure 3-6. Within this cohort, the 
average HCV viral load was 5.6 ± 1.0 log10 IU/ml. Viral loads in patients ranged from 1.39 
– 7.30 log10 IU/ml and the ranges were comparable for both genotype 1a and genotype 3 
patients. Subjects infected with genotype 3a had a similar average viral load (5.6 ± 0.9 
log10 IU/ml) to subjects infected with genotype 1a (5.7 ± 0.8 log10 IU/ml). After 
stratification by genotype, females infected with HCV had, on average, a lower viral load 
(5.4 ± 1.0 log10 IU/ml) than that of their male counterparts (5.7 ± 0.9 log10 IU/ml) (p=0.01). 
When analysed by both HCV genotype and gender, a marked pattern in viral load emerged. 
Females with genotype 3 infections were found to have significantly lower viral loads (5.2 
± 0.9 log10 IU/ml) than males infected with either genotype 1a (5.8 ± 0.9 log10 IU/ml) or 
genotype 3 (5.7 ± 0.8 log10 IU/ml) (p = 0.002 and 0.015 respectively).   
 
Figure 3-6; Viral load  
(A) Viral load distribution by gender and HCV genotype. (B) Viral load distribution by severity of liver 
disease 
The average viral load of individuals with cirrhotic livers was also found to be significantly 
lower (5.4 ± 0.9 log10 IU/ml) than the viral load of individuals who did not have cirrhotic 
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livers (5.7 ± 1.0 log10 IU/ml) (p = 0.009). This trend was explored further using patient 
data on the severity of liver disease and viral load. An analysis of viral load and Fibroscan 
results (available for 67.6% subjects, n=347) showed a poor correlation between liver 
disease and viral load within our cohort (figure 3-7, A). However a Chi-squared analysis, 
using a high viral load cut-off of ≥5.9 log10 (equates to 800,000 IU), indicated that high 
viral loads were significantly less common among those with cirrhotic livers (figure 3-7, 
B). These results suggest that the HCV virus is less capable of replicating in a diseased 
liver.  
 
Figure 3-7; Viral load and liver disease 
(A) Correlation between HCV viral load and Fibroscan results with a trend line and 95% confidence 
intervals. (B) Results of a univariable analysis of the frequency of high viral loads (VL ≥ 5.9 log10) in 
patients according to liver cirrhosis status.  
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3.5 Chapter conclusions 
The ages of individuals infected with HCV ranged from 7-82 and all genotypes, apart from 
gt5 and gt7, were identified within the population. Whilst this does suggest some diversity 
within the HCV-positive population in Scotland, the majority of HCV infections in the 
population sampled were either gt1a or gt3,  This is similar to the distribution of HCV 
genotypes observed across the UK although there appears to an increased prevalence of gt3 
infection in Scotland (Public Health England, 2015). Most of the cohort comprised 
individuals with a history of injecting drug use which  is known to have been to have been 
a significant problem in Scotland, particularly in Glasgow, during the 1990s (Frischer et 
al., 1993; Hay et al., 2009). Glasgow has been documented to have had one of the highest 
rates of HCV infection among IDUs in Western Europe and consequently rates of HCV 
infection remain high within the region (Hutchinson et al., 2002; Roy et al., 2007). 
Previous work has highlighted longer injecting careers, relatively high rates of 
incarceration and the delayed provision of needle exchange services in the region as 
contributing factors (Hutchinson et al., 2002; Parsons et al., 2002; Judd et al., 2005). 
Males comprised almost three-quarters of this cohort which is consistent with higher rates 
of IDU typically being reported among males (2, 11). Other routes of transmission were 
rare in the population and typically associated with individuals of an older age. This older 
age may reflect a number of transmissions via infected blood product transfusions prior to 
introduction of HCV testing. The rates of blood-transfusion associated HCV infection were 
fairly low in our cohort and the number of transmissions from an unknown source 
relatively high. The reasons for this particular finding were unclear, although they may be 
associated with the study focus on gt1a and gt3. HCV genotypes gt1a and gt3 are strongly 
associated with PWID and other genotypes, such as gt1b and gt2 are more frequently 
observed in older patients with have a history of blood transfusion (Smith et al., 1997). The 
low numbers of gt1b and gt2 infected patients in the study may therefore have contributed 
to the low numbers of blood-transfusion associated HCV infection observed.       
Rates of treatment among our cohort were not high and reasons for this are unclear. 
Among those that were treated, SVR rates were low but a majority of subjects were still 
undergoing treatment and the non-SVR rates suggested eventual outcomes were good for a 
cohort most likely treated with PEG-IFN-α  (Manns, Wedemeyer and Cornberg, 2006). 
Both male gender and cirrhosis have been previously correlated with poor responses to 
treatment (Veldt et al., 2007; Innes et al., 2012). In our cohort, rates of cirrhosis were 
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higher among those not achieving SVR (37.5%) than in those who did achieve SVR 
(16.7%). In the cohort, 81.25% of individuals not achieving SVR were male, also 
suggesting this may be a factor in the poor SVR rates observed as studies have previously 
identified higher SVR rates among women, particularly for gt3 viruses (Manns et al., 2001; 
Innes et al., 2012).  
Data from the cohort suggested that a number of factors may contribute to a more rapid 
progression of liver disease. Rates of cirrhosis were higher in both males and individuals 
with gt3 infections compared to females and those with gt1a infections. Being of male 
gender has been previously correlated with an increased risk of progression towards 
cirrhosis (Thierry Poynard, Bedossa and Opolon, 1997). Studies have suggested that this 
may be attributable to the protective effects of oestrogen (22) or findings that females are 
less likely to be heavy drinkers (23). There was some evidence of this in our cohort with 
higher rates of excessive alcohol intake observed in males (32.6%) relative to females 
(27.6%). Genotype 3 HCV infections have previously been correlated with a more rapid 
disease progression and increased rates of steatosis and fatty liver disease relative to other 
genotypes (Poynard, 2003; Probst et al., 2011). In vitro studies have implicated a probable 
role for the gt3 core protein in triggering increased triglyceride accumulation and 
upregulating fatty acid synthase activity (Abid et al., 2005; Jackel-Cram, Babiuk and Liu, 
2007). Prolonged accumulation of fatty acids within the liver occurs as a direct 
consequence and this has been associated with the upregulation of inflammatory markers 
and reduced metabolic competence (Anderson, 2008). The high numbers of both males and 
gt3 infections in our Scottish cohort suggest that increased understanding of these factors 
and their contribution to HCV progression will be important in improving patient outcomes 
in the region.         
High rates of comorbidities were observed within our cohort and this is consistent with 
previous studies indicating that rates of hospitalisation for any cause were significantly 
higher among HCV-positive individuals relative to the rest of the population within 
Scotland (McDonald et al., 2011). The range of additional comorbidities identified among 
individuals with HCV also indicates that whilst the virus primarily infects the liver, chronic 
HCV infection is a complex systemic disease, associated with numerous extra-hepatic 
manifestations. Our findings here point towards a complex mixture of factors that are 
likely linked to both the high rates of IDU in the population and occurring as a direct result 
of HCV infection. Previous studies have correlated high rates of substance abuse with 
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mental health (Regier et al., 1990; Crawford, Crome and Clancy, 2003). IDU and addiction 
are frequently recorded clinically as psychiatric disorders, and therefore observing high 
rates of psychiatric disorders in a population with high rates of transmission via IDU was 
an expected correlation. Infection with HCV has also been correlated with a marked 
cognitive impairment and depression in many patients and this may be contributing to the 
high rates of psychiatric disorders recorded (Forton et al., 2002; Hilsabeck et al., 2003). 
Gastrointestinal complications and neurological disorders have both been previously linked 
with HCV infection (Louie et al., 2012; McCarthy and Ortega, 2012). The central role of 
the liver in both digestion and metabolism means that liver dysfunction consequently 
causes numerous gastrointestinal disorders and it is therefore no surprise that high rates are 
observed in HCV-positive individuals. In terms of neurological disorders, numerous 
studies have linked HCV to poly- and mono-neuropathies, transverse myelopathy and 
cognitive impairment (Heckmann et al., 1999; McCarthy and Ortega, 2012). Withdrawal 
from alcohol is known to cause seizures (Delanty, Vaughan and French, 1998) and, in our 
cohort, 54.7% of patients with neurological disorders were also found to have a history of 
excessive alcohol consumption. This is significantly higher than the rate of alcoholism 
among individuals without neurological disorders which was 29.1% (p<0.01), suggesting 
that this is likely to be a contributing factor to the high levels of neurological disorders. In 
the cohort, 72.7% of subjects had a history of injecting drug use and the high rates of 
trauma, stabbing and assault observed may be associated. Individuals participating in 
injecting drug use are often described as having chaotic lifestyles (March, Oviedo-Joekes 
and Romero, 2006) and among those with a history of trauma, stabbing and assaults, it was 
more common to find a history of both injecting drug use (89.6%) and excessive alcohol 
consumption (61.3%).  
The univariable and multivariable analyses showed good correlation and highlighted a 
number of interesting trends within the data. They indicated a wide range of interacting 
factors making the management of patients with HCV a complex process involving 
multiple specialities. In both analyses, psychiatric disorders were significantly more 
common in women. It has previously been reported that higher rates of eating disorders, 
depression, anxiety disorders and mood disorders are often observed in female substance 
abusers (Brooner et al., 1997; Chander and McCaul, 2003).. Histories of gynaecological 
treatment and obstetric complications have been highlighted in the literature as triggers for 
the development of substance abuse in females (Busch, McBride and Benaventura, 1986). 
Rates of cirrhosis were higher among male patients than female patients and this may 
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partially explain the high rates of gastrointestinal disorders observed among males. The 
large number of comorbidities associated with cirrhosis highlights the central role of the 
liver in interactions with other organ systems. Successful treatment of HCV has been 
shown to significantly slow progression towards fibrosis and cirrhosis, alleviating many of 
the associated comorbidities (George et al., 2009; Pearlman and Traub, 2011; Hsu et al., 
2014). Ageing itself has been associated with a decline in liver function and an increased 
prevalence of co-morbidities (Schmucker, 2005). In this study, rates of both 
gastrointestinal and haematological disorders were increased in patients aged 45 and over, 
but without a HCV negative cohort for comparison, the significance of this finding is 
unclear. Rates of cirrhosis among older patients were also elevated at 34.6%. Similar 
findings have been recorded in previous studies (Gramenzi et al., 2010). With HCV-
infected individuals frequently remaining asymptomatic for more than a decade, many of 
these individuals are unaware of their infection status until they become ill and 
consequently, HCV is rapidly becoming a disease of the elderly. Treatment and disease 
management is often more complex in older patients and those over the age of 65 
frequently have contradictions for therapies (NIH Consensus Development Panel, 2002; 
Mindikoglu and Miller, 2009). These findings underscore the importance of early 
diagnosis and intervention whilst there is a strong chance of improving patient prognoses.    
The only significant differentially occurring co-morbidity identified between gt1a and gt3 
patients was neurological disorders which were more common in gt3 patients. Previous 
studies have linked the HCV core protein with neurotoxic effects associated with 
upregulation of extracellular signal-related kinase (ERK) via TLR-2 signalling (Paulino et 
al., 2011). The gt3a HCV core protein has been previously shown to induce distinct effects 
on fatty acid metabolism (Jackel-Cram, Babiuk and Liu, 2007) and therefore it is possible 
that it is also causing additional neurotoxic effects. The significance of this finding is 
unclear however as data was not available on the exact nature of the neurological disorders 
occurring amongst patients in the cohort. A range of neurological disorders are found in 
HCV–positive patients including neuropathies, encephalitis, myelitis and cognitive 
impairment (McCarthy and Ortega, 2012). Neurological disorders, such as 
encephalomyopathy, are also common amongst patients with histories of excessive alcohol 
consumption and cirrhosis, regardless of whether or not they are HCV positive. Both 
excessive alcohol consumption and cirrhosis were frequently reported in the patient 
histories within this cohort, making it difficult to infer if the neurological disorders 
recorded are specifically related to HCV. In order to further confirm the significance of 
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these findings, it would be useful to repeat the analysis after excluding patients with a 
history of excessive alcohol consumption and see if the increased rate of neurological 
disorders in gt3 patients is still evident.        
A number of significant trends were associated with viral load. The viral load was on 
average lower in females infected with HCV gt3 relative to other patient groups. Previous 
studies have also correlated gt1 infection with higher viral loads relative to gt3 and other 
genotypes (Berger et al., 1996; Soriano et al., 2008; Rong et al., 2012). Females with gt3a 
infections have the best response rates to IFN-based therapy (Manns et al., 2001; Innes et 
al., 2012),  and rates of spontaneous clearance are higher among females (Wiese et al., 
2000; Barrett et al., 2001; Micallef, Kaldor and Dore, 2006), suggesting that immune 
responses against HCV in females are more effective than in males. Studies have suggested 
these findings are linked to the protective effects of oestrogen although the exact 
mechanisms involved remain to be elucidated (Baden, Rockstroh and Buti, 2014). In this 
study, HCV viral load was additionally found to be significantly lower in individuals with 
cirrhotic livers. A study by Duvoux et al. (1999), documented similar findings, showing 
that lower viremias were detected in patient with more severe cirrhosis (Duvoux et al., 
1999), Intriguingly, the study also found that viral loads rapidly increased in patients after 
liver transplants, indicating that something in the cirrhotic liver was likely to be restricting 
viral replication (Duvoux et al., 1999). During liver cirrhosis, the hepatic environment 
becomes highly dysregulated, the number of hepatocytes is reduced and there is an 
accumulation of fibrotic tissue. It is possible that these factors are interfering with the 
viruses’ ability to replicate and transmit via cell-to-cell routes. 
Whilst this chapter has highlighted a number of interesting trends among the HCV-infected 
population in Scotland, there are a number of limitations to the study. Our study cohort 
was sampled from patients residing only in the Glasgow or Paisley postcode district areas 
and therefore, a number of the trends we identified may be region-specific and not as 
common elsewhere in the UK. Studies utilising wider geographical areas would be 
required in order to confirm or refute this issue.  Patient sampling was also through clinical 
contact, hence our study was likely biased towards older individuals with chronic HCV 
infection. The asymptomatic nature of acute HCV and chaotic lifestyles of many IDUs 
means that interaction with healthcare providers is often poor. Sampling throughout this 
study is, therefore, likely biased towards recovering PWID rather than active drug users 
and individuals sampled are likely to have more stable lifestyles as a result. Patients within 
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our cohort will also be more likely to engage with clinical services if they are in ill-health 
(HCV-related or otherwise) and this may have inadvertently increased the levels of co-
morbidities observed within our cohort. This study relied heavily on clinical coding and it 
is possible that differences in disease categorization and biases of medical professionals 
may have unduly influenced the data.  Human error, when recording and transferring data, 
may also have affected small numbers of samples, such as the male patient identified as 
having a gynaecological condition. As mentioned previously, it was not clear within our 
cohort whether or not the factors identified were a direct consequence of established HCV 
infection and this makes interpretation of the data complex. In order to understand the 
long-term trends associated with HCV infection, long-term prospective studies looking at 
larger cohorts are required. This study also lacked data on treatment outcomes. Given the 
recent increase in treatment options for HCV, an improved understanding of the most 
common co-morbidities associated with HCV and their impact on therapeutic adherence 
and outcomes would be of benefit to clinicians.   
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4 Chapter 4: Screening for mixed 
genotype infections  
 
4.1 Background introduction 
Whilst the recent licencing of DAA therapies for HCV has revolutionised treatment of the 
disease, many of the new drugs have been developed in the USA where gt1 is most 
prevalent infection, affecting just under 75% of the total infected population (Hajarizadeh, 
Grebely and Dore, 2013; Gower et al., 2014). As a result, many of the new treatments have 
been shown to have genotype-specific efficacies and are particularly adept at treating gt1 
infections (EASL, 2015). Trials examining treatment efficacy in other genotypes have not 
been widely funded and the ability of these drugs to treat other genotypes remains to be 
seen. Their impact on multiple genotype infections is also unclear and several studies have 
hypothesised that mixed genotype infections may only be partially resolved by use of 
inappropriate therapies (Loulergue, Mir and Sogni, 2012; McNaughton et al., 2014). 
Previous studies examining the prevalence of mixed genotype HCV infections also show 
significant differences in the testing methods used and the populations sampled, leading to 
wide variation in the prevalence findings (table 1-2). In the UK, a relatively small study 
looking specifically at PWID and haemophiliacs found prevalence rates of 9% and 19% 
respectively (Buckton et al., 2006). Given the wide availability of the new DAA drugs, it 
was felt that an improved awareness of mixed genotype prevalence within the UK may be 
useful for clinicians. In order to do this, a cohort of HCV –positive patients from across 
Scotland was curated in collaboration with the WSSVC and the BBV Edinburgh. Highly 
sensitive genotype-specific nested PCR assays were developed targeting the E1-E2 region 
and used to screen samples within the cohort infected with either gt1a or gt3 for the 
presence of a mixed genotype infections. As genotypes 1a and 3 contribute upwards of 
90% of the total HCV infections in the UK, it was decided to only to screen for these 
genotypes as by our estimations, this should enable us to identify around 90% of the mixed 
infections present in the population sampled.  
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Figure 4-1; Workflow for the mixed infection screening 
Workflow for the screening of mixed gt1a/gt3 infections and the subsequent testing performed on each 
sample 
 
After screening of the cohort, samples with secondary infecting genotypes detected had 
both the gt1a and gt3 strains sent away for Sanger sequencing to confirm the presence of 
multiple genotypes (figure 4-1). Samples then underwent qPCR with genotype-specific 
primer and probe sets to examine the proportions of the different genotypes present in 
these individuals. Samples with mixed genotype infections present also underwent 
amplicon-based deep sequencing on the Illumina MiSeq platform and this is discussed in 
chapter 5.      
4.2 Study controls  
4.2.1 Selection of controls 
H77 (accession number NC_004102) (Kolykhalov et al., 1997) was used as the basis for 
the design of the genotype 1a controls. Selection of genotype 3a control was challenging as 
there are multiple reference strains used throughout the field with the most commonly cited 
strains being NZL-1 (NC_009824.1), S52 (GU814263.1) and DE (X76918.1) (Sakamoto et 
al., 1994; Gottwein et al., 2010). HCV S52 was isolated from a chimpanzee infected with 
HCV and therefore deemed not suitable for use as a control. The NZL-1 and DE were both 
found to have numerous mismatches in the primer binding regions of early assay designs. 
Numerous sequences were considered with a patient-isolated strain from a 2005 UK study 
eventually being selected as the most appropriate control (accession number GQ356206) 
(Humphreys et al., 2009) (see appendix figure 8-1). Early assay designs were generated 
Samples collected 
Multiple genotypes 
detected 
Sanger sequencing 
(chapter 4) 
qPCR 
(chapter 4)  
Deep sequencing  
(chapter 5) 
No additional genotype 
detected Samples  screened with  
genotype specific nested PCR 
RNA extraction & cDNA 
synthesis 
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using mostly locally-circulating sequences and the assays were re-designed at a later date 
to ensure broad specificity across the gt3a sub-type.   
4.2.2 Production of controls 
A protocol was successfully established that enabled the amplification of synthetic dsDNA 
fragments and subsequent transcription of the fragments into RNA for use as assay 
controls (section 2.3.1). The E1-E2 transcripts were used as controls for the nested PCR 
assay and the NS5B transcripts were used for relative quantification with the qPCR assay 
developed in section 4.5. Using this protocol, transcript controls were successfully 
produced for gt1a and gt3a. Fidelity of the amplification and transcription protocol was 
checked with Sanger sequencing of the fragments. Fragment sizes, positions in the HCV 
genome and any observed changes are highlighted in figure 4-2.  
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Figure 4-2; Synthetic control transcripts and primer positions 
Illustration of the synthetic control fragments (not drawn to scale) designed to be used for the optimisation of mixed-genotype infection screening assays. Positions within the HCV 
genome are indicated and primers (A-K, table 2-5) are indicated by orange arrows (nested PCR) and green arrows (pan-genotypic primers). Discrepancies between the designed 
sequence and the control sequence after ligation into plasmids are highlighted with the resulting amino acid changes.  
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Sanger sequencing of the controls revealed single nucleotide substitutions in the gt1a 
NS5B control and both the E1-E2 and NS5B gt3 controls. All substitutions consisted of a 
G→A switch, resulting in non-synonymous changes to the encoded amino acid sequence 
and are indicated in figure 4-2. The substitutions are likely to have been introduced during 
the cloning and subsequent propagation of plasmids during production of the controls 
(section 2.31 for protocol).  None of the sequence changes were located in primer or probe 
binding sites and they were therefore assumed unlikely to influence assay sensit ivity. 
Agarose gel electrophoresis and spectrophotometer 260nm/280nm and 260nm/230nm 
ratios suggested the prepared transcripts were of good quality and suitable for the intended 
purpose. Transcripts were stored in RNA storage medium (Life Technologies) with 
0.1U/ml RNasin (Promega) rather than nuclease free water as it is thought to improve the 
recovery of the transcripts after freeze-thaw cycles. Recovery of the transcripts by cDNA 
synthesis and subsequent nested PCR assays showed that the RNA produced was of a good 
quality and that the transcripts could be detected at low dilutions. The E1-E2 transcripts 
could be detected at 1 (gt1a) and 10 (gt3a) copies/μl and the NS5B transcripts were 
detected at 10
2
 copies/μl (both genotypes) (figure 4-3).  
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Figure 4-3; Recovery of the control transcripts by PCR 
Results from PCR assays with serial dilutions of the gt1a and gt3a control fragments demonstrating the 
recovery of the E1-E2 and NS5B transcripts at low dilutions. The concentration of the dilutions tested is 
indicated along with the negative control (N). 1000bp (green arrow) and 500bp (orange arrow) are 
highlighted on the ladder.  
 
4.3 Assessment of assay sensitivity 
4.3.1 Probit analysis for E1-E2 assay controls 
Primers for the nested PCR assays were designed in regions where there were ≥4 divergent 
nucleotides between the genotypes in order to confer genotypic specificity for the assays. 
Both the gt1a and the gt3 assay were tested with high dilutions (≥104 copies/μl) of the 
alternative control and samples of the genotype they were not specific for and no 
amplification was detected, indicating the assays were functioning as intended and there 
was no cross-reactivity.  
Assay sensitivity was evaluated using known dilutions of the H77 and GB.2005 transcript 
controls. Dilutions of the gt1a and 3a E1-E2 transcript controls were tested in batches of 8 
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replicates with a negative control (figure 4). Results of the replicate testing were converted 
into probit values using Finney’s table and assay outcomes are given in table 4-1 (Finney, 
1952) (appendix table 8-3).   
 
Figure 4-4; PCR replicates for probit analysis  
A gel of 8 nested PCR replicates of the gt1a transcript at 7 copies/μl used to calculate probit value. Positive 
results are indicated  by + and negative results by -. A negative control (N) was used and 1000bp and 500bp 
are highlighted on the ladder. 
 
Graphs were constructed by plotting probit values against Log10 copies/ µl of the transcript 
concentrations tested to obtain equations (table 4-1 and figure 4-5). The value of X was 
then calculated when Y=6.28 for each graph, this value being equivalent to a 90% 
detection rate. Using these values, a 90% detection rate of 18 copies/reaction (9 copies/µl) 
for gt1a, and 42 copies/reaction (21 copies/µl) for gt3a was calculated for the assays.   
 
Table 4-1; Detection limits as determined by probit analysis 
The detection limit of screening assays as determined using H77 E1-E2 (gt1a) and GB.2005 (gt3a) 
control transcripts and values used for determination of 90% detection rate. Log10 copies/ µl and the 
Probit value were plotted on a graph (figure 4-5) to obtain the equation used to calculate the assay 
sensitivity (indicated in antilog column)  
Genotype copies/µl (n) 
Log10 copies/ 
µl 
+ (%) Probit value 
Probit value 
(90% 
detection) 
Log10 Antilog 
1a 
7 0.84 75 5.67 
6.28 0.94 8.63 
5 0.70 38 4.69 
3a 
10 1 63 5.33 
6.28 1.32 21.34 
6 0.78 37.5 4.69 
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Figure 4-5; Equations used for the probit analysis  
Graphs and corresponding equations used for the calculation of assay sensitivity. Values used for plotting the 
graph are indicated in table 4-1. Equations for x were solved for y = 6.28, equivalent to a 90% detection rate.  
 
 
4.3.2 Mock mixed infections 
Mock mixed infections were prepared using RNA prepared from the gt1a and gt3a 
transcript controls. Three different minor strain concentrations were tested in backgrounds 
of 10
6 copies/μl of the other genotype. Aliquots of unmixed minor strain transcripts were 
used as positive controls for the assays and H2O was used as a negative control. Results are 
shown in figure 4-6 and table 4-2. Minor strains were consistently detected at low limits in 
a high background of the other genotype. Sanger sequencing was used to confirm that 
positive results indicated the correct genotype had been detected and there were no issues 
with primer specificity.  
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Figure 4-6; The detection of mock mixed infections  
A gel of nested PCRs performed on mock mixed infections. The minor strain concentration (copies/μl) in 
each sample is shown on the gel. 104 copies/μl of the minor strain being tested for were used as positive 
controls (+). Negative controls (-) were run and 1000bp and 500bp are highlighted on the ladder. 
 
 
Table 4-2; Assay sensitivity for mock mixed infections 
Concentrations of major and minor strain spikes used to assess the specificity of the PCR assays 
Minor 
strain 
copies/µl 
Major 
strain 
copies/µl Detected 
Sequencing 
result 
1a 25 3a 106 Y gt1a 
1a 50 3a 106 Y gt1a 
1a 100 3a 106 Y gt1a 
3a 25 1a 106 Y gt3a 
3a 50 1a 106 Y gt3a 
3a 100 1a 106 Y gt3a 
 
4.4 Screening 
4.4.1 Prevalence of mixed gt1a/gt3 infections 
A cohort of samples to screen for mixed gt1a/gt3 infection was compiled over the period 
August 2013-march 2014, consisting of any gt1a or gt3 sample that had been recently 
genotyped at the WSSVC and had ≥140 μl serum available. A total of 205 gt1a samples 
and 206 gt3 samples were collected and merged with an additional cohort of 48 gt1a and 
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47 gt3 samples collected as part of an earlier study. In order to screen for mixed genotype 
infections, the gt1a samples were screened using the gt3-specific nested PCR assay 
(section 2.3.3.2) and the gt3 samples were likewise screened with the gt1a-specific assay. 
Samples were screened alongside positive and negative controls to ensure the assay was 
functioning as intended. Positive results were based on the detection of a PCR product of 
the expected size (figure 4-7) and all positive results were confirmed by Sanger sequencing 
and BLAST analysis and phylogenetic analysis of the returned sequence. The positive 
result for sample G3-51 is illustrated in figure 4-7. 
 
Figure 4-7; Illustration of a positive result in the mixed gt1a/gt3 screening 
Results from the screening of the gt3 samples G3-48 – G3-54 for evidence of gt1a infection. A positive result 
for G3-51 (blue arrow) was identified during the screening of these samples. The positive control (+) was 104 
copies/μl of the gt1a control and the negative control (N) was nuclease free water. The 1000bp and 500bp 
markers are highlighted on the ladder. 
 
A total of 506 patients, clinically diagnosed with either gt1a or gt3 infection, were screened 
for the presence of a mixed gt1a/gt3 infection. Overall, 20 samples were identified that had 
a mixed gt1a/gt3 infection, but two of these samples were found to be serial samples from 
the same patient, taken approximately a month apart. These serial samples (G3-80 and G3-
125) are discussed further in section 4.4.2 and both samples were taken forward for 
subsequent analysis (section 4.5 and chapter 5). In order to calculate the prevalence of 
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mixed gt1a/gt3 infection however, one sample was excluded on the basis that both G3-80 
and G3-125 came from the same patient. Therefore, mixed gt1a/gt3 infections were 
detected in 19 individuals, giving a prevalence rate of 3.8% within the population that was 
sampled (figure 4-8). Of 253 gt3 samples screened for the presence of a co-infecting gt1a 
strain, 17 samples were found to have an undiagnosed gt1a strain, giving a mixed genotype 
infection prevalence rate of 6.7% within genotype 3-infected individuals. In the 
corresponding screen for gt1a diagnosed individuals, 2 out of 253 individuals were found 
to have an undiagnosed gt3a strain, giving a prevalence rate of 0.8%. The difference in the 
prevalence rates of mixed infection between the two genotypes was found to be significant 
using a Chi-squared test (p<0.05). No evidence of mixed gt1a/gt3 infections was detected 
in any of the 20 samples identified in this study by the WSSVC.    
  
 
Figure 4-8; The prevalence of mixed genotype infections  
The numbers of gt1a and gt3 samples with mixed gt1a/gt3 infections detected within the cohort. Samples 
genotyped as gt1a are shown in red and gt3 samples are shown in blue. Samples testing positive for mixed 
gt1a/gt3 infections are shown in black. 
 
Mixed gt1a/gt3 HCV infections were detected in samples collected from individuals 
residing throughout Scotland (see figure 4-9, postcode data was not available for 7 
samples) suggesting that no region is particularly affected by mixed genotype HCV 
infections. The average age of individuals with mixed infections was 41 ± 9.22 years 
which is comparable to the overall average age of the cohort sampled (42.6 ± 9.8 years). 
Individuals with mixed infection ranged in age from 24-61 years of age. Information was 
available on the viral load for 10/19 samples, and the average viral load was 5.39 ± 1.03 
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log10. This was similar to the average viral load observed in the cohort 5.56 ± 1.0 log10 
IU/ml (p=0.66).  
 
Figure 4-9; Postcodes of patients with mixed genotype infections  
The locations of the individuals identified with mixed genotype HCV infections in Scotland. 
 
Due to the ethical approval for collection of clinical data being restricted to the Glasgow 
and Paisley postcode districts, linked clinical data was only available for 4 of our subjects 
with mixed genotype infections. There was a mix of both male (n=2) and female (n=2) 
patients in the cohort and 3/4 subjects had a history of IDU. Liver disease was common 
amongst the subjects with 2/4 individuals having cirrhotic livers and another 1/4 having a 
history of fibrosis in their medical records. There was a wide range of co-morbidities in the 
group with an average of 2.75 co-morbidities per subject (range 1-6). All 4 of the patients 
had a history of psychiatric disorders. Three of the 4 patients had received treatment for 
their HCV infection and of these, 1/3 had not yet completed treatment and the other 2/3 
had failed to achieve an SVR.    
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4.4.2 Phylogenetic analysis 
Gt1a and gt3a isolates from samples that had mixed gt1a/gt3 infection detected in them 
underwent Sanger sequencing. The returned sequences were analysed in a maximum-
likelihood phylogenetic tree (figures 4-10 and 4-11). Of the 19 samples identified with 
mixed genotype infections, paired gt1a and gt3a sequences were successfully obtained 
using Sanger sequencing for 19/19 samples.  
Analysis of the returned sequences confirmed the presence of both genotype 1a and 
genotype 3a viruses in 19/19 samples (figures 4-10 and 4-11). For both genotypes, the 
level of variation among the strains involved in the mixed infections suggested that there 
are no viral-specific features in the E1-E2 region that are associated with involvement in a 
mixed genotype infection. The gt1a region of the tree also displayed the characteristic 
bifurcating topology often seen in HCV gt1a trees. Samples involved in mixed infections 
were found within both branches of the gt1a tree, further highlighting the diverse nature of 
strains detected in this study.  
Table 4-3; Comparative pairwise distances of strains involved in single genotype and mixed genotype 
infections 
Overall average pairwise distances of E1-E2 sequences from 19 samples with mixed genotype infection 
compared with gt1a (n=48) and gt3a (n=47) sequences isolated from individuals negative in the mixed 
genotype infection screen. All samples were collected from patients in a similar geographical region.  
Sample group 
Pairwise 
distance gt1a 
Pairwise 
distance gt3a 
Mixed genotype infection 0.176 0.185 
Single genotype infection 0.182 0.174 
Both 0.184 0.177 
 
A pair-wise analysis of the sequences isolated from samples with mixed gt1a/gt3 infection 
was compared with sequences isolated from samples that were negative in the mixed 
infection screen (table 4-3).  Comparable variation was observed within both sample 
groups, supporting the assertion that there a diverse range of samples involved in the 
mixed genotype infections. Diversity among the mixed infection gt1a sequences may have 
been reduced by the close relationships observed between some of the gt1a sequences. 
Gt1a sequences from G45 and G30 were shown to be closely related and formed a 
polytomy within the tree. Sequences isolated from G3-166 and G3-176 also appeared to be 
closely related. The bootstrapping analysis also indicated that there was more support for 
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the cladal relationships within the gt1a tree than there was in the gt3a tree, where only a 
single node had bootstrap support of ≥70%, the level generally considered significant. It is 
possible that some of the close relationships observed within the gt1a tree have made 
cladal definition easier and therefore aided reconstruction of the sequence phylogeny.    
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Figure 4-10; Gt1a strains isolated from samples with mixed gt1a/gt3 infections   
Region of a maximum likelihood phylogenetic tree showing gt1a E1-E2 sequences (red) obtained from 
samples with mixed gt1a/gt3 HCV infections analysed alongside reference gt1a stains (black). Samples 
genotyped by the diagnostic laboratory as gt1a are indicated by ●. Paired gt3a sequences (blue) from the 
samples are shown in figure 4-11. Two distinct gt1a strains were isolated from sample G-30 and 
consequently, multiple sequences for the sample are analysed in the tree (see section 4.4.3).  Bootstrap 
support of >70% after 1000 replicates is indicated on the tree. 
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Figure 4-11; Gt3a strains isolated from samples with mixed gt1a/gt3 infections   
Region of a maximum likelihood phylogenetic tree showing gt3 E1-E2 sequences (blue) obtained from 
samples with mixed gt1a/gt3 HCV infections analysed alongside reference gt3 stains (black). Samples 
genotyped by the diagnostic laboratory as gt3 are indicated by ●. Paired gt1a sequences (red) from the 
samples are shown in figure 4-10. Bootstrap support of >70% after 1000 replicates is indicated on the tree. 
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By careful analysis of the cohort data, two of the samples with mixed genotypes (G3-80 
and G3-125) were identified as having originated from the same patient. Sample G3-80 
was collected in October 2013, when the patient was undergoing treatment and 
subsequently a further sample (G3-125) was collected a month later. The genotype 3a 
strains sequenced from this individual were identical but differences were observed in the 
gt1a sequences isolated. Specifically, the gt1a strain detected in G3-125 was very closely 
related to the gt1a control strain (H77) and this may suggest the sample was contaminated 
with the gt1a E1-E2 control sequence at some point. The sequences had 15.7% sequence 
heterogeneity at the nucleotide level. These samples are discussed further in section 4.5.2.  
 
4.4.3 Identification of multiple strains in a single sample 
 
Figure 4-12; Sample G-30  
Section of the chromatogram obtained from the Sanger sequencing of G-30 gt1a. 
 
One sample, G30, had a mixed genotype infection involving multiple minor strains. The 
sample was diagnosed by the clinical laboratory as gt3 infection and tested positive for 
gt1a during the initial screening process. Despite repeated attempts to sequence the gt1a 
strain, the chromatograms showed mixed nucleotide peaks suggesting that multiple strains 
may be present (figure 4-12). Clonal analysis was performed on the sample and two 
distinct gt1a strains were identified in the sample in addition to the gt3a strain that was 
diagnosed within the clinical laboratory (figure 4-13). The two gt1a strains were 
determined to be distinct strains on the basis that they demonstrated >10% sequence 
heterogeneity at the nucleotide level, with 16% of the nucleotides being discrepant 
between the two strains, and they grouped into phylogenetically distinct clades with strong 
bootstrap support. Five sequences from the cloning of the gt1a strains were successfully 
sequenced with a major gt1a strain comprising 80% of the gt1a population (n=4) identified 
and a second strain comprising the remaining 20% of the gt1a viral population also 
isolated. In figure 4-9, the gt1a strains display a bi-furcating topology and the two gt1a 
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strains detected in sample G-30 are present in separate clades, further evidencing the 
differences between these two strains. This bi-furcating topology of the gt1a subtype has 
been well-described in previous studies (Pickett, Striker and Lefkowitz, 2011; Luca et al., 
2015) and the two clades have been linked with differing prevalences of NS3 resistance 
associated variants, particularly Q80K (Luca et al., 2015).  
 
 
Figure 4-13; Gt3 and multiple gt1a strains detected within sample G-30  
A maximum likelihood tree showing a complex mixed infection detected in sample G-30. Gt1a sequences are 
highlighted in red and gt3a sequences in blue. Bootstrap support of >70% after 1000 replicates is indicated 
on the tree. 
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4.5 qPCR 
4.5.1 Optimisation of qPCR 
Genotype-specific qPCR assays targeting the NS5B region were developed in order to 
quantify the relative proportions of gt1a and gt3a present in samples that were found to 
have mixed genotype infections. Primer and probe designs for gt1a- and gt3a-specific 
qPCR assays (primers D-I, table 2-8)  were tested in triplicate with the H77 and the 
3a.GB.2005 NS5B transcripts respectively. Consistent detection at levels of 10-100 
copies/µl was obtained for both assays, suggesting they had excellent sensitivity (figure 4-
14). Negative controls (dH2O) were tested in triplicate alongside the samples and were not 
detected after 40 cycles of qPCR. The gt1a qPCR assay was tested in triplicate with 104, 
105 and 106 copies/μl of the gt3a control transcript and a selection of gt3 samples and vice 
versa for the gt3 qPCR assay with the gt1a control and a selection of gt1a samples. No 
amplification was shown for either assay with the control transcripts or the samples tested 
indicating that there was no cross-reactivity between the assays. Adjustments to cycling 
temperature, primer concentration and probe concentration yielded no further increases in 
sensitivity. 
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Figure 4-14; Sensitivity of the qPCR gt1a and gt3a qPCR assays  
Assay sensitivity as demonstrated by qPCR of the gt1a (H77) and the gt3a (gt3a.GB.2005) control 
transcripts. Negative controls (H2O) were run alongside the transcripts in triplicate and were not detected in 
all cases. 
 
4.5.2 Quantification of mixed infection samples 
Mixed genotype HCV positive samples were analysed with genotype-specific qPCR assays 
to determine the individual genotype viral loads (figure 4-15). Of the 20 samples tested, 15 
samples were positive by qPCR for both genotypes. Failures were attributed to sample 
degradation (n=3) or primer incompatibility (n=2).  The major genotype detected 
correlated with the clinical genotyping result of the patient in 14/15 cases. The exception 
was the sample G3-85 which was clinically listed as gt3 but qPCR analysis suggested that 
gt1a was the major viral genotype present within the sample. Diagnosis with gt3 using the 
in-house genotyping method at WSSVC was reliant on the absence of a result for a specific 
genotyping probe (see section 2.2.2 and appendix figure 8-3). This may suggest that the 
gt1a strain in G3-85 was not recognised by the gt1a-specific probe and, due to the lack of a 
specific result, the sample was misclassified as gt3.  
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In all gt1a-diagnosed individuals, the major genotype present was gt1a (n=2). Minor gt3a 
strains in these individuals were found to comprise 0.5 and 6.91% of the total viral load. In 
gt-3a diagnosed individuals, gt3a was the major genotype present in 92.3% of cases 
(12/13). Minor gt1a strains were found to comprise 0.01-21% of the total viral load. 
Taking into account the discrepancy with sample G3-85, where the clinically diagnosed 
genotype was the minor strain, gt3a was found to be the major strain present in 80% of 
cases (12/15). Whilst minor strains ranged from 0.02-20.63% of the total viral load, they 
were generally detected at low levels with two-thirds of samples having minor strains 
present at levels <1%.  
 
Figure 4-15; Relative proportions of gt1a and gt3a in samples with mixed gt1a/gt3 infections  
The proportions of gt1a and gt3 detected in samples with mixed genotype infections. Samples G3-80 and G3-
125 have been highlighted (*) as they were taken from the same patient, roughly a month apart. Samples 
E15, E49, G-30, G3-44 and G3-51 were not detected by the qPCR assays. See table 4-4 for further details. 
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The gt1a and gt3a viral loads detected by qPCR were added together to calculate the total 
viral load present in each sample analysed (table 4-4). Both the calculated and clinical 
laboratory viral load results were available for 10/20 samples with mixed genotype 
infections. For most of samples, the two results were comparable with 90% of samples 
(9/10) having the two results within 0.5 log10 of each other (table 4-4). This suggests that 
our qPCR assay has a similar sensitivity to the assays used within the clinical testing 
laboratory. Sample G-45 had a discordant result between labs with almost a 2 log10 lower 
calculated viral load than the clinical viral load, which was much higher. This sample was 
collected, processed and stored for around 18 months prior to this study and it is probable 
that repeated freeze-thaw cycles or suboptimal freezing conditions degraded some of the 
viral RNA in the sample, reducing the amount detectable by qPCR.   
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Table 4-4; Viral loads of samples with mixed genotype infections 
Genotype-specific viral loads detected in samples with mixed genotype infections and calculated viral loads. 
Estimated viral loads were converted from copies/µl to copies/ml using a calculation given in the appendix 
adjusting for sample concentration and dilution during extraction and subsequent testing (appendix figure 8-
2). Viral loads from the clinical laboratory have been given where available.  
Sample 
Calculated 
3a VL 
Calculated 
1a VL 
3a % 1a % 
Major 
genotype 
identified 
Calculated 
total VL 
(copies/µl) 
Calculated 
VL (log10 
copies/ml) 
Clinical VL 
(log10 
copies/ml) 
G3-44 NK NK NK NK NK NK NK 5.78 
G-30 NK NK NK NK NK NK NK NK 
E-15 NK NK NK NK NK NK NK 3.74 
G3-51 NK NK NK NK NK NK NK 6.06 
E-49 NK NK NK NK NK NK NK 5.89 
G-27 5878 9.44 99.84 0.16 3a 5887 5.70 5.50 
G45 393 10.65 97.36 2.64 3a 404 4.54 6.42 
G3-36 27064.79 13.2 99.95 0.05 3a 27078 6.37 NK 
G3-41 15479.58 19.75 99.87 0.13 3a 15499 6.12 NK 
G3-67 34198.66 71.75 99.79 0.21 3a 34270 6.47 6.07 
G3-73 1020.66 265.27 79.37 20.63 3a 1286 5.04 NK 
G3-80 30.24 3.55 89.49 10.51 3a 34 3.46 2.93 
G3-85 9.92 2781.49 0.36 99.64 3a 2791 5.38 NK 
G3-125 627.31 44.37 93.39 6.61 1a 672 4.76 4.96 
G3-128 20448.3 6.85 99.97 0.03 3a 20455 6.24 NK 
G3-155 12557.81 2.75 99.98 0.02 3a 12561 6.03 5.99 
G3-166 44811.86 13.25 99.97 0.03 3a 44825 6.58 NK 
G3-176 763.48 1.67 99.78 0.22 3a 765 4.82 4.62 
G1a-92 55.69 13363.43 0.42 99.58 1a 13419 6.06 6.37 
G1a-128 71.79 967.27 6.91 93.09 1a 1039 4.95 5.21 
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The linked samples G3-80 and G3-125 (representing serial samples from a single patient) 
both gave satisfactory qPCR results. The first sample collected from this individual 
(sample G3-80) had a viral load of 2.93 log10 and was collected whilst the patient was 
undergoing treatment for HCV. One month later (sample G3-125) the viral load had 
increased to 4.96 log10. This viral increase of >2 logs is considered an unfavourable 
prognostic indicator. Closer examination of the data indicated that the viral loads of both 
genotypes had increased between sampling with the gt3a viral load increasing (x20.7) by 
more than the gt1a viral load (x12.5). The proportion of gt1a present in the sample 
increased from 6.6% to 10.6% during the testing interval. A viral load increase of >2 logs 
whilst on treatment is unlikely and it is possible that the patient was taken off treatment 
during the sampling interval without an SVR being achieved. The final outcome of this 
individual’s treatment is unknown but the data suggests this patient did not respond 
favourably to treatment. 
qPCR results for sample G-30, which was highlighted previously in section 4.3.3 as having 
two gt1a and one gt3 strains were inconclusive and neither genotype within the sample was 
amplified by the qPCR assays. Sample G-30 was collected in 2011 during the initial phase 
of sample collection and the extracted RNA was approximately two years old at the time of 
testing. Of the mixed infection positive samples collected in this batch, 3/5 (G-30, E-15 
and E-49) yielded inconclusive PCR results. It is probable that the RNA extracted from the 
samples has degraded over time and it is unclear to what extent the presence of multiple 
gt1a strains has also contributed to the unsatisfactory qPCR result in the case of G-30.  
Although the majority of samples with mixed genotype HCV infections have minor strains 
contributing <1% of the total viral load, there was wide variation in the relative 
contributions of the minor strains. All samples in which the minor strain contributed >5% 
of the total viral load (n=4) had viral loads <10
4
 copies/ml (figure 4-16). The R
2
 value 
obtained from the correlation between viral load and minor strain proportion was 0.303 
suggesting that this is not a significant trend, perhaps because the numbers of samples that 
were analysed was low.  
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Figure 4-16; Viral load of the minor strains  
HCV viral load of the minor strains plotted against the estimated minor strain proportion with a fitted trend 
line and R2 value. Data taken from table 4-4.   
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4.6 Chapter conclusions 
In this study, a genotype-specific nested PCR-based approach targeting the E1-E2 region 
was developed and used to screen HCV positive samples for the presence of mixed 
gt1a/gt3 infections. This approach was selected as it was felt that it offered both a high 
degree of sensitivity and specificity. After screening 506 samples, 20 samples were 
identified as having mixed gt1a/gt3a infections. By targeting the relatively conserved 
regions flanking the hypervariable regions, a highly specific assay can be developed and 
subsequently used to detect secondary infecting genotypes in a high background of the 
primary genotype. A review of the previous literature found that screening of the E1-E2 
region had only been used for 5/27 of the previously published studies (Herring et al., 
2004; Li et al., 2008; Du et al., 2012; Grebely, Pham, et al., 2012; McNaughton et al., 
2014) on mixed genotype infection identified, with the 5’UTR and core regions being 
favoured (table 1-2). Whilst these regions can be used effectively for genotyping, diversity 
is restricted within them and they are not always suitable for sub-typing HCV strains 
(González et al., 2013). Samples identified as positive for mixed genotype infections were 
also tested with genotype-specific qPCR assays targeting the NS5B region of the virus. 
The nested PCR that was developed and tested in this chapter appeared to be more 
sensitive than the qPCR assay which yielded inconclusive results for 5/20 tested samples. 
Viral load results were available from the clinical testing laboratory for 4/5 of the samples 
with inconclusive qPCR results and, of these only 1/4 samples (E-15) had a low viral load 
(table 4). 3/5 samples with inconclusive results were also 12-18 months older than other 
tested samples and it is probable that repeated freeze-thawing of the samples or suboptimal 
freezer conditions has led to partial degradation of the viral RNA within the samples, 
reducing its quality. The qPCR assay consisted of 40 cycles of amplification, whereas the 
nested PCR had a first round of 40 cycles and an additional second round of 25 
amplification cycles. These additional 25 amplification cycles have likely increased the 
sensitivity of the nested PCR, enabling more consistent detection of very low viral load 
samples. Previous studies have suggested that the use of nested qPCR protocols, where an 
additional amplification step is incorporated prior to the quantitative amplification, can 
significantly improve sensitivity for the detection of low copy number pathogens 
(Takahashi and Nakayama, 2006; Tran et al., 2014).  It may be worthwhile investigating if 
such techniques are able to increase qPCR sensitivity for mixed genotype HCV infection.  
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Within the infected population that was screened, mixed HCV infections were detected in 
individuals at a prevalence of 3.8%. A significant difference between the number of gt1a- 
diagnosed individuals with mixed infection (0.8%) and the number of gt3a-diagnosed 
individuals (6.7%) was observed (p < 0.05). This overall rate is similar to the low 
prevalence rates observed in some previous studies (Blatt et al., 2000; Yun et al., 2008; 
Butt et al., 2011). The stringent focus on gt1a and gt3a and broad sampling approach used 
in this study may have contributed to the low prevalence rates observed. Genotypes 1a and 
3 are the most common genotypes within the UK and are estimated to be responsible for an 
estimated 90% of all HCV infections in the region (Public Health England, 2015). Given 
that mixed genotype infections involving a wide range of different genotypes have been 
documented (van de Laar et al., 2009; Grebely, Pham, et al., 2012), this suggests the true 
prevalence of mixed genotype infection may be up to 10% higher if all genotypes were 
analysed. Whilst higher rates of mixed infection in gt3a-diagnosed individuals were 
observed in the original pilot study (10.6%) (McNaughton et al., 2014), that study 
selectively sampled individuals with a known history of IDU. Individuals with a history of 
IDU are likely to have significantly higher exposure to multiple HCV challenges than other 
members of the population, therefore mixed genotype HCV infections are likely to be more 
common within this subset of individuals (Herring et al., 2004; Backmund et al., 2005; 
Pham et al., 2010). Recent studies have also indicated that there may be a higher 
prevalence of superinfection and re-infection occurring within populations of PWID than is 
currently estimated and that factors such as long testing intervals and rapid viral clearance 
are hindering their detection (Vickerman et al., 2012; Sacks-Davis et al., 2013, 2015). It 
has also been suggested that opiate use induces immune suppression and this may be 
additionally contributing to the higher rates of mixed genotype infections observed in 
populations of PWID (Peterson et al., 1987; Wang et al., 2002; Moore and Dusheiko, 
2005). Two of the twenty samples identified as mixed gt1a/gt3 positive in this study were 
also found to have been sampled from the same patient. It is therefore possible that other 
individuals may have contributed multiple samples to our original screening cohort without 
us being aware of it. If this is the case, it would again suggest that the prevalence rate of 
mixed genotype infection detected in this cohort is an underestimation of the true 
prevalence rate within the population.  
Previous studies based on data from England have estimated the average age at which 
injecting habits develop to be 21-22 years of age (De Angelis, Hickman and Yang, 2004; 
Mcnaughton et al., 2015). In Glasgow, the average injecting career length has been 
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estimated to be 8 years (Sutton et al., 2012). Given that the average age of subjects within 
our cohort is 42.6 ± 9.8  years, this suggests a large proportion of our cohort are no longer 
actively injecting drugs at the time of sampling and therefore likely to have chronic HCV 
infections. Many multiple genotype infections have been shown to be transitory in nature 
and it is not clear how common chronic infection is with multiple genotypes (Osburn et al., 
2010; Grebely, Prins, et al., 2012). Diagnostically, it is difficult to differentiate between 
acute and chronic infection and it is therefore unclear if the mixed infections detected 
within this cohort are transitory or if both genotypes have established a chronic infection. 
The average age of individuals with mixed genotype infection detected was 41 ± 9.22 
years, and like the overall cohort are unlikely to be actively injecting drugs implying that at 
least a proportion of them are likely to be infected with chronic multiple infections. Linked 
clinical data from the cohort indicated that 28.2% of individuals in our study had also been 
treated at some point, with around 80% of those either not completing or not finishing 
treatment. It is possible that in a number of cases, whilst an SVR was not achieved, the 
treatment has cleared one or more of multiple infecting genotypes in individuals with 
mixed infections, again reducing the prevalence observed within the study (McNaughton et 
al., 2014; Abdelrahman et al., 2015).  
The low prevalence rate observed in this study may also be associated with the size of our 
study. An analysis of previous studies on mixed genotype infection prevalence found that 
studies with larger numbers of samples tended to find lower prevalence rates of mixed 
infection, with all studies sampling over 250 individuals reporting a prevalence of <10% 
(n=5) (figure 4-17). As our study was one of the larger studies on mixed infection rates and 
our sampling method was not selective for a particular patient group, such as groups with 
high exposure rates, the relatively low prevalence rates observed in our study are in 
keeping with previous research. A review of previous studies also indicated that the 
method used to detect mixed genotype infections could also be a limiting factor in the 
detection of mixed genotype HCV infections. In general, higher rates of mixed infection 
were reported in studies using PCR and lower rates in studies using LiPA, RFLP and HMA 
based methods (table 1-2). This indicates that the testing approach can have a considerable 
impact of the results of the study and that PCR-based methods may be superior for the 
detection of mixed genotype infections.   
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Figure 4-17; Mixed HCV infection prevalence studies 
The number of patients sampled per study correlated with the prevalence rate of mixed infections detected by 
the study (data from table 1-2). 
The results from this chapter suggest that whilst levels of mixed infection are low within 
the sampled population, they disproportionately affect individuals clinically diagnosed 
with gt3 infections. This disparity was identified in the pilot study for the project 
(McNaughton et al., 2014) and has remained evident throughout the screening of the larger 
cohort. The reasons for this difference are likely complex and possible contributing factors 
may be viral-specific and host immunology. Work by Robinson et al. (2015), demonstrated 
that gt1a and gt3a viruses induce distinct transcriptome profiles during infection and this 
may be a contributing factor (Robinson et al., 2015). Evidence in the literature also 
suggests that gt1 HCV infections can be harder to resolve with interferon-based treatments 
than other HCV genotypes (Zein, 2000; Harris et al., 2007). It is possible that gt1a 
infections may be able to establish in the background of a gt3 infection but that gt3 viruses 
struggle to establish in the corresponding situation. Host factors may also be contributing 
to the differences observed. The favourable CC single nucleotide polymorphism at 
rs12979860 (rather than TT or C/T) in IL-28B has been shown to have strong associations 
with improved treatment responses and spontaneous clearance (Ge et al., 2009; Thomas et 
al., 2009; di Iulio et al., 2011; de Castellarnau et al., 2012). It would be interesting to 
investigate if the frequency of these favourable genotypes is lower in individuals with 
mixed HCV infections. HCV infection is frequently associated with poor cross-protective 
immunity (Vickerman et al., 2012) and infection with one genotype rarely confers 
protection against infection with other genotypes. Other studies have however conversely 
indicated that the rate of infection among PWID who test anti-HCV positive is lower than 
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for those who are previously unexposed, suggesting there may be some form of partial 
immunity (Grebely et al., 2006; Dore and Micallef, 2007). It may be the case that gt1 
viruses are able to confer a broader cross-protective immunity than other genotypes 
although this subject is not widely studied. Without long-term follow-up and sequential 
sampling of individuals with mixed genotype HCV infections, it is difficult to know what 
may be responsible for this difference.  
The use of synthetic RNA transcripts based on prototype HCV sequences has proven to be 
a useful tool in assay development (McLeish et al., 2012), enabling a standardised method 
of assay characterisation throughout this project. Using probit analysis, the gt3a E1-E2 
assay sensitivity was less (21 copies/µl) than the gt1a assay (9 copies/µl). Whilst this may 
be linked to true variation in assay sensitivity, the larger difference between the lower and 
upper dilutions tested in the gt3a assay may also have affected the result through the 
creation of greater statistical uncertainty during probit analysis leading to a lower 
calculated sensitivity. It should be noted also that a greater number of gt1a minor 
infections were identified in this study (section 4.4.1), possibly suggesting that the gt3 
assay was less sensitive to very low viral load minor infections. However, no difference in 
assay specificity or sensitivity between the genotypes was demonstrated in the detection of 
the E1-E2 controls in mock mixed genotype samples, and the qPCR result for the gt3 
minor strain in sample G3-85 indicated that the gt3 assays were capable of detecting minor 
gt3 strains with very low viral loads. Many genotyping assays in use in the clinic currently 
rely on the use of multiplex PCRs and often the result is interpreted from a panel of results. 
The clinical laboratory where these samples were collected from used an in-house qPCR-
based approach with multiple probes to ascertain viral genotype at the time of sampling 
(appendix figure 8-3 for details). Whilst gt1 diagnosis was reliant upon a specific result, 
gt3 was diagnosed based on a positive viral load result coupled with  the absence of a 
specific typing probe result (appendix figure 8-3). Multiplex qPCR methods such as these 
are incapable of resolving mixed genotype infections and the widespread use of these 
methods will therefore underestimate the prevalence of mixed genotype infections in 
general.  
HCV viral loads in individuals with chronic infections are known to fluctuate over the 
course of infection (Halfon et al., 1998). Previous work analysing sequential samples from 
individuals with mixed genotype infections has documented large fluctuations (>1 log) in 
the viral load of infecting genotypes in the subjects studied (Pham et al., 2010; Grebely, 
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Pham, et al., 2012). For the majority of our cohort, we only have a single sample from each 
subject, providing us with a snapshot view of a single time point in the course of the 
infection. For the single subject where we had two samples collected a month apart, large 
increases in the viral load of both genotypes were observed over the course of a month, 
despite the subject undergoing treatment at the time. It is probable that both strains within 
this sample have increased their replicative rate after the evolutionary bottleneck effect of 
developing resistance to treatment and the changes observed in this sample are therefore 
unlikely to be associated with natural fluctuation in viral load. Previous studies have 
suggested that the competition between the viral strains in mixed infections is rapid and 
that in most cases the strain with the highest viral load becomes dominant (Laskus et al., 
2001; Pham et al., 2010; Ramirez et al., 2010). This suggests that either the viral load of 
one virus is higher as it is able to replicate at a faster rate than the minority strain or that 
the minority strain is constrained by a stronger immune response (Freeman et al., 2003; 
Alizon and van Baalen, 2008). Studies have also indicated that in the case of HCV 
superinfection, the primary strain generally remains persistent and that the super-infecting 
strain is transitory in nature (Pham et al., 2010). Currently, without more patient history, 
there is no method available to differentiate between coinfection and superinfection and it 
is therefore unclear in which order the viral strains infecting our subjects were contracted. 
In the case of super-infecting HCV strains, evidence has also suggested that HCV is 
capable of establishing extra-hepatic sites of replication and it has been posited that 
minority strains may survive by being better adapted at replication within these extra-
hepatic sites (Blackard, Kemmer and Sherman, 2006). It would be interesting to compare 
the population structure in sera, PBMCs and liver biopsy samples from individuals with 
mixed HCV infections to look for evidence of this.  
The majority of minor strains identified in this study were found to contribute less than 
<1% of the total viral load present in individuals with mixed infections. Whilst this is 
considered relatively low, our understanding of the significance of these infections and the 
implications for the patients remains poor. In particular, the outcome of treatment, the 
progression of disease and monitoring the proportions of the genotypes present within 
these individuals over time requires further research. The collection of linked clinical data 
associated with the mixed genotype infections in this study was restricted by the large 
number of health boards from which the samples originated and a lack of ethical approval 
for samples outside of the Glasgow and Paisley postcode districts. Subsequently, there was 
not enough data to draw meaningful conclusions about the clinical impact of mixed 
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genotype HCV infections. Data was available on 4/20 samples though and analysis did 
suggest that liver disease was more common among these individuals relative to mono-
infected individuals and that their responses to treatment were not effective. Anecdotal 
evidence from one individual undergoing treatment (samples G3-80 and G3-125) also 
supported concerns that treatment of mixed genotype infections may be difficult. A recent 
study has indicated that mixed genotype HCV infections may be difficult to treat with 
PEG-IFN-α and ribavirin, particularly in individuals also co-infected with HIV (Bagaglio 
et al., 2015).There have been suggestions in the literature that having mixed HCV 
infections can lead to increased liver damage relative to individuals infected with a single 
genotype (Kao et al., 1994; Widell et al., 1995). Numerous DAAs targeting HCV have 
been noted to have genotype-specific efficacies; Telaprevir and Boceprevir in particular 
have reduced efficacy against gt3 infections (Garber, 2011; EASL, 2015). Additionally 
whilst PEG-IFN-α and ribavirin are not genotype-specific, treatment response rates are 
significantly better for gt2 and gt3 patients than for other genotypes (Zeuzem et al., 2009) . 
It is possible that in mixed infections, undetected minority variant naturally drug-resistant 
genotypes will expand to replace the successfully treated majority variant genotypes, 
presenting in many cases as non- or partial responses to treatment (McNaughton et al., 
2014). In addition to following up the mixed infection cohort, it may be of interest to re-
genotype a number of gt3 patients who have failed treatment with either standard of care or 
triple therapy to examine the frequency of genotype switching within this patient group. If 
genotype switching is observed, it may suggest the presence of previously undiagnosed 
mixed HCV infections. Increased efforts should be made to identify patients with mixed 
genotype infections prior to the initiation of treatment to enable assessment of the efficacy 
of the new DAAs on mixed infections. 
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5 Chapter 5: Analysis of mixed 
infection cohort by deep 
sequencing 
 
5.1 Background introduction 
 
New sequencing technologies have made the rapid sequencing of large numbers of 
sequences affordable, offering the potential to enhance current clinical diagnostic practises 
across numerous fields. Potential advantages in virology include the ability to rapidly 
sequence entire viral genomes, even when the pathogen is not known, and the ability to 
sequence to a great depth which may have applications in the detection of low-level 
resistance variants and mixed genotype infections. The majority of HCV genotyping assays 
used currently in the clinic only detect the major genotype present and minor sub-groups 
including co-infecting genotypes and pre-existing DAA-resistant strains are frequently not 
identified. Data from previous studies looking at drug-resistant minority variants (Fonseca-
Coronado et al., 2012; Abdelrahman et al., 2015) and data from chapter  4, looking at 
mixed genotype infections, indicated that many co-infecting and minority variant strains 
can be present in very low amounts (frequently <1% of the total viral load) and therefore 
sequencing to a great depth may be advantageous when trying to detect them. In addition, 
many commercially available assays for HCV only facilitate genotypic identification and 
supplementary sequencing assays may be required to differentiate viral sub-types. The use 
of deep sequencing technologies within a diagnostic context offers the opportunity to 
exploit sequence-based genotyping which, as well as being cheaper and faster than 
currently available alternatives, are also far more discriminatory for the sub-typing of HCV 
strains. Many clinical decisions are currently made on genotypic-based information and 
increased information on viral sub-type offers the opportunity to further stratify patient 
populations, which given the large numbers of new DAAs available, will provide more 
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accurate information on the treatment specificity of many therapies, as well as providing an 
improved prognostic and epidemiological understanding of HCV.  
 
In this chapter the objective was to evaluate the potential application of deep sequencing 
for the detection of mixed genotype HCV infections by developing a HCV genotyping 
assay compatible with the Illumina MiSeq deep sequencing platform. In order to 
accomplish this, an amplicon-based approach was selected as it was thought likely to be 
more sensitive than enrichment or metagenomics-based methods, especially given that 
two-thirds of the mixed infections identified had minor strains that contributed <1% of the 
total viral load (section 4.5.2). Consequently, two pan-genotypic PCR-based assays were 
developed targeting the E1-E2 and NS5B regions of the HCV genome. The E1-E2 region 
was selected in order to enable a direct comparison with the sequences isolated using the 
nested PCR assay developed in chapter four. Considerable intra-host diversity is also 
observed within the E1-E2 region (section 1.6), making it a suitable region for diversity 
comparisons. The NS5B region, and particularly the Okamoto region which is targeted by 
our assay, was selected as phylogenetic analysis of the region has been shown to reliably 
produce topologies comparable to those of the whole genome and polyprotein (Hraber et 
al., 2006). This makes the region highly discriminatory for the sub-typing of HCV strains 
and therefore the most appropriate region for accurate typing analyses. These assays were 
used to amplify and sequence samples identified as having mixed genotype infections in 
the initial mixed genotype infection screen.  Controls for fidelity, contamination and 
multiple genotype detection as well as gt1a and gt3 samples with single genotype 
infections were assessed concurrently with the samples. Results from the deep sequencing 
analysis were compared with the nested PCR and qPCR methods developed in chapter four 
and the diagnostic specificity and sensitivity of the assays evaluated. Additionally, an 
analysis of the inter-genotypic diversity present within the samples was also undertaken.  
 
5.1.1 Assessment of assay sensitivity 
 
Two pan-genotypic assays were developed targeting the E1-E2 and the NS5B regions of 
the virus. The E1-E2 amplicon covered 1296-1812 (516 bp) and the NS5B amplicon 8257-
8636 (379 bp) (table 2-5). The sensitivity of the primers was calculated by performing 
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multiple PCR replicates of the control transcripts at suitable dilutions and implementing 
probit analysis. Results are given in table 5-1 and figure 5-1. Despite the high degeneracy 
of the pan-genotypic primers, initial tests on both the control transcripts and cDNA 
extracted from the serum of HCV positive patients demonstrated they were highly specific 
and only amplified the regions of interest. TapeStation analysis, which measures the length 
of DNA applicons, demonstrated that the generated amplicons were of a consistent size, 
515-530bp for the E1-E2 amplicon and approximately 360-385bp for the NS5B amplicon. 
The ranges in sizes were due to technical variation inherent on individual TapeStation runs 
and the presence of insertions/deletions in the nucleic acid sequences of the individual 
virus strains that were analysed.   
 
  
Table 5-1; Probit analysis of pan-genotypic assay sensitivities  
The concentration of transcripts, detection rates and probit values derived from the results used to calculate 
the assay sensitivity for the pan-genotypic E1-E2 and NS5B PCR assays. Both the E1-E2 and NS5B assays 
were assessed using the gt1a and gt3a control transcripts produced in chapter 4 (section 4.2). 
Genotype Assay copies/µl 
Log10 
copies/ µl 
Positive* 
(%) 
Probit value 
Assay 
sensitivity 
(copies/µl) 
1a 
E1-E2 
1 0 83 5.95 
2.2 
0.1 -1 50 5.00 
NS5B 
25 1.40 83 5.95 
22.1 
7 0.85 50 5.00 
3a 
E1-E2 
15 1.18 67 5.44 
38.0 
10 1 33 4.56 
NS5B 
10 1 67 5.44 
14.1 
7 0.85 33 4.56 
*Positive indicates the percentage of PCR replicates that were positive 
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Figure 5-1; Equations used for the probit analysis 
Graphs and corresponding equations used for the calculation of assay sensitivity in table 5-1. Equations for x 
were solved for y = 6.28, equivalent to a 90% detection rate. 
 
Calculated using the equations generated from the probit analysis, the sensitivity of the E1-
E2 assay was determined to be 2.2 copies/µl for gt1a samples and 38.0 copies/µl for gt3a 
samples. The sensitivity of the NS5B assay was calculated to be 22.1 copies/µl for gt1a 
and  14.1 copies/µl for gt3 samples. This suggested that assay sensitivity may be affected 
by inter-genotypic variation.   
Trial runs performing library preparations on the E1-E2 and NS5B amplicons in an 
identical manner to the planned protocol were performed and demonstrated that the 
methodology worked in principle (see figure 5-2). TapeStation analysis on both the E1-E2 
and the NS5B amplicons demonstrated that after library preparation the amplicons 
increased in size by approximately 120bp. This increase in size is consistent with the 
expected increase in size after successful ligation of adapters (8bp) and indexing tags 
(~50bp) onto the 5’ and 3’ ends of the amplicons.   
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Figure 5-2; Trial library preparation of amplicons 
TapeStation analysis of E1-E2 and NS5B amplicons prior to and after undergoing library preparation for 
deep sequencing. The amplicons were generated from randomly selected gt1a samples that were negative for 
mixed genotype infection during the screening process. Upper (1,500bp) and lower (25bp) peaks are also 
indicated.  
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5.1.2 Assessment of pan-genotypic specificity 
The pan-genotypic primers were tested against a panel of different HCV genotypes 
comprising of gt1a, gt1b, gt2, gt3, gt4 and gt6 samples that was curated from an in-house 
sample collection. The range of genotypes included in the panel was considered 
representative of the genotypic diversity present in the UK currently (Public Health 
England, 2015). Samples underwent two rounds of PCR (40 cycles plus 25 cycles) using 
the same primer pairs for both rounds of amplification. Positive results were sent away for 
Sanger sequencing. Returned sequences were genotyped using phylogenetic analysis with 
a selection of HCV reference sequences available from the Los Alamos HCV Database 
(Kuiken et al., 2004). Results from the testing are shown in table 5-2 and figure 5-3.   
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Figure 5-3; Genotyping by phylogenetic clustering 
Mid-point rooted maximum likelihood trees of 64 E1-E2 and 64 NS5B sequences (coloured text, red – gt1a, 
orange – gt1b, green – gt2, blue – gt3, yellow – gt4, black – gt5, purple – gt6 and grey – gt7) amplified using 
the respective pan-genotypic primers and obtained using Sanger sequencing.. Returned sequences were 
analysed alongside HCV reference strains (black text) that were used to define the genotype of the isolates. 
Bootstrap support of >70% after 1000 replicates is indicated on each tree. 
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Table 5-2; Results of the genotyping panel 
Results of the genotyping panel used to assess the breadth of the pan-genotypic E1-E2 and NS5B primers. 
The reported genotype from the diagnostic laboratory is given along with the typing results for the E1-E2 and 
NS5B amplicons generated with the primer pairs. The number of each sub-type tested is also indicated.  
HCV 
genotype 
Reported 
genotype 
Number 
tested 
E1-E2 
typing 
results 
Number 
amplified  
NS5B 
typing 
results 
Number 
amplified  
1 
1a 20 1a 20 1a 20 
1b 8 1b 8 1b 8 
1c 1 1g 1 1g 1 
2 2 9 
2a 5 2a 5 
2b 4 2b 4 
3 3 20 3a 20 3a 20 
4 4 5 
4a 3 4a 3 
4d 2 4d 2 
6 6 1 6a 1 6a 1 
 
 
Both the E1-E2 and the NS5B primer sets were able to amplify 64/64 of the samples 
included in the test panel, giving products of the expected size in each case. The products 
were sent away for Sanger sequencing and sequences were returned in 64/64 samples for 
both the E1-E2 and NS5B assay. After analysing the sequences in maximum likelihood 
phylogenetic trees alongside HCV genotype reference sequences, 63/64 sequences for both 
the E1-E2 and the NS5B sequences gave identical genotyping results to the clinical 
genotyping reports. One sample was reported as a gt1c sample but phylogenetic analysis of 
both the E1-E2 and NS5B regions indicated it is was actually a gt1g strain (figures 5-3 and 
5-4).   A useful feature of the method developed here is that sequencing of these regions 
enables sub-typing of the HCV strains in the panel. This sub-typing result provides more 
information than current clinical testing protocols which only involve sub-typing of the gt1 
strains. Whilst the tree topology for the E1-E2 and NS5B trees was not identical, 64/64 
samples were successfully sub-typed and the results for the E1-E2 and NS5B fragments 
were identical for every sample. There was a discrepancy between the two trees in 
resolving the phylogenetic relationships relating to the gt6 E1-E2 sequences. In the E1-E2 
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tree, the gt6 sequences bifurcated into two distinct clades whereas, in the NS5B 
phylogenetic tree, they form a single group. There is known to be significant diversity 
within the HCV gt6 viruses and there are currently 24 subtypes assigned within the 
genotype (Smith et al., 2014). Additionally, the E1-E2 fragment contains two 
hypervariable regions within it and is the most variable region of the viral genome. It is 
likely that the inherent high level of diversity within this region has complicated the 
resolving of the tree topology. Previous studies have indicated that the relationships 
represented by the NS5B amplicon, which contains the Okamoto region,  are more likely to 
mirror the true viral phylogeny (Hraber et al., 2006).  
The single sample not matching with the original typing results was recorded as a gt1c 
sample by the diagnostic laboratory. Our data, from the sequencing of both the E1-E2 and 
the NS5B regions, suggests that it was in fact a gt1g sample and had been mistyped (figure 
5-4). Both gt1c and gt1g samples are rare in the UK, and diagnosis of this genotype is 
likely to have required sequence analysis. The mistyping detected here may suggest that 
the region currently being sequenced in cases such as this by the diagnostic laboratory is 
not optimal.   
 
Figure 5-4; Sequence analysis of the ‘gt1c’ strain 
Excerpts from an E1-E2 and an NS5B alignment of "gt1c" strain (grey) alongside two gt1c reference 
sequences (red) and one gt1g reference sequence (dark red) indicating re-classification as a gt1g sequence. 
 
 
  
141 
 
5.2 Deep sequencing  
 
In the following sections, two runs performed on the Illumina MiSeq platform are 
analysed. All samples in the runs underwent identical sample preparation prior to 
sequencing. The samples were divided between the two runs on the basis of the presumed 
major genotype present to reduce the likelihood of cross-contamination. The gt3a run (run 
1) consisted of 17 samples with mixed genotype infection, 20 samples identified as gt3a 
mono-infected, fidelity controls and mock mixed infection controls. The gt1a run (run 2) 
consisted of 3 samples with mixed genotype infection, 20 samples identified as gt1a mono-
infected, fidelity controls and mock mixed infection controls. Both runs included a serum 
negative control from an individual not infected with HCV. The total number of reads 
generated per sample and the number of reads mapping to specific HCV genotypes in each 
sample are listed in tables 5-3 and 5-4.  
 
5.2.1 Evaluation of methodology 
 
Controls for assay fidelity, multiple genotype detection and contamination were prepared 
and run alongside the samples for both of the deep sequencing runs. The controls were 
prepared using the E1-E2 and NS5B transcripts described in chapter 4. As the control 
transcripts were prepared from a synthetic dsDNA fragment, any deviation from the 
original sequence can be presumed to be error introduced during the library preparation, 
the sequencing run or an issue related to the reading of the sequences.   
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Table 5-3; Deep sequencing reads from the control samples 
Results of control samples loaded on the deep sequencing runs (raw data in tables 5-4 and 5-5). Y indicates 
the genotype was detected and N indicates no detection. * indicates the percentage of reads identified as 
either gt1a or gt3 
RUN 1 (gt3) 
gt1a 
detected 
%* 
gt3a 
detected 
%* 
Gt3a control N   Y 100 
Gt3a control N   Y 100 
Gt3a control N   Y 100 
99.9% gt3a:0.1% gt1a Y 10.27 Y 89.73 
99% gt3a:1% gt1a  Y 15.72 Y 83.5 
90% gt3a:10% gt1a  Y 68.32 Y 31.67 
H2O neg N   N   
Serum neg N   N   
RUN 2 (gt1a)         
Gt1a control Y 99.99 N   
Gt1a control Y 99.99 N   
Gt1a control Y 99.99 N   
99.9% gt1a:0.1% gt3a  Y 92.26 Y 7.37 
99% gt1a:1% gt3a  Y 92.97 Y 7.69 
90% gt1a:10% gt3a  Y 40.87 Y 59.05 
H2O neg N   N   
Serum neg N   N   
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Results from the sequencing of the controls suggested the assay was functioning as 
expected and capable of detecting multiple genotypes when they were present. On the gt3 
run, all three gt3 transcript controls were sequenced and all of the sequences were 
identified by phylogeny as gt3a. For the control spike-ins, where the minor strain was 
spiked in at concentrations of 0.1%, 1% and 10% of the total viral load, both gt1a and gt3 
were detected in every case. Whilst lower concentrations of minor strain spike-in resulted 
in a lower proportion of reads mapping to the minor strain, the proportions of reads were 
not consistent with the calculated amount of minor strain spiked into the samples. This 
suggests that there is some PCR-bias occurring in which sequences from the minor strain is 
being over-amplified relative to the major strain. On the gt1a run, all 3 gt1a transcript 
controls were successfully sequenced and genotyping identified 99.99% of the sequences 
as being gt1a. Again for the control mixed infections, gt1a and gt3 were detected in all 3 
samples tested. Both the 0.1% and the 1% controls produced similar proportions of reads 
(7.37% and 7.69% respectively) for the minor strain spiked into the samples. Similar to the 
gt3a run, the number of reads mapping to gt1a and gt3 was not proportional to the actual 
amount of minor strain spiked into the sample. Whilst this data demonstrates that the 
assays are capable of detecting multiple genotypes in the same samples, they also indicate 
that the assay is susceptible to PCR bias and therefore unsuitable for the quantitative 
estimation of the proportions of each genotype present in the samples. For both runs the 
serum negative controls had no reads mapping to HCV suggesting that contamination 
between samples was not an issue during these sequencing runs. Quantification of the 
DNA by Qubit for the H2O negative control, which was prepared alongside the samples 
and controls, was below the detectable level, further suggesting that contamination 
between samples was not an issue during the library preparations. 
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Figure 5-5; Decline in read quality along the amplicon length 
FastQC plot showing read quality along the amplicon from read 1 of the gt3a major control with 0.1% gt1a . 
The graph illustrates the typical decline in quality score towards the end of the Illumina read that was 
consistently observed for samples from both runs.  
   
Consensus sequences from the reads generated for the three control sequences in each run 
revealed consistent results. The gt1a E1-E2 control fragments all contained the G→A 
nucleotide substitution at position 1777, introduced into the transcript during production. 
For 1/3 controls, the sequence was 100% identical to the expected sequence. In the other 
two transcripts, six or seven nucleotide substitutions over positions 1552-1563 were 
observed. The gt3 E1-E2 controls were 100% homologous to the original control sequence, 
apart from in the region 1491-1570 where there were a number of errors introduced into 
the gt3 E1-E2 sequence and a 30bp region of the read that was either not sequenced or was 
unmapped. As paired-end sequencing was used, the middle of the sequence equates to the 
end of the individual reads of the amplicons. Read quality often deteriorates towards the 
end of the read, and the read quality observed throughout our data towards the end of reads 
was very poor (see figure 5-5). Reads were trimmed to mitigate for this but the quality of  
the data, particularly at the end of reads, was poor in this study and this must be considered 
during the analysis. It is unclear however why this issue has not affected the gt1a E1-E2 
control sequences to the same degree and this may indicate that the issue is with the 
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bioinformatic mapping of the reads. On the whole sequencing of the NS5B region was 
more consistent. The NS5B amplicon was shorter (382bp) than the E1-E2 amplicon 
(520bp), therefore there was a greater overlap between the forward and reverse reads in the 
middle of the NS5B amplicon. It is probable that this has contributed to the improved 
consistency of the reads in this region. The gt1a NS5B controls all had a G→A nucleotide 
substitution at position 8605, a mutation introduced into the transcript during its production 
and consequently, all the sequences had 100% sequence homology with the control 
transcript. The gt3 controls were also found to be identical to the control transcripts apart 
from a G→A nucleotide substitution at position 8512 which was observed in all three gt3 
controls sequenced. This substitution was not previously detected in the control transcript.    
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Figure 5-6; Phylogenetic analysis of the control consensus sequences  
Maximum likelihood phylogenetic trees comparing control consensus sequences from the deep sequencing runs with the original transcript sequences. There is a key identifying the 
controls in the tree. Gt11a strains are highlighted in red and gt3a strains in blue. Bootstrap support of >70% after 1000 replicates is indicated on each tree. 
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Multiple sequencing of the control transcripts was used as a marker for the fidelity of the 
process. As the transcripts were all derived from the same sequence, any deviation from the 
sequence must stem from either the introduction of errors during cDNA synthesis, subsequent 
amplification or from an error resolving the images during sequencing. The levels of fidelity 
observed were not consistent across the length of the transcripts, with a number of errors 
being identified in the middle of the sequences. In addition to the known decline in read 
quality towards the end of the read, Illumina have also acknowledged issues with the 
chemistry of the v3 300 bp paired-end kits. The issues are known to be causing a significant 
drop in the quality of the reads much earlier than expected, making longer fragments over 500 
bp difficult to sequence accurately.  It is likely that this issue is contributing to some of the 
loss of fidelity observed during this study.     
 
5.2.2 Clinical Samples 
 
Data on the genotypes detected in each sample and the number of reads generated from the 
gt3a and the gt1a runs is given in tables 5-4 and 5-5 respectively. The majority of samples 
produced between 10,000-800,000 reads mapping to the major genotype. There was 
significant variation throughout the samples however with a range of 20-6,000,000 reads 
mapped. Despite pooling the NS5B and E1-E2 amplicons together in equimolar ratios, in the 
majority of samples, approximately 10-fold more reads were obtained for the NS5B amplicon 
compared to the E1-E2 amplicon. Generally, recovery of both amplicons was good although 
there was an issue with the mono-infected gt1a samples (run 2). The E1-E2 amplicon was 
missing for 70% of these samples during the library preparation stage. In the 30% of gt1a 
mono-infected samples where the E1-E2 amplicon was retained, it was detected at much 
lower levels than the corresponding NS5B amplicon. This issue was detected when the 
samples underwent Tapestation analysis prior to loading them onto the sequencing cartridge 
and it not known why the E1-E2 amplicons were lost during the library preparation. It may 
suggest that combing the amplicons in equimolar ratios was not ideal however and that if the 
runs were repeated, the E1-E2 and NS5B amplicons should undergo library preparation 
sepaerately. The E1-E2 PCR and library preparation was repeated for the affected samples 
and they were included in the run with different tags from the original samples.   
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Table 5-4; Deep sequencing results from run 1 
Deep sequencing results from run 1 which included the gt3 mono-infected samples and mixed infection samples where 
gt3 was thought to be the major genotype present. The total number of reads is given and the proportion mapping to each 
genotype and amplicon. NK indicates that reads for the genotype were detected (and a consensus sequence isolated) but 
that the proportion of reads contributed was not quantified.  Y indicates that the genotype was detected in the sample and 
ND indicates that the genotype was not detected. DTan* indicates that the genotype was not detected by the k-mer 
genotyping algorithm but was identified using Tanoti. Reads mapping to H77 (gt1) and JFH-1 (gt2) are shown; these 
sequences were contaminants from another source (section 5.2.3).  
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Table 5-5; Deep sequencing results from run 2 
Deep sequencing results from run 2 which included the gt1a mono-infected samples and mixed infection samples where 
gt1a was thought to be the major genotype present. The total number of reads is given and the proportion mapping to 
each genotype and amplicon. NK indicates that reads for the genotype were detected (and a consensus sequence isolated) 
but that the proportion of reads contributed was not quantified. Samples E1a-1 – E1a-20 are the E1-E2 only repeats of 
the samples that lost their E1-E2 amplicon during the initial library preparation. Y indicates that the genotype was 
detected in the sample and ND indicates that the genotype was not detected. DTan* indicates that the genotype was not 
detected by the k-mer genotyping algorithm but was identified using Tanoti. H77 (gt1) and JFH-1 (gt2) indicate that 
whilst gt1 and gt2 reads were detected during the analysis, they were contamination from another source (section 5.2.3). 
1c** indicates that whilst gt1c was detected in the sample using the k-mer algorithm, sequence-based analysis of the 
consensus sequence generated from the reads demonstrated it was in fact gt1a (section 5.1.2).  
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5.2.3 Contamination 
 
Aside from the expected gt1a and gt3a reads detected in the samples, gt1c was reported in 
E1a-18, gt2 was reported in 21 samples and gt1a was found in 7 of the mono-infected gt3a 
samples. The gt1c sequence detected in E1a-18 was not reported in the corresponding NS5B 
sample (1a-18). A comparative analysis of the gt1a and gt1c consensus E1-E2 sequences 
from the sample identified that there were just 13/541 nucleotides varying between the two 
sequences. Phylogenetic analysis consistently grouped the gt1c sequence with other gt1a 
sequences, indicating that it was in fact a gt1a sequence (figure 5-7) and the 1a and ‘1c’ 
consensus sequences isolated from sample E1a-18 were shown to cluster next to each other 
with strong bootstrap support. This misclassification suggests that there may be issues with 
using such a short fragment length (37bp) in the k-mer genotyping pipeline, especially in a 
highly variable region of the viral genome.  
 
Figure 5-7; Phylogenetic analysis of gt1c strain detected in sample E1a-18 
Maximum likelihood phylogenetic tree comparing the gt1c E1-E2 consensus sequence from E1a-18 (E18-1c, 
highlighted with black arrow) with gt1a and gt1c reference strains (red and orange respectively). The gt1a 
consensus sequence from E1a-18 (E18-1a) has also been included in the tree. Bootstrap support of >70% after 
1000 replicates is indicated on the tree.  
 
Genotype 2a was detected in 21 samples from both run 1 and run 2. In 20/21 cases, only the 
NS5B fragment was detected suggesting that a replicon may be the contaminating source. 
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Phylogenetic analysis indicated also that all the gt2 reads detected in the samples were highly 
similar to JFH-1 (figure 8). JFH-1 sub-genomic replicons, constructed from the non-structural 
HCV genes and often containing a lucierferase reporter element, are a widely used tool within 
the building where this work was carried out. The library preparations were however 
performed in a laboratory where JFH-1 replicons are not handled and laboratory users are 
required to change lab coats between the two laboratories to prevent such contamination. The 
detection of JFH-1 in a large number of these samples suggests that these measures have 
however been insufficient to prevent contamination and transfer of material is occurring 
between the two sites.  
 
 
Figure 5-8; Phylogenetic analysis of gt2 sequences detected in the samples 
Maximum likelihood tree of gt2a NS5B consensus sequences detected during the deep sequencing runs. 
Bootstrap support of >70% after 1000 replicates is indicated on the tree and the JFH-1 reference strain has been 
underlined.  
 
152 
 
Of the 21 gt2 NS5B consensus sequences analysed, the sequence from sample 1a-8 was found 
to be the most distantly related to the JFH-1 replicon with substitutions occurring at 16/385 
sites. A comparative analysis of the two sequences identified a 40bp region within sample 1a-
8 that was identical to H77 (figure 5-9). This suggests it may be contamination from a 
chimeric replicon, which is also widely used in the laboratory.  
 
 
Figure 5-9; Sequence analysis of gt2 sequence detected in sample gt1a-8 
Alignments and illustration indicating that the sequence gt1a-8 (1a-12-2-70.sam) is derived from JFH-1 and 
H77. 
 
A gt2 sequence occurring in both the E1-E2 and the NS5B regions was detected in sample E-
15. Phylogenetic analysis of the NS5B sequence indicated that it was closely related to the 
JFH-1 replicon strain (figure 5-8). The E1-E2 sequence was found to be missing a 73bp 
region in the middle of the fragment at a similar location to the gaps identified in the gt3 
control sequences. Analysis of the E1-E2 sequence found that it was distantly related to JFH-
1 but was closely related to HC-J6.D00944, a strain isolated from a patient in Japan in 1991 
(figure 5-10)  (Okamoto et al., 1991). The strain is commonly used in HCV research for 
HCVcc culture systems and again, was used within the building where these libraries were 
prepared. This is further indication that the measures used whilst handling these samples on 
the open bench were insufficient to prevent contamination and that ideally, work of this 
nature should be done in allocated facilities.   
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Figure 5-10; Phylogenetic analysis of gt2 sequence detected in sample E-15 
Phylogenetic analysis showing the distant relationship of the E-15 E1-E2 consensus sequence and JFH-1. 
Bootstrap support of >70% after 1000 replicates is indicated on the tree.   
 
Both E1-E2 and NS5B gt1a sequences were detected in 5/20 mono-infected gt3 samples that 
had been previously screened and found to be negative for the presence of gt1a strains (figure 
5-11). Additionally an E1-E2 sequence was detected in sample 3-13 and an NS5B sequence 
was detected in sample 3-8.  All seven samples had previously tested negative for the 
presence of gt1a strains using the nested PCR assay developed in chapter 4. Phylogenetic 
analysis of the sequences indicated that the majority of the sequences detected were closely 
related to H77 and therefore likely to be a result of contamination. In the NS5B tree, all the 
sequences were closely related to H77 apart from the gt1a sequence detected in sample gt3a-
2.  This sequence was attributed to a single NS5B read isolated in the sample. In the E1-E2 
region, there were 8 gt1a reads isolated from sample gt3a-2 and they were near-identical to 
the H77 control strain. The gt1a NS5B sequence from sample gt3a-17 was also found to be 
incomplete and had two large 60bp deletions within it. This is likely a result of the low 
numbers of reads contributing to the consensus sequence (table 5-4). In the E1-E2 tree, all the 
unexpected gt1a sequences samples were closely related to H77 except the sequences isolated 
from samples gt3a-1 and gt3a-6. The gt1a sequences from both samples gt3a-1 and gt3a-6 
were highly similar to H77 apart from 6 or 10 nucleotides respectively in the middle of the 
sequences (figure 5-12). These heterogeneous regions were located within the region where 
gaps were identified within the gt3a control sequences. As the number of reads contributing 
to these sequences was relatively low, read coverage in this region is likely to be even lower 
still and sequence calling may have been affected by the excess of signals from other gt3 
amplicons on this sequencing run. Whilst sequence clustering was reduced and a high Phi-X 
spike-in was used to control for issues of this nature, they may have still affected sequence 
calling in some cases.    
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Figure 5-11; Phylogenetic analysis of gt1a sequences detected in gt3a only samples 
Maximum likelihood trees showing the gt1a sequences detected in the non-mixed infection samples that were 
similar to H77. Samples included are gt3a-1 (3-1), gt3a-2 (3-2), gt3a-6 (3-6), gt3a-8 (3-8), gt3a-9 (3-9), gt3a-13 
(3-13) and gt3a-17 (3-17). Bootstrap support of >70% after 1000 replicates is indicated on the trees.   
 
 
Figure 5-12; Sequence analysis of gt1a sequences isolated from gt3a-1 and gt3a-6 
Inserts in the E1-E2 consensus sequences from samples gt3a-1 and gt3a-6. 
 
The source of the H77 contamination is unclear but there are two possible sources. H77 
replicons are frequently used in other laboratories in the building where this work was carried 
out. From the analysis of the gt2 strains, there is evidence of transfer between two 
laboratories and this may explain some of the H77 contamination detected. The gt1a control 
transcripts developed for this project in chapter 4 are also based on H77 and they included 
both the E1-E2 and NS5B regions targeted by the pan-genotypic assay. It is possible that 
some of the samples analysed here have been contaminated with the control transcripts. The 
detection of H77 in both the E1-E2 and the NS5B assays however suggests that if the control 
transcripts were the contaminating source, the samples were contaminated on two separate 
occasions and this is unlikely.   
As a result of these analyses indicating that the additional genotypes detected were either as a 
result of genotype misclassification or contamination, they have been excluded from the 
subsequent analysis.  
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5.2.4 Genotype 1a and genotype 3a samples 
 
20 gt1a and 20 gt3 samples were selected randomly from our cohort of samples previously 
screened for mixed gt1a/gt3. All samples had previously tested negative for the presence of 
mixed gt1a/gt3 infection using the nested PCR assays developed in chapter 4. Libraries were 
prepared from the E1-E2 and NS5B amplicons for each sample and the samples then 
underwent deep sequencing on the Illumina MiSeq platform. Deep sequencing reads were 
obtained for 20/20 gt1a samples and 19/20 gt3 samples. No reads were obtained for either the 
E1-E2 or the NS5B amplicons of sample gt3a-7. It is unclear why this occurred as the library 
concentration obtained using Qubit was satisfactory but it may indicate that the sample was 
loaded into the final sequencing pool at an inadequate concentration. In addition to the 20 
gt1a and the 19 gt3 sequences expected from these samples, initial results indicated that a 
number of the samples may contain multiple genotype infections. Analysis of the sequences 
indicated they were closely related to either JFH-1 (gt2) or H77 (gt1a), implying that they 
were contaminating sequences. These sequences were therefore excluded from the analysis, 
meaning that no additional genotype sequences were detected in either the 20 gt1a or the 19 
gt3a samples. A phylogenetic analysis of the consensus sequences obtained for these 39 
samples is shown in figure 5-13. The NS5B sequence from sample gt1a-10 has been excluded 
from the tree as it was only 219bp in length. BLAST analysis of the sequence indicated it was 
gt1a and that the sequence was distinct from the H77 control. In both the E1-E2 and NS5B 
trees, the sequences were highly divergent from the control sequences included in the analysis 
and also from each another, indicating that they are derived from patient isolates and not the 
result of contamination.  
 
One issue encountered during the library preparation of the mono-infected samples was the 
loss of the E1-E2 fragment from the gt1a samples during the library preparation (table 5-5). 
This occurred despite mixing the E1-E2 and NS5B fragments together in equimolar ratios, as 
was done for all the other samples in this study. The E1-E2 pan-genotypic PCR was repeated 
for these samples, library preparations were performed and they were loaded into the final 
sequencing pool with separate tags. It is unclear however why this issue particularly affected 
these samples.   
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Figure 5-13; Phylogenetic analysis of sequences isolated from the gt1a only and gt3 only samples 
Maximum likelihood phylogenetic trees of the consensus sequences for the single-genotype infected gt1a and 
gt3 samples. Gt1a sequences have been highlighted in red and gt3 sequences have been highlighted in blue. 
Control gt1a and gt3 sequences have also been underlined. Bootstrap support of >70% after 1000 replicates is 
indicated on the trees. 
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5.2.5 Mixed genotype 1a/genotype 3 samples 
The 20 samples of mixed gt1a/gt3 infections also underwent deep sequencing analysis. E1-E2 
and NS5B pan-genotypic PCRs were performed on the samples, libraries were prepared and 
the samples were then sequenced on the Illumina MiSeq platform. Samples where the major 
genotype was presumed to be gt3 were loaded onto run 1 (n=17) and samples where genotype 
1a was presumed to be the major genotype were loaded onto run 2 (n=3). Reads were 
obtained for 20/20 samples and the results from the runs are given in the table 5-4 and 5-5. 
Differences were noted in the detection sensitivity between the E1-E2 and NS5B pan-
genotypic assays, with the E1-E2 assay appearing to be more sensitive for the detection of 
mixed genotype infections (table 5-7). This issue is discussed in section 5.2.6 and the analysis 
here focuses on the detection of E1-E2 reads, for which there were comparative sequences 
available, generated by Sanger sequencing (see chapter 4). All of the major genotypes were 
identified by deep sequencing. An initial analysis of the minor genotype using the k-mer 
genotyping algorithm detected gt1a reads in 7/17 (41%) of gt3 samples and gt3 reads in 0/3 of 
the gt1a samples (table 5-6). Further analysis of the reads from the samples using Tanoiti 
(Vattipally, 2014) was able to detect gt1a reads in an additional 5/17 (29%) of the major gt3 
samples (run 1)  and 3/3 (100%) of the major gt1a samples (run 2). Whilst gt1a deep 
sequencing reads were detected for sample g3-176, phylogenetic analysis indicated that they 
were identical to H77 (highlighted in figure 5-14). These sequences were likely the result of 
contamination and the gt1a minor strain from g3-176 was classed as not detected.  Overall 
using both the k-mer detection algorithm and Tanoti (Vattipally, 2014), mixed gt1a/gt3 
infections were detected in 15/20 (75%) of the samples tested. Gt2 was also identified in 
11/20 samples and analysis indicated that all the gt2 sequences detected were highly similar 
to JFH-1 (figure 5-8). They were excluded from subsequent analysis as they were considered 
to be contaminants.   
 
Among these samples, the major genotype present was identified as gt3 in 15/17 samples 
from run 1 and the major genotype was found to be gt1a in 3/3 samples from run 2. Previous 
qPCR results from sample g3-125 had indicated that the gt1a minor strain comprised 6.6% of 
the total viral load. In contrast to this, just 11.4% of the deep sequencing reads were gt3a and 
88.6% of the reads were gt1a, implying that gt1a was the major strain present in this sample 
(after exclusion of gt2 reads). In sample E-15, 88.0% of the total reads were found to be gt1a 
and 12.0% of the reads were genotyped as gt3 (after exclusion of gt2 reads). Previously qPCR 
assays on the sample had not yielded a result and subsequently, gt3 was presumed to be the 
major genotype present in the sample on the basis of genotyping results from the clinical 
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laboratory. It should be noted that results from the sequencing of the controls (table 5-3) 
indicated that PCR bias was an issue with assay and that the deep sequencing assays should 
be used solely for detection of the genotypes, and not for estimating the proportions of the 
genotypes present in the samples. Without comparable qPCR results, it is difficult to draw 
robust conclusions on the major genotype present in E-15 based on these results.   
 
In figures 5-14 (gt1a sequences) and 5-15 (gt3 sequences), the E1-E2 sequences detected by 
both Sanger sequencing and deep sequencing from the major and minor strains isolated from 
the samples have been compared. Major genotypes for the samples (as indicated by qPCR or 
by the diagnostic laboratory) are listed in table 5-7. Consensus sequences generated from the 
deep sequencing runs in the phylogenetic trees are identifiable by the tag ‘.ds’. The 
comparison of the major strain E1-E2 sequences indicated that 18/20 (90%) of the consensus 
sequences generated from deep sequencing reads were identical or highly similar to the E1-
E2 sequences produced by Sanger sequencing and they can be seen to cluster with high 
bootstrap values (highlighted in yellow). Considerable heterogeneity between the deep 
sequencing and Sanger sequences of the major strain was observed for g3-92 and E-15. As 
discussed previously, it was not clear what the major genotype present in sample E-15 was. 
The sample was genotyped as gt3 by the diagnostic laboratory but deep sequencing produced 
substantially more gt1a reads than gt3 reads. The gt1a consensus read from the deep 
sequencing clustered closely with the gt1a Sanger sequence whereas the two gt3 sequences 
did not. This may suggest that the majority stain in the sample is in fact gt1a although ideally, 
qPCR would be used to confirm this.  Correlation between the Sanger sequences and the deep 
sequencing consensus sequences was not consistent for the minor strains analysed however 
and just 2/15 minor strain sequence sets, gt1a-128 and E-49, were found to cluster together in 
the analysis. The minor strain for E-49 contributed just 0.46% of the total reads and was 
detected using Tanoti (Vattipally, 2014), suggesting it too contributed a low amount of the 
total reads from the sample. The fact that sequences for these minor strains clustered together 
despite the low number of reads attributed to them indicates that additional factors, such as 
contamination, poor read quality or the presence of previously undetected strains, are also 
likely to be impacting clustering of the minor strain sequences within the tree.   
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Figure 5-14; Phylogenetic analysis of gt1a Sanger sequences and deep sequencing consensus sequences 
Region of a maximum likelihood phylogenetic tree comparing gt1a E1-E2 sequences of mixed infection positive 
samples obtained by Sanger sequencing and E1-E2 consensus sequences from deep sequencing. Control strains 
are underlined and samples without a corresponding consensus sequence from deep sequencing are highlighted 
in red. Sequences from the same sample grouping next to each other in the tree are highlighted in yellow and 
those grouping separately in the tree are highlighted in green. Bootstrap support of >70% after 1000 replicates is 
indicated on the tree. Red dots have been used to highlight the major strains (as determined by qPCR). Blue 
arrows have been used to highlight sequences from G3-176, where the gt1a deep sequencing reads were found 
be contaminants.  
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Figure 5-15; Phylogenetic analysis of gt3 Sanger sequences and deep sequencing consensus sequences 
Region of a maximum likelihood phylogenetic tree comparing gt3a E1-E2 sequences of mixed infection positive 
samples obtained by Sanger sequencing and E1-E2 consensus sequences from deep sequencing. Control strains 
are underlined and samples without a corresponding consensus sequence from deep sequencing are highlighted 
in red. Sequences from the same sample grouping next to each other in the tree are highlighted in yellow and 
those grouping separately in the tree are highlighted in green. Blue dots have been used to highlight the major 
strains (as determined by qPCR). Bootstrap support of >70% after 1000 replicates is indicated on the tree.     
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A comparative analysis of the method used to detect the minor strain in the deep sequencing 
reads and the estimated proportion of the minor strain as calculated by qPCR (chapter 4) 
indicated that minor strains were more likely to be detected if they comprised >1% of the 
total viral load (table 4-4).  Using the k-mer algorithm and Tanoti (Vattipally, 2014), all 
minor strains comprising >1% of the viral load were detected. Strains detected using the k-
mer algorithm comprised, on average, a greater proportion of the viral load (7.59% ± 8.54) 
than the strains detected using Tanoti (1.54% ± 2.56) although there was considerable 
variation within both groups of samples. This indicates that Tanoti may be a more sensitive, 
albeit more time-consuming, method for the detection of minor strains. In samples in which 
the minor genotype was not detected by deep sequencing, qPCR indicated that all had minor 
strain populations comprising < 0.25% of the total viral load. Minor strains were however 
detected by the k-mer algorithm or Tanoti in five other samples where the minor strain 
comprised <0.25% of the total viral load.  
 
Table 5-6; Proportion of the minor strain and method of detection in the deep sequencing reads 
Comparison of the minor strain viral load (%) as determined by qPCR (table 4-4, chapter 4) compared with the 
method used to detect the minor strain in the E1-E2 deep sequencing reads. Average viral load for each detection 
method and the standard deviation (SD) are also given. *All samples detected by k-mer analysis were also 
detectable with Tanoti but have not been included in this analysis to emphasise the sensitivity of Tanoti.  
Detected by 
K-mer algorithm 
Detected by  
Tanoti* 
Not detected 
sample % sample % sample % 
E-15 NK g3-51 NK g-30 NK 
E-49 NK g3-85 0.36 g3-44 NK 
g-27 0.16 g3-92 0.42 g3-67 0.21 
g3-36 0.05 g1a-128 6.91 g3-155 0.02 
g3-73 20.63 g3-128 0.03 g3-176 0.22 
g3-80 10.51 g3-41 0.13     
g3-125 6.61 g3-166 0.03     
    g-45 2.64     
Average 7.59 Average 1.54 Average 0.15 
SD 8.54 SD 2.56 SD 0.11 
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By deep sequencing of g3-80 and g3-125 both genotype 1a and genotype 3a strains were 
detected in both samples using the k-mer algorithm.  The consensus sequences of the gt3 
strains (major genotype) for both samples were highly similar and grouped together closely in 
the phylogenetic tree with their comparable Sanger sequences. Consistent with previous 
work, the gt1a strains that were identified from the samples by deep sequencing demonstrated 
significant heterogeneity from each other and were incongruent relative to their respective 
Sanger sequences. Only the major gt3 strain within the sample G-30 was detected using deep 
sequencing. The presence of two distinct gt1a strains with a 16% difference at the nucleotide 
level was detected previously in sample G-30 by clonal analysis (chapter 4).  
 
5.2.6 Comparison of E1-E2 and NS5B assays 
 
An analysis of the NS5B amplicon reads from the deep sequencing runs found that the major 
strain was identified in 19/20 (95%) samples (table 5-7). NS5B amplicon reads for the minor 
strains were identified in 6/20 (30%) samples using both the k-mer algorithm and Tanoti 
(Vattipally, 2014). These pairs are highlighted in a phylogenetic analysis of the sequences 
(figure 5-16).  Neither the major nor the minor NS5B seqeunces were identified for sample 
G-30 and there were no comparable NS5B sequences available for the samples to analyse 
alongside the deep sequencing sequences. Relative to the deep sequencing analysis of E1-E2 
where 75% of the minor strains were detected using either the k-mer algorithm or Tanoti 
(Vattipally, 2014), the NS5B assay appears to be considerably less sensitive with just 30% of 
the minor strains detected. This was also despite the fact that in 60% of the mixed infection 
cohort, approximately 10-fold more NS5B reads were detected than E1-E2 reads (tables 5-4 
and 5-5).  For those samples in which minor strain NS5B reads were detected, previous qPCR 
results indicated that the minor strain comprised >5% of the total viral load for 3/6 samples. 
For E-15, qPCR results were not available and for G3-92 and G3-85 the qPCR results 
indicated that the minor strain comprised <0.5% of the total viral load. There were not enough 
samples with a gt3 minor strain (n=3) to make meaningful comparisons about the inter-
genotypic sensitivity of the either the E1-E2 or the NS5B assay.  
 
163 
 
 
Figure 5-16; Phylogenetic analysis of consensus NS5B sequences 
Maximum likelihood phylogenetic tree of consensus NS5B generated from the deep sequencing of the mixed 
infection positive samples. Samples for which both the major and minor strains were detected are highlighted 
with arrows. Bootstrap support of >70% after 1000 replicates is indicated on the tree.  
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Table 5-7; Gt1a and gt3 strains detected in the samples by nested PCR and deep sequencing 
Sequences identified in mixed infection positive samples by nested PCR, E1-E2 deep sequencing assay and 
NS5B deep sequencing assay. The major genotype for each sample is shown. Y indicates a sequence was 
identified and N indicates a sequence was not detected. Y* indicates that sequences detected were similar to 
controls. 
 
Sample 
Major 
genotype 
E1-E2 nested 
PCR  
E1-E2 deep 
sequencing 
NS5B deep 
sequencing 
1a 3a 1a 3a 1a 3a 
G27 3a Y Y Y* Y N Y 
G30 3a Y Y N Y N N 
G45 3a Y Y Y Y N Y 
E15 3a Y Y Y Y Y Y 
E49 3a Y Y Y Y N Y 
G3-36 3a Y Y Y* Y N Y 
G3-41 3a Y Y Y Y N Y 
g3-44 3a Y Y N Y N Y 
g3-51 3a Y Y Y Y N Y 
G3-67 3a Y Y N Y N Y 
G3-73 3a Y Y Y Y Y* Y 
G3-80 3a Y Y Y Y Y Y 
G3-85 1a Y Y Y Y* Y* Y 
G3-125 3a Y Y Y Y Y* Y 
G3-128 3a Y Y Y Y N Y 
G3-155 3a Y Y N Y N Y 
G3-166 3a Y Y Y Y N Y 
G3-176 3a Y Y N Y N Y 
G3-92 1a Y Y Y Y* Y Y 
G1a-128 1a Y Y Y Y Y N 
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5.3 Diversity analysis 
 
An advantage of the deep sequencing approach used within this chapter is that it also offers 
the opportunity to analyse the diversity of the strains present within the samples. There were 
two main objectives for this analysis, and they were firstly to examine the samples for 
evidence of multiple strains of the same genotype and secondly, to compare the diversity of 
strains isolated from mixed genotype-infected samples with strains from samples infected 
with a single genotype. Clonal analysis was used to identify the presence of multiple gt1a 
strains in sample G-30 (chapter 4). Whilst no gt1a strains were detected for G-30 during the 
deep sequencing runs, there may be multiple intra-genotype strains present in other samples. 
The second objective was to compare the diversity within the mixed genotype infected 
samples with the diversity of samples infected with a single HCV genotype. Numerous 
approaches were either attempted or considered for this analysis including, pair-wise analysis, 
phylogenetic analysis, Swarm (Tiffin and Ross-Ibarra, 2014) and CD-Hit (Li and Godzik, 
2006; Fu et al., 2012). Given the large number of reads detected per sample (frequently 
>100,000), both phylogenetic and pair-wise analysis were too time consuming and required a 
significant amount of computing power. The long length of these amplicons meant that after 
ligation of the adapters and sequencing primers, there was little overlap between the paired-
end reads (figure 5-17). In phylogenetic and pair-wise analysis, this may have meant only 
being able to analyse read 1 or read 2 and therefore the loss of approximately half of the 
sequence and diversity information contained within it. The early testing of Swarm suggested 
the programme was more appropriate for quasispecies analysis but there was difficultly 
reducing the numbers of clusters identified by the programme. A detailed description of the 
pipeline used to analyse the samples is given in the materials and methods section (chapter 2).   
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Figure 5-17; Amplicon length and read coverage 
The impact of amplicon length (after library preparation) on read coverage using 2 x 300bp paired end reading. 
Read coverage for short fragments, the NS5B and the E1-E2 amplicon are illustrated.  
 
CD-Hit analysis utilises a greedy incremental algorithm that works by taking the longest read 
in a dataset and comparing all the other reads in the dataset to it (Fu et al., 2012). Reads are 
grouped into clusters on the basis of their similarity (user-assigned threshold) to the longest 
read and clusters with >500 associated reads are considered to be real variants. It should be 
noted for this analysis that the reads from each sample were firstly separated by genotype 
using Tanoti (Vattipally, 2014) and that in samples with multiple genotypes detected within 
them, clustering analysis has been performed on each genotype separately. Raw data from the 
CD-Hit analysis, after removal of the gt2 (JFH-1) and gt1 (H77) contaminating sequences, is 
given in the appendix, tables 8-4 (run 1) and 8-5 (run 2). A consolidated table of the data, 
showing the average number of clusters detected in each sample group is shown in table 5-8. 
 
Examination of the data indicates that the analysis can be influenced by the numbers of reads 
produced by the samples. Particularly large numbers of clusters were observed in the 10% 
gt3a control (run 1) and in the gt1a NS5B and E1-E2 samples, which had the largest number 
of reads. An excessive amount of the 10% gt3a control (run 1) was loaded into the final 
sequencing pool in error and this sample produced 10-fold more reads than average in the 
run. On run 2, many of the twenty gt1a-only sample E1-E2 fragments were lost during the 
library preparation, resulting in a greater proportion of reads produced for the NS5B fragment 
relative to other samples. The repeated E1-E2 amplicons were prepared separately without the 
NS5B amplicons and consequently, the number of E1-E2 reads produced by these samples is 
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higher than the number produced by other samples. The increased number of E1-E2 reads in 
these samples is likely to have inflated the numbers of clusters detected within the samples. 
These factors make it difficult to draw meaningful conclusions from the gt1a-only samples as 
they cannot be easily compared to other samples. The control samples from both run 1 and 2, 
which were derived from a synthetic dsDNA fragment and should show no variation, 
constitute up to 30 clusters (discounting the gt3a 10% control). More clusters were also 
identified in controls from run 2 (particularly the gt1a transcript controls) relative to run 1. It 
is unclear why this should occur, as similar numbers of reads were produced for each set of 
controls and neither set of controls was excessively contaminated with JFH-1. PCR-deep 
sequencing is known to be highly error-prone as errors are introduced into the reads during 
the initial PCR of the amplicons, during library amplification and during the sequencing run 
itself. Additional errors can also be introduced when reading the sequences as strong 
fluorescence from many reads with identical nucleotides can mask weaker signals from other 
variants. Both sets of samples underwent identical library preparation however and there was 
no difference in the number of PCR cycles that the samples underwent. The transcript and 
mixed genotype transcript controls also show a similar diversity between the E1-E2 
fragments and the NS5B fragments. As the E1-E2 amplicon spans HVR-1 and HVR-2, we 
would expect to observe higher diversity within this amplicon than in the NS5B region.  
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Table 5-8; Diversity analysis of the deep sequencing reads using CD-Hit 
Summary statistics of a CD-Hit analysis of the deep sequencing data from runs 1 and 2 (using 0.9 similarity threshold) stratified into mixed genotype, single genotype and controls. The 
average number of clusters is presented for each group and the standard deviation. In mixed genotype samples and controls, only the major genotype has been analysed in this table. 
Many of the E1-E2 fragments were lost from the single gt1a samples in run 2 during the library preparation stage and the repeated E1-E2 libraries have been analysed separately in the 
single gt1a (E) group. *denotes the number of distinct clusters identified with >500 or >1000 reads within the cluster. **the large number of reads associated with the 10% mixed 
genotype control were confounding in this analysis and this sample has therefore been excluded.   
 
 
Group >500* >1000* >500* >1000* Group >500* >1000* >500* >1000*
Mixed gt 13.5 7.5 11.5 6.1 Mixed gt 24.0 13.0 20.0 11.3
SD 6.9 4.2 5.1 3.1 SD 12.5 8.2 21.1 10.6
Single gt3 13.3 8.2 5.7 3.3 Single gt1a 2.7 1.8 24.4 12.2
SD 6.7 3.5 7.5 4.1 SD 5.1 3.5 13.3 6.8
Controls** 7.2 5.2 6.4 3.0 Single gt1a (E) 28.5 16.5 0.0 0.0
SD 1.8 1.3 3.4 1.0 SD 14.0 7.7 0.0 0.0
Controls 14.5 7.0 18.0 9.3
SD 11.9 4.4 11.8 5.2
E1E2 NS5B E1E2 NS5B
RUN 1 RUN 2
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Examination of the data from run 1 comparing diversity indicates several interesting trends. 
Firstly both single genotype infection sample groups have a greater number of clusters within 
the E1-E2 analysis relative to the controls and the NS5B analysis, indicating that as expected, 
more diversity was detected within the E1-E2 reads relative to the NS5B reads. Secondly, in 
the NS5B analysis, more clusters were identified within the mixed infection cohort at both 
the >500 and >1000 thresholds (11.5 and 6.1 respectively) than were identified in the samples 
with a single genotype infection (5.7 and 3.3). In contrast, the numbers of clusters identified 
within the E1-E2 analysis were comparable for both groups of samples. This suggests that gt3 
viruses, in the context of a mixed genotype infection, are more diverse than gt3 viruses that 
are involved in single genotype infections. Reasons for this observed difference are unclear 
but it may indicate either a higher exposure rate among those with mixed infections or that 
the gt3 viruses are subjected to the added selective pressures likely encountered in multi-
genotypic infections leading to an increase in quasispecies breadth.  
 
Caution should also be used however when interpreting the level of diversity that these 
identified clusters are taken to represent. It is widely accepted that distinct strains within the 
same HCV subtype can be confidently distinguished if they show a >10% divergence at the 
nucleotide sequence level whereas quasispecies diversity is usually characterised at levels of 
<5% divergence from the major variant(s) present. In this analysis, a similarity threshold of 
0.9 was used to identify clusters of sequences showing 10% divergence from the longest read. 
However, given the large numbers of clusters identified in the control samples, this analysis 
appears to have over-estimated the diversity present within the samples. Without consensus 
sequences from each of the clusters, it is impossible to comment on whether these clusters 
indicate the presence of multiple strains or a highly divergent quasispecies or if they are 
simply due to the additive effect of a high error rate during library preparation and 
sequencing on normal levels of quasispecies divergence. Adjusting the parameters such that 
control samples show approximately 1 cluster may give a more accurate estimate of the 
number of within-subtype strains present in the patient samples.    
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5.4 Chapter conclusions 
The regions targeted by the pan-genotypic primers in this method were selected because of 
the informative nature of the amplicons produced. The NS5B amplicon encompasses the 
Okamoto region, a small region (329nt) that is often used for HCV genotyping because of its 
ability to describe the entire HCV phylogeny. Phylogenetic trees of the Okamoto region have 
been shown to be highly similar to phylogenetic trees of entire HCV genomes, enabling 
consistent genotyping from a relatively small genomic region (Hraber et al., 2006). Our data 
indicated that the NS5B amplicon produced by our assay was useful for genotyping and we 
were able to accurately genotype and sub-type all the samples we tested it with (n=64). The 
region targeted by the E1-E2 pan-genotypic primers contained the HVR-1 and HVR-2  and 
was therefore selected as analysis of the reads can reveal insight into the quasispecies 
diversity present within each sample. Regions on either side of the HVRs, particularly 
nucleotides 1400-1490 and 1680-1760 (absolute numbering based on H77), are however 
highly conserved at a sub-genotype level. The E1-E2 fragment amplified by this assay was 
also shown to be useful for the sub-genotypic classification of HCV strains, despite the 
additional variation encoded by the HVRs. Although the tree topology described by the E1-
E2 and NS5B analyses were different, the clustering of the sequences alongside the reference 
strains was consistent for every sample tested. A systematic review by Jacka et al. (2013), 
found that the E1-E2 was rarely used in genotyping studies and that when it was used, it was 
frequently as part of a fragment >1000 bp in length (Jacka et al., 2013). Data in this chapter 
indicates that when using sequencing-based genotyping, the relatively short E1-E2 region 
targeted by this assay can also be highly discriminatory. Additionally, the misclassification of 
the HCV gt1g strain as a HCV gt1c strain suggests that the region being used by diagnostic 
laboratories may not be the most informative region for sequence analysis. Although rates of 
gt1g and gt1c are very low in the UK, the misclassification of sub-types may lead to 
inaccurate conclusions being drawn about associated clinical morbidities and response rates 
to treatments. In an era when we have numerous therapeutic options available for more 
personalised treatments of individuals with HCV, the careful and accurate stratification of 
HCV genotypes will be crucial to ensure that the most appropriate treatment plan is followed.   
The pan-genotypic assays and the analysis pipelines used (k-mer algorithm and Tanoti) were 
able to detect 75% (E1-E2) and 25% (NS5B) of the mixed genotype infections identified by 
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Sanger sequencing in chapter 4. Previous studies have correlated read-sequencing sensitivity 
with qPCR thresholds (Rosseel et al., 2012; Prachayangprecha et al., 2014; Thorburn et al., 
2015) and a similar trend was observed within this study. For both assays, sensitivity for the 
minor strain decreased if the qPCR results (chapter 4) indicated that the minor strain was 
present at levels <0.25% of the total viral load.  Samples in which the minor strain 
contributed >2% of the total viral load were also more likely to be identified. Considerable 
heterogeneity between the E1-E2 minor strain sequences from samples with mixed gt1a/gt3 
infection identified by deep sequencing and Sanger sequencing (chapter 4) was also observed 
(figures 5-14 and 5-15). This heterogeneity was not evident for the major strains and suggests 
that the low number of reads from which a number of the minor stain consensus sequences 
were derived may have been a contributing factor. This may have been exacerbated by the 
very poor read quality observed in the majority of sequences generated for this study (figure 
5-5). For the E1-E2 amplicon, which was at the limits of maximum read length for the 2 x 
300bp sequencing kits, this means both the middle and end of the sequences were likely to be 
either trimmed or of poor quality and this may have adversely affected the consensus 
sequences generated from the deep sequencing reads, particularly when they were derived 
from low numbers of reads. In addition to this, JFH-1 contamination was identified in a 
number of samples, including both mono- and mixed infected samples. Whilst not ideal, this 
contamination has demonstrated that amplicon-based deep sequencing pipelines can be used 
to detect the presence of multiple genotypes within samples. The findings indicate that the 
detection of multiple genotypes within a single sample is possible but that very low levels of 
the minor strain(s) make detection less probable. The results from this chapter also support 
the evidence from the qPCR results (chapter 4) indicating that in the majority of the mixed 
infections identified, the minor strain was present at very low amounts, with 66.7% of 
samples tested (n=15) having a minor strain that contributed <1% of the total viral load.  
Previous studies have identified PCR-bias as a major determinant of assay sensitivity and 
error in deep sequencing, with rates of frequency being distorted by margins of up to 100-fold 
relative to the true frequency (Jabara et al., 2011; McElroy, Thomas and Luciani, 2014). 
PCR-bias was observed in the control mixed infections which had minor strains spiked in at 
concentrations of 0.1%, 1% and 10%. In all samples and in both the E1-E2 and NS5B assays, 
the minor strain was however over-amplified relative to the spike-in and was therefore easier 
to detect as a result. As the bias dynamic within our assay suggests that minor strains (present 
at ≥0.1%) are liable to be over-amplified and therefore detectable, this again suggests that the 
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majority of the minor strains in the mixed infection samples are present at extremely low 
levels. Previous work has indicated that enzyme selection and specific primer annealing 
dynamics are major sources of bias in sequencing-based studies (Polz and Cavanaugh, 1998; 
Hong et al., 2009; Aird et al., 2010). The pan-genotypic primers developed for the pipeline in 
this study were highly degenerate in order to facilitate broad coverage and consequently are 
liable to be a large source of bias. For the E1-E2 primers, there were 16 sense and 96 anti-
sense combinations and 48 sense and 8 anti-sense for the NS5B primer set. Certain nucleotide 
combinations within the primers will anneal with better efficacy relative to other 
combinations and are therefore more likely to result in effective amplification. 
Concentrations of the most effective primer pairs that are able to amplify a given sequence 
within the master mix will also be relatively low when degenerate primers are used and this 
may also impact amplification biases. For enzyme selection,  KAPA HiFi is widely regarded 
to be the leading enzyme for Illumina library preparation because of its high fidelity and 
improved coverage of G+C or A+T rich regions relative to most other enzymes (Quail et al., 
2011). KAPA HiFi was used for all amplification steps throughout this study as a result. 
Early testing of the pan-genotypic assays with a non-proof reading taq polymerase indicated 
however that the sensitivity of the assay was curtailed by the use of a high-fidelity enzyme, as 
might be expected.  
Many deep sequencing protocols still have relatively high error rates of around 1% (Radford 
et al., 2012; Sims et al., 2014) and are clearly highly prone to contamination. Given that our 
qPCR data suggests that most minor strains in mixed infections comprise <1% total viral 
load, many of these reads would likely have been discarded as error if 5% or 1% cut-offs 
were used and the mixed genotype infections would not have been detected. Viral diversity 
would therefore likely be underestimated in many cases using deep sequencing, unless an 
appropriate protocol can be developed. Until deep sequencing fidelity improves and low-
frequency variants can be confidently and accurately distinguished, the data in this study 
indicates that amplicon-based deep sequencing methods will be inferior to genotype-specific 
nested PCR assays (chapter 4). The bioinformatic pipeline developed for this analysis was 
tailored for this project (by Sreenu Vattipally, CVR bioinformatician) and the k-mer based 
genotyping algorithm developed for it used 37bp k-mers. In one sample, this algorithm 
misclassified gt1a k-mers as belonging to gt1c, over-estimating the diversity present within 
the sample. HVR-1 is 27 amino acids in length and evolution and diversity within the region 
is rarely constrained by the viral genotype.  This may suggest that phylogenetic algorithms, or 
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a longer k-mer, would be more accurate for genotyping than the 37bp k-mer used in this 
pipeline, particularly for the E1-E2 reads. Longer k-mers however increase the risk of 
mismatches occurring and may require more computing power than smaller k-mers. 
Contamination can be particularly problematic in deep sequencing studies and can complicate 
interpretation in studies on diversity and mixed genotype infections. This study was affected 
by high levels of JFH-1 contamination, particularly in run 1. Run 1 contained the majority of 
the mixed infection samples which were particularly badly affected by the JFH-1 
contamination. As these samples underwent more tests than other samples, they were handled 
more and consequently have had a higher exposure to any contaminating sources. Measures 
were in place to reduce the risk of contamination including clean room facilities for reagents, 
the separation of extraction facilities from amplification facilities and a strict clean-down 
protocol with diluted bleach. Despite rigorous adherence to these practices, contamination 
was still a serious problem in this study, and is likely a consequence of the fact that library 
preparations for the samples were performed on an open bench as there was a lack of 
alternative options. Ideally, the library preparations for a study of this nature should be 
processed in dedicated facilities, where the exposure of samples to possible contaminants can 
be controlled for.  New facilities recently installed at the Centre for Virus Research (where 
this work was undertaken) provide a discrete facility for handling clinical samples prior to 
reverse transcription and for handling cDNA prior to down-stream amplification. Run 2 
samples E1a-1 to E1a-20 were some of the first samples to be handled in this facility and no 
evidence of JFH-1 contamination was detected in these samples. If deep sequencing protocols 
similar to this are to be developed for use in clinical environments, the implementation of a 
multi-step clean room system incorporating the separation of procedures and facilities 
according to contamination risk will be a vital part of the quality assurance management.   
An analysis of the diversity present within the samples suggested that individuals with mixed 
genotype HCV infections may harbour more diverse viral populations than individuals 
infected with just a single genotype. This is in agreement with a previous study by Toyoda et 
al., which observed that a greater quasispecies diversity was present in samples with mixed 
genotype infection (Toyoda et al., 1998). In this study it was however difficult to draw 
conclusions about whether this inferred the samples were more likely to be infected with 
multiple strains of the same genotype or if it indicated that the quasispecies within the mixed 
infection samples was more diverse. Additionally no gt1a reads were detected in sample G30 
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by PCR-NGS, from which two distinct gt1a strains were previously identified by PCR 
methods. If reads had been available for this sample or any other sample with multiple inter-
genotypic strains were analysed, it would be expected that this greater divergence would be 
identified by cluster analysis. The result does however suggest that individuals with mixed 
genotype infection either have had higher HCV exposure rates relative to those with single 
genotype infections or that the viruses within these individuals have evolved a more diverse 
quasispecies. Given the high IDU rates observed within our study population (>70%) and the 
diverse range of ages observed in our mixed infection cohort, a significant difference in 
exposure rates is unlikely. The diversity observed within the controls indicated that CD-Hit 
was over-estimating the diversity in all the studied samples making it more plausible that the 
increased diversity observed in the mixed infection samples is reflective of an increased 
quasispecies breadth. Over-estimation of diversity in the samples may also have been 
associated with the poor data quality observed in this study which indicated that sequencing 
errors were likely to be a problem in reads generated. The detection of differences in the viral 
intra-genotype diversity between mixed and mono infected individuals implies that there may 
be immunological characteristics specific to mixed genotype infection. Previous studies have 
identified genotype-specific transcriptional profiles with HCV gt1 inducing an elevated type 
1 IFN response relative to gt3 (M. Robinson et al., 2015; M. W. Robinson et al., 2015). This 
may suggest that the increased diversity observed during mixed infection is a viral response 
to increased and/or different immune pressures and intra-viral competition for resources. Data 
from the diversity analysis was also confounded by the fact that samples with larger numbers 
of reads generated larger numbers of clusters during the analysis. Future analysis of this 
nature should digitally normalise the numbers of reads in each sample, reducing the numbers 
of duplicate reads in the samples and providing a similar of number of reads from each 
sample for downstream analysis.    
Amplicon-based deep sequencing was used for this study as it offers a vastly increased depth 
relative to other approaches. Despite this increased depth, the very low viral loads of many 
minor strains and PCR-bias have meant that the detection of mixed infections was poor 
relative to the Sanger-based genotype specific assays. Numerous methods to reduce PCR-bias 
have been developed and the inclusion of target-enrichment protocols or linear amplification 
strategies such as multiple displacement amplification, rather than amplicon-based 
approaches may have been superior methods to try (Dean et al., 2002). The inclusion of such 
steps into a protocol would however incur longer preparation and testing turn-around, in 
175 
 
addition to further financial cost. When these factors are all considered, deep sequencing 
approaches are currently not competitive or cost-effective when compared with current 
Sanger-based techniques for the detection of mixed genotype infections.  In the short term, 
the incorporation of more sequence-based genotyping methods into clinical diagnostics will 
improve the diagnosis of mixed genotype infections, leading to better patient stratification for 
clinical trials and follow-up studies as well as providing data of interest to public health 
bodies. The two pan-genotypic assays developed for this study were shown to be more 
informative than currently used typing methods and were effective at amplifying and typing 
gt1, gt2, gt3 and gt4 strains and one gt6a isolate. It would be of interest to test the assay 
against genotypes rarely seen in the UK including other gt3 subtypes, gt5 and more gt6 
isolates to ascertain the suitability of this assay for clinical diagnostics in other regions. HCV 
genotypes 4 and 6 are particularly diverse with 14 and 24 subtypes respectively (Smith et al., 
2014) and it would be important to demonstrate that there is sufficient diversity in the E1-E2 
and NS5B regions to resolve the typing of these entire genotypes. Data collected during the 
project (during assay optimisation) suggested that the primers were able to function 
effectively with at least 1-2 known mismatches suggesting that there are unlikely to be any 
significant issues amplifying these strains.   
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6 Chapter 6: Analysis of the 
dinucleotide biases in hepatitis 
C viruses and other Flaviviridae 
 
6.1 Background introduction 
Differences between the HCV genotypes may reach as much as 25-30% at the nucleotide 
level and distinct geographical and clinical associations have been attributed to the different 
genotypes. The implications of infection with multiple HCV genotypes are poorly 
understood, both in terms of the viral evolution and the clinical prognosis. It is possible that 
unique selective pressures are placed on the viruses during mixed infections. Previous work 
during this PhD identified a number of samples which had mixed gt1a/gt3a infections. In 
most of the mixed infections identified, gt3 was the major strain present (figure 4-14) and the 
reasons for this were unclear. It may be the case that gt3 strains have a competitive advantage 
relative to gt1a strains, enabling them to more readily adapt in vivo during infection and 
replicate faster. Reductions in both CpG and UpA motifs in RNA viruses have previously 
been shown to confer an increased replicative rate to other +ssRNA viruses in vitro (Atkinson 
et al., 2014).  In this chapter, an in-depth analysis of differences in the dinucleotide 
expression and codon bias between mixed and mono-infected samples, and the different HCV 
genotypes is presented. A previous study by Kapoor et al. has also highlighted the potential 
of nucleotide composition analysis for the inference of probable viral host species (Kapoor et 
al., 2010) and the application of this approach to explore the evolutionary history of HCV is 
considered in this chapter. The evolutionary origins of hepatitis C virus are relatively 
unknown and, unlike HIV, a cross-species transmission event from a progenitor virus has not 
been identified. It remains unclear if a single ancestral virus developed the ability to infect 
humans from which multiple genotypes subsequently evolved or, similar to HIV, if multiple 
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ancestral viruses evolved the ability to infect humans separately and each gave rise to a 
different genotype.  
Developing this analysis further, the dinucleotide biases of the Flaviviridae were analysed 
and factors that may be shaping observed patterns were investigated. The diverse range of 
hosts infected by the Flaviviridae and the use of arthropod vectors by a number of viruses 
mean that these similar viruses have had to adapt to a range of different environments and 
that the evidence of this should be visible within their genomes. In general, among  +ssRNA 
viruses, the CpG and UpA dinucleotide pair frequency within the genome mimics that of 
their host genome, suggesting there is some form of recognition capacity within the host 
(Greenbaum et al., 2008; Lobo et al., 2009). The Flaviviridae encompasses a diverse family 
of around 70 viruses that are sub-divided into 4 genera, flaviviruses, pegiviruses, pestiviruses 
and hepaciviruses. The family includes a large number of important veterinary and medical 
pathogens and are spread via mosquito-borne, tick-borne, respiratory or parenteral 
transmission routes. They are found globally, infecting a wide range of both vertebrate and 
invertebrate species. Given that the main drivers of selection for dinucleotide pair frequencies 
and RSCU are thought to be either the host immune system or the viruses’ ability to translate 
within the host, this variation in both host and transmission route make the Flaviviridae an 
interesting family to investigate dinucleotide pair frequencies and relative synonymous codon 
usage (RSCU) within.  
 
6.2 Dinucleotide frequencies in mixed genotype infections 
6.2.1 CpG and UpA in mixed genotype infections 
Working under the hypothesis that differences in the CpG or UpA expression between the 
genotypes may be giving gt3 viruses a competitive edge during infection, an analysis of the 
CpG and UpA dinucleotide frequencies in the E1-E2 Sanger-sequenced isolates from both the 
gt1a and gt3a strains within the mixed gt1a/gt3 positive samples was undertaken. This data 
was compared with identical analyses from other gt1a and gt3a E1-E2 sequences from 
samples that were not associated with mixed genotype infections. The results are shown in 
figure 6-1.  
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Figure 6-1; CpG and UpA expression within mixed infection positive samples 
CpG and UpA expression within the E1-E2 region of gt1a and gt3a Sanger-sequenced isolates involved in both 
mixed (striped colour) and mono (solid colour) infections. In samples with mixed genotype infection, both the 
gt1a and gt3a sequences isolated from the samples have been analysed separately. Statistical significance was 
calculated using t-tests.  
 
In the E1-E2 sequences isolated from mono-infected individuals, CpG levels were 
significantly lower in gt3a strains (0.51 ± 0.07) than in gt1a strains (0.65 ± 0.05). A similar 
trend was observed in the sequences isolated from the mixed gt1a/gt3 infected samples with 
the CpG levels in gt3 strains (0.44 ± 0.07) being significantly lower than those in the gt1a 
strains (0.64 ± 0.06). Interestingly, whilst the CpG expression in gt1a strains from both mixed 
and mono-infected samples was similar (0.64 ± 0.06 and 0.65 ± 0.05 respectively),   the 
sequences isolated from gt3a viruses in mixed gt1a/gt3a infections expressed significantly 
lower CpG (0.44 ± 0.07) than gt3 sequences isolated from mono-infected samples (0.51 ± 
0.07). Additionally, no differences were identified in the UpA levels between any of the 
sample groups analysed.  
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In section 4.5, qPCR assays were used to quantify the relative amounts of gt1a and gt3a virus 
in the mixed gt1a/3a infections. Where data was available, the estimated proportion of the 
minor strain present was plotted on a graph with the level of CpG and UpA expression in the 
gt3a E1-E2 sequences isolated from the same sample (figure 6-2). No correlations between 
the proportion of the minor strain and the relative levels of CpG or UpA were identified.  
 
 
Figure 6-2; Proportion of the minor strains and their CpG and UpA expression 
Correlation between the proportion of the minor HCV genotype and the O/E ratios of CpG and UpA expression 
in gt3a E1-E2 sequences. Trend lines are shown with calculated R2 values. 
 
Consensus sequences were available for gt3a NS5B sequences from 15/20 mixed infection 
samples that underwent deep sequencing. Dinucleotide frequency analysis was carried out on 
these samples and compared with an analysis of gt3a NS5B sequences (figure 6-3). A subset 
of the samples used for the E1-E2 analysis were used in the NS5B analysis since a number of 
samples had to be excluded due to having only partial genome sequences available. There 
were not enough gt1a NS5B sequences obtained from the mixed infection samples during the 
deep sequencing to enable a similar comparative analysis. 
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Figure 6-3; CpG and UpA expression in the NS5B region of mixed infection positive samples 
CpG and UpA expression within a 390bp region of NS5B in genotype 3a sequences involved in both mixed 
gt3a/gt1a (striped colour) and single genotype (solid colour) infections. 
 
Both CpG and UpA were repressed within the NS5B region analysed, with O/E ratios of <0.5 
calculated for each dinucleotide pair in both groups. In contrast to the E1-E2 region however, 
no difference was observed between the CpG levels in the two sample groups analysed. This 
suggests that the decreased CpG levels observed during mixed infections may only occur 
within selected genome regions. There were no differences observed between the expression 
of CpG and UpA in the NS5B region (0.01 and 0.01 respectively) unlike in the E1-E2 region 
where differences ranged from 0.17 (gt1a mono infection) to 0.45 (gt3a mixed infection).  
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6.2.2 CpG and UpA frequency in other mixed genotype infection 
studies 
In order to further investigate the reduced CpG expression in gt3a viruses in mixed 
infections, a literature search was carried out to identify publications on mixed genotype 
HCV infections that also published sequences from the study in Genbank. Once identified, 
the sequences were downloaded, aligned and the CpG and UpA levels within them were 
analysed. Results from the study are shown in figures 6-4 and 6-5. The accession numbers of 
analysed sequences are listed in table 8-1.   
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Figure 6-4; CpG and UpA expression in E2, sequences from Smith et al. (2010) 
CpG and UpA expression in a 225bp region of E2 in patients with mixed HCV infections. Patient number is denoted before genotype and sequences were taken from Smith et 
al., (2010) (Smith et al., 2010).  
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In a study by Smith et al., (2010) (Smith et al., 2010), 10 patients were identified with acute 
mixed genotype HCV infections. Seven individuals were identified as having mixed 
infections involving gt3a and 6/7 of these involved at least one other genotype. An analysis of 
the CpG and UpA expression levels in the sequences isolated from the subjects is shown in 
figure 6-4.  Consistent with previous observations, genotype 3a viruses were shown again to 
have particularly strong repression of CpG dinucleotides, having an average O/E of 0.43 ± 
0.03 compared to gt1a strains (average O/E of 0.74 ± 0.03). Gt3a sequences were also the 
only genotype to consistently have CpG repressed to a greater extent than UpA. They also 
demonstrated the greatest difference between the levels of CpG and UpA expression with an 
average difference of O/E of 0.44 compared to 0.04 for gt1a and 0.30 for gt1b. Evidence also 
suggests that repression is greater in mixed infections containing at least one other genotype 
than in mixed infections containing multiple gt3a strains (patient 1), although there is only 
one example in this study. Of the 8 infections involving genotype 1a, only the sequences 
from subjects 8 and 9 repressed CpG to a greater extent than UpA.  
 
 
Figure 6-5; CpG and UpA expression in E1-E2, sequences from Herring et al. (2004) 
CpG and UpA expression in a 490bp region spanning E1-E2 in samples from a cohort of injecting drug users. 
Sequences were published by Herring, et al., (2004) (Herring et al., 2004) and have been analysed by genotype.  
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A study by Herring, BL et al., (2004) (Herring et al., 2004) followed a cohort of injecting 
drug users over a period of 12 months and identified a high rate of superinfection within the 
cohort. A dinucleotide frequency analysis was performed on sequences published from the 
study and the results are presented in figure 5. Whilst it was not possible to distinguish the 
individual patients in this study, the gt3a strains can again be seen to have an increased 
repression of CpG dinucleotides (O/E 0.52 ± 0.05) relative to the other genotypes (O/E 0.70 ± 
0.04 for gt1a and 0.82 ± 0.06 for gt1b).  As seen previously, there was no difference in the 
levels of UpA expression between the different genotypes analysed.  
6.3 CpG and UpA dinucleotide frequency within the 
hepatitis C genotypes 
6.3.1 Genotypic differences 
The hepatitis C viruses show a significant amount of diversity, having up to 30% sequence 
diversity between the genotypes at the nucleotide level. Differences in transmission 
associations, disease progression and response to therapy have all been documented. Given 
these differences, and the differences observed between gt1a and gt3 in section 6.2, it was 
hypothesised that there might also be differences in the relative dinucleotide expression of the 
other genotypes. An expanded analysis, looking at full-length HCV sequences and grouping 
them by genotype was undertaken. It is possible that any differences detected may improve 
our understanding of the evolutionary history of HCV which is still relatively unknown. All 
the analysed sequences are presumed to be isolated from individuals with single genotype 
infections. The number of sequences that were analysed is indicated in table 6-1 and the 
results are shown in figure 6-6.  
 
 
 
 
185 
 
Table 6-1; Sequences analysed during HCV genotype study  
Numbers of full-length HCV sequences of each genotype downloaded from the Genbank database (October 
2014) and analysed for CpG and UpA dinucleotide frequency.  
HCV genotype 
Number of sequences 
analysed 
1a 373 
1b and 1(other) 452 
2 172 
3 69 
4 66 
5 11 
6 81 
7 1 
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Figure 6-6; CpG and UpA expression in the HCV genotypes 
O/E ratios of CpG and UpA dinucleotide frequencies in all available full-length HCV sequences downloaded from Genbank. Recombinant strains were excluded from the 
analysis and sequences have been grouped by genotype.  
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An analysis of all full-length HCV sequences available in the NCBI Genbank database 
indicated there was wide variation in the CpG and UpA frequency ratios between the HCV 
genotypes. The ratio of O/E CpG frequency averaged 0.73 ± 0.03 across the genotypes and 
UpA averaged 0.77 ± 0.03. In the majority of sequences, CpG was repressed to a greater 
extent than UpA. The lowest CpG levels were observed in gt2 sequences which were found 
to have an average O/E ratio of 0.68 ± 0.02. A closer look at the gt2 sequences indicated that 
gt2b was largely responsible for this low CpG level. HCV gt2b had the lowest levels of CpG 
across the genome with an average O/E of 0.65 ± 0.02. The highest levels of UpA expression 
were observed in gt5 and gt6 sequences although there was significant variation, particularly 
among the gt6 sequences. Despite there being fewer sequences available to analyse, greater 
variation in CpG expression was observed in gt4, gt5 and gt6 than in gt1. The average O/E 
for CpG in gt1a was 0.73 ± 0.01, and this was similar to the O/E calculated for gt3 sequences 
(0.72 ± 0.02). This indicates the large differences in CpG expression between gt1a and gt3 
strains observed during mixed infections in sections 6.2.1 and 6.2.2 are likely to be region-
specific. The difference between UpA and CpG expression appeared to be less for gt1 and gt4 
sequences relative to the other genotypes analysed. The ratio of O/E UpA frequencies in 
genotype 4 was also found to be lower on average (0.75 ± 0.02) than for other genotypes. 
These findings correlate well with previous work by Washenberger et al. (2008) 
(Washenberger et al., 2008), who found that gt2 and gt3 strains expressed greater amounts of 
UpA dinucleotides relative to gt1 strains.  
 
6.3.2 Across the hepatitis C genome  
Whilst the HCV genome is transcribed as a polyprotein, an analysis of the CpG and UpA 
dinucleotide frequency by gene may still be useful as it allows insight into the uniformity of 
CpG and UpA along the full length of the genome. The CpG and UpA levels across the HCV 
genome were analysed after grouping by viral genotype and splitting the genome up into its 
gene products. Results are shown in figure 6-7.  
The data indicated that repression levels varied significantly throughout the genome and that 
differences between the genotypes were present.  All the HCV genotypes showed similar 
trends of CpG repression across their gene products with the lowest levels of CpG expressed 
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within the E2 and NS4B regions. Gt2 viruses were also noted to have particularly low CpG 
expression in their p7 and NS2 regions. The highest levels of CpG expression were generally 
observed in the 5’UTR and the core region. Both these regions have been shown to have high 
levels of secondary structure (Mauger et al., 2015) and as a result, the adaptability of these 
regions is constrained. In the majority of analysed regions CpG is suppressed to a greater 
extent than UpA, although exceptions do occur, noticeably in the core, E1 and NS5A regions.  
In terms of genotypic differences, the average difference between CpG and UpA repression is 
greater for gt2 (26%) than for either gt1a (5%), gt3a (16%) or all genotypes (7.4%). This 
greater difference occurs because in general, gt2 sequences had lower CpG expression across 
the genome and higher UpA levels relative to the other genotypes. Gt2 viruses were found to 
repress CpG more than UpA in 9/11 regions analysed and gt3 viruses in 8/11 regions. Among 
the gt1a viruses, CpG was repressed to a greater extent than UpA in 6/11 regions analysed. 
Gt3 viruses also had the greatest variation in levels of CpG repression across the regions with 
a 38% difference in the expression levels between core and NS4B. For gt1a, the maximum 
difference was 23%, for gt2 it was 28% and for all the genotypes it was 21%. The differences 
between the expression levels of UpA in different regions were similar for gt3 (46%) and gt2 
(47%) viruses. Less variation in the levels of UpA was again observed in gt1a viruses (37%) 
and within all the genotypes (31%). Higher levels of CpG expression are observed in the E1 
and E2 regions of gt3 in figure 6-7 than were observed in figure 6-1. This was a result of the 
fact that the sequences analysed in figure 6-1 were short regions spanning E1 and E2 
(approximately nt 1200 - 1800 on H77) and did not include the full E1 or E2 sequences. This 
data indicates that the E1-E2 region and HVR-1 and HVR-2 have low CpG expression 
relative to the full E1 and E2 sequences.    
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Figure 6-7; CpG and UpA expression across the HCV genome 
Analysis of CpG and UpA frequencies across the HCV genome for gt1a (n=373), gt2 (n=172), gt3 (n=69) and averaged across all genotypes (n=1225). The analysis 
performed using all available full-length HCV sequences downloaded from Genbank (table 6-1). 
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6.4 Dinucleotide frequency within the Flaviviridae 
6.4.1 Dinucleotide expression within the Flaviviridae genera 
Full-length Flaviviridae reference genomes, including viruses from all 4 genera, were 
analysed to determine the O/E ratio of each dinucleotide pair. Results are displayed in figure 
6-8. Across the Flaviviridae, patterns of dinucleotide pair frequency are relatively conserved 
with almost all the viruses repressing CpG and, to a lesser extent UpA dinucleotide pairs. 
Increases in other dinucleotide pair frequencies that are likely to be compensatory also appear 
to be conserved across the family, with TpG and CpA having O/E ratios greater than 1.2 in 
the majority of viruses analysed. The majority of other dinucleotide pairs clustered together 
with O/E ratios of between 0.8 – 1.2, suggesting there was little or no repression or selection 
for these combinations of nucleotides. The O/E ratio of the CpG levels ranged from 0.36 
(porcine pestivirus) to 0.84 (rodent pegivirus). The corresponding values for UpA ranged 
from 0.42 (TBEV) to 0.95 (pestivirus). The average difference in O/E expression between the 
most and least expressed nucleotides was 0.75 ± 0.2. The HCV reference strains 1-6 followed 
the typical pattern of repression observed throughout the virus family but did not show 
particularly low CpG and UpA frequencies when compared to the rest of the virus family. 
The average difference between the O/E for the most and least expressed dinucleotides of the 
HCV viruses was 0.53 ± 0.04. The viruses showing the greatest difference in their expression 
levels (> 1.0) were Dengue virus-2, YFV and TBEV. O/E ratios within the coding regions of 
the human genome have been estimated to be 0.43-0.46 for CpG dinucleotides (Duret and 
Galtier, 2000; Witteveldt, Martin-Gans and Simmonds, 2016) and 0.51 for UpA dinucleotides 
(Duret and Galtier, 2000). Whilst expression levels of CpG and UpA dinucleotides among 
dengue viruses, TBEV, WNV and YFV are similar to those observed in human mRNA, the 
expression of CpG and UpA within the hepaciviruses and pegiviruses is considerably higher 
than that observed in humans.   
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Figure 6-8; dinucleotide pair frequencies within the Flaviviridae 
 Whole genome analysis of dinucleotide pair frequencies of Flaviviridae  reference strain sequences available from the Genbank database. The dinucleotides CpG, UpA, CpA 
and TpG have been highlighted in colour. Lines indicating O/E ratios of 0.8 (grey), 1.0 (black) and 1.2 (grey) have been included.   
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An analysis of the UpA and CpG expression patterns of 76 full-length Flaviviridae reference 
genomes indicated that the patterns of dinucleotide expression were closely associated with 
the phylogenetic grouping of the viruses (figure 6-9). Distinct phylogenetic groups clustered 
in the phylogram either on the basis of their genus or on the basis of their transmission vector. 
In the 56.6% of cases, CpG is repressed to a greater extent than UpA. The average difference 
between the UpA and the CpG O/E expression was 0.16 ± 0.17, indicating there was 
considerable variation of both the CpG and UpA expression levels throughout the viruses. In 
general, vertebrates have been shown to repress both CpG and UpA whereas invertebrates 
only repress UpA motifs in their genomes (Bird, 1980). Viruses infecting only insects, the 
insect flaviviruses (ISFV), showed a similar pattern to their insect hosts, repressing UpA but 
not CpG. The ISFV had the highest level of CpG expression with an average O/E of 0.85 ± 
0.07. Similarly to work presented by Lobo et al. (2009)  (Lobo et al., 2009), viruses infecting 
vertebrates repressed both UpA and CpG motifs, reflecting the trends of their hosts. 
Exceptions were observed within the pegiviruses and the hepaciviruses, both of which had a 
relatively high expression of both UpA and CpG when compared with the other Flaviviridae 
and their mammalian hosts. The difference between the amount of CpG repression relative to 
UpA was also less for this group of viruses. Insect flaviviruses, insect-like flaviviruses, 
(ISFV-L) and tick-borne flaviviruses were also unusual as they all repressed UpA to a greater 
extent than CpG. The viruses showing the greatest repression of CpG were the pestiviruses 
with an average O/E of 0.38 ± 0.05. The pestiviruses also had the highest levels of UpA 
expression, with an average O/E of 0.90 ± 0.03. The expression patterns observed in the 
culex spp. and two aedes spp. transmitted viruses were all within a relatively similar range 
(O/E 0.3-0.6). Of the viruses transmitted by Culex spp., 80% repressed UpA to a greater 
extent than CpG whereas among the aedes-transmitted viruses only 11.8% of viruses were 
found to do so. This may represent evolutionary adaptations the viruses have made to their 
respective hosts. Interestingly, the types of infections caused by the two virus groups are 
clinically distinct with Culex-transmitted viruses causing mainly encephalitis-like conditions 
and aedes-transmitted viruses causing acute febrile fevers.  
In both figures 6-8 and 6-9, large differences between the CpG and UpA expression within 
the HCV reference sequences for gt2, gt3, gt5 and gt6 can be observed. In the genotype 
reference sequences for gt1 and gt4, very little difference between the expression levels of 
CpG and UpA is observed. These trends within the reference sequences correlate well with 
the data from figure 6, analysing all full-length HCV sequences that could be identified in the 
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Genbank database. In figure 6-6, a low expression of CpG in the gt2 sequences can be 
observed and for gt3, gt5 and gt6, a higher expression of UpA is observed. The expression of 
both UpA and CpG is similar for both gt1 and gt4 in figure 6-6.   
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Figure 6-9; CpG and UpA expression in the Flaviviridae  
Phylogram and graph illustrating the phylogenetic relationships of the Flaviviridae and the levels of UpA and 
CpG across their genomes. Strain reference sequences, available from the Genbank database, were used for the 
analysis. Phylogenetic ordering groups the viruses into flaviviruses, pestiviruses, pegiviruses and hepaciviruses. 
Using similar groupings to Moureau et al., (2015) (Moureau et al., 2015), the flaviviruses have been further 
grouped into (1)insect flaviviruses (ISFV), transmission by (2)ticks, (3)aedes mosquito species and (5)culex 
mosquito species and (4) host not known (NK). Grey bars have been used on the axis on the right to highlight 
the groups as indicated on the left axis.  
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6.4.2 The impact of viral host range within the hepaciviruses and 
the pegiviruses 
Findings presented in section 6.4.1 indicate that viral host range may influence the relative 
expressions of CpG and UpA. The influence of host range was examined with an expanded 
analysis of hepatitis C viruses and closely related hepaciviruses and pegiviruses (figure 6-10). 
Phylogenetically, pegiviruses and hepaciviruses grouped together on the basis of the host 
they infect, suggesting that the specific adaptations required to infect and adapt to host 
species leaves an imprint on their viral genomes. In general, the patterns of UpA and CpG 
expression were reasonably consistent across the viruses, with 55.4% of viruses repressing 
CpG to a greater extent than UpA. Greater repression of UpA relative to CpG was more 
common among the pegiviruses relative to the hepaciviruses. In the majority of cases, the 
difference between UpA and CpG expression was not large, with the average difference in 
O/E for the two dinucleotides being 0.08 ± 0.08. On average, the difference between the 
expression of CpG and UpA was found to be similar for both the hepaciviruses (0.08 ± 0.06) 
and the pegiviruses (0.07 ± 0.1) although there was considerable variation within the 
pegiviruses. The difference in expression levels was greater in the pegiviruses and this was in 
large part due to the expression patterns observed in viruses infecting bats. In almost all bat 
pegiviruses analysed UpA was repressed to a greater extent than CpG. Viruses infecting bats 
had the highest levels of CpG expression and had the greatest difference in the expression 
levels of the two dinucleotide pairs.  
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Figure 6-10; CpG and UpA expression in the hepaciviruses and the pegiviruses 
Phylogram and graph illustrating the phylogenetic relationships of full-length hepacivirus (highlighted in 
yellow) and pegivirus (highlighted in grey) genomes and their relative expression of UpA and CpG. 
Phylogenetic ordering can be observed to group the viruses by host (illustrated) in the majority of cases. 
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6.5 Relative synonymous codon usage 
There are 20 amino acids and 64 possible codons, therefore many amino acids can be 
encoded by multiple codons. This degeneracy in the genetic code enables organisms to select 
for and against certain codons.  Numerous factors are thought to influence the codon use bias 
in organisms including translational efficiency, genetic drift and RNA stability. Selection for 
and against specific dinucleotide pairs within the genome will additionally impact on the 
codon usage of organisms. In the following sections, the synonymous codon usage within the 
hepatitis C virus genotypes and then within the Flaviviridae is analysed.  
6.5.1  Relative synonymous codon usage within the hepatitis C 
viruses 
The RSCU of 1273 full-length HCV genomes were analysed and then an average calculated 
for each genotype. The results are given in figure 6-11 (gt1a to gt7) and the numbers of HCV 
sequences for each genotype are given in table 6-1. An overall suppression of CpG and UpA-
containing dinucleotides was observed and, for 12/14 of the amino acid- encoding codons, 
compensatory increases were observed in codons without these dinucleotide signatures.  The 
results indicated a particularly strong suppression of UpA-containing codons in the HCV 
genome. A particularly strong repression of TTA (L) was identified in all the genotypes 
analysed. There was also a strong bias against the use of GTA (V) in all genomes, and this 
appeared to drive strong selection for the GTG (V) codon in its place. In the case of tyrosine 
(Y) where both codons contain UpA motifs, there was a marked preference among all 
genotypes for TAC rather than TAT. The ATA (I) codon for isoleucine (I) was also repressed 
in all genotypes and a compensatory preference for the ATC (I) codon was consistently 
observed in the sequences. Whilst repression of CpG-containing codons was also observed, it 
was not consistent. GCG (A) was not repressed in 5/8 of the analysed genotypes despite there 
being 3 other codons encoding the amino acid. A strong bias against CGA (R) was also 
evident in all the genotypes but CGC and CGG both appeared to be used preferentially 
despite containing CpG and there being two other codons available that don’t include a CpG 
motif. All the genotypes displayed a strong repression of CpG-containing codons for proline 
(P) (CCG), serine (S) (TCG) and threonine (S) (ACG), and compensatory preferences for 
CCC (P), TCA (S), TCC (S) and ACC (T) were observed. 
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Differences were identified between the genotypes in the extent to which some codons were 
favoured relative to others. Gt1a was observed to show the strongest biases in selection for 
isoleucine, leucine and valine codons. Gt3 sequences showed less codon bias relative to the 
other genotypes. The O/E ratio for many of the CpG- and UpA-containing codons was 10-
20% higher for the gt3 sequences when compared with other genotypes. Preferential selection 
for alternative codons was also less for gt3 sequences. This suggests that the g 3 viruses are 
less constrained by codon bias although the implications of this are unclear. Gt5 sequences 
showed similarity with the RSCU observed in genotype 3 strains although it should be noted 
there were only 11 genotype sequences available for this analysis.  
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Figure 6-11; Relative synonymous codon usage of the HCV genotypes 
RSCU values were determined for gt1a, gt1b, gt2, gt3, gt4, gt5, gt6 and gt7 as an average calculated from all available full-length HCV genomes (table 6-1 and table 8-1).  
Codons containing TpA (UpA) and CpG nucleotides have been highlighted with green and black arrows respectively. Codon use bias was also examined in the E1-E2 
sequences from samples with mixed infections (mixed groups) and compared with samples of the same genotype not involved in mixed infections (mono groups). Lower than 
expected codon use is highlighted in blue and higher than expected codon use in red.. 
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The second part of figure 6-11 shows the RSCU within the E1-E2 sequences isolated from 
individuals with mixed gt1a/3a infection compared with sequences from individuals with 
either a gt1a or a gt3a infection (mono groups). This is an identical sequence set to the one 
previously analysed in figure 6-1. In these sequences, there are marked differences between 
the two genotypes. Although gt3 (7/8) and gt1a (6/8) sequences demonstrated a selection bias 
against a similar number of CpG-containing codons, the selection bias was stronger in 
general for the gt3a sequences.  In gt3a sequences, there was a strong selection bias for the 
two Arginine (R) codons that did not contain any CpGs whereas all four of the CpG-
containing codons were strongly repressed. In gt1a sequences, only 3 of the 4 CpG-
containing arginine codons were selected against with positive selection for CGC (R) 
observed. Of the other two codons for arginine, only AGG showed a positive selection bias. 
Gt3a strains showed a selection bias against CGC (A) which was not observed in gt1a 
sequences. These differences observed in the RSCU patterns between the two genotypes 
suggest that these viruses may adapt differently to pressure from the host immune system 
within this region. Sequences from individuals with mixed infections showed the same RSCU 
biases as those from individuals with a single genotype infection. The selection against CpG-
containing codons in mixed gt3a infections was comparable to the selection biases observed 
in the mono-infected groups. This suggests that the difference observed in figure 6-1, 
whereby overall CpG is repressed to a greater extent in mixed compared to mono-infected 
gt3a samples, is the result of CpG repression in multiple codons rather than one particular 
codon. The repression of UpA-containing codons was comparable for both gt1a and gt3 with 
both genotypes repressing 7/8 UpA-containing codons. The exception was TAC (Y) which 
was actively selected for by both the genotypes in the E1-E2 region in preference to TAT, the 
only other triplet encoding tyrosine.  
As the HCV genome is translated as a single polypeptide it is unusual that stop codons were 
encountered in the analysis of the full-length genomes and also that repression of the two 
UpA-containing codons occurred alongside an increase in the only non-UpA stop codon. All 
genotypes preferentially used the TGA stop codon rather than TAA or TAG which both 
contain UpA dinucleotides. Evidence for the presence of stop codons within the genome of a 
virus that is translated as a single polypeptide was unexpected. Given that the virus has a 
3’UTR at the end of the genome, a single stop codon at this position would be expected but 
the data presented here indicating a preferential use of the TGA stop codon implies that there 
must be multiple stop codons within the genome. In the analysis of the E1-E2 sequences from 
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mixed and mono-infected individuals, all sequences displayed a strong repression of all the 
stop codons. Given that the sequences analysed are from a region of a virus that translates a 
polyprotein, we would not expect to find any stop codons within this region and the data 
supports this. It is possible that a number of stop codons may be present within the 5’ and 3’ 
UTRs in the full-length genome analysis as they would have a negligible effect on the 
translation of the genome in this position. It is also probable that a number of stop codons 
may be the result of sequencing errors although the preferential use of the non-UpA codon 
would suggest they are occurring naturally within the genome. 
6.5.2 Relative synonymous codon usage within the Flaviviridae  
The synonymous codon usage of full-length reference genomes of the Flaviviridae were 
analysed and the results are shown in figure 6-12.  The results indicate that within the 
Flaviviridae there is a strong repression of codons containing either UpA or CpG, with the 
possible exception of TAT and TAC, perhaps because these triplets are the only ones 
encoding tyrosine. In viruses where there was a strong overall repression of either CpG or 
UpA, the codons containing those dinucleotides were strongly repressed. Likewise, in viruses 
where relatively little CpG or UpA repression was observed, the codon use patterns are also 
less biassed. In particular, strong selection against UpA containing stop codons and CpG 
containing arginine codons is evident throughout the family. The three most repressed 
codons, with an average O/E of <0.6 are TTA (L), CGA (R) and GTA (V). Amino acids with 
a single codon, M and W, show exactly the expected codon frequency (O/E = 1.0 +/- y), as 
viruses are unable to preferentially favour an alternate codon for these amino acids. 
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Figure 6-12; Relative synonymous codon usage within the Flaviviridae 
A heat map of the RSCU within the Flaviviridae. Codons containing TpA (UpA) and CpG nucleotides have 
been highlighted with green and black arrows respectively. Lower than expected codon use is highlighted in 
blue and higher than expected codon use in red. Phylogenetic ordering groups the viruses into flaviviruses, 
pestiviruses, pegiviruses and hepaciviruses. The flaviviruses have been further grouped by transmission 
vector as (2)tick, (3)aedes mosquito species and (4)culex mosquito species. Remaining viruses have been 
grouped as either  (1)insect flaviviruses (ISFV) or (4) host not known (NK). 
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Many of the observations in this study mirror those found previously in the dinucleotide 
frequency analysis. ISFV show a bias against UpA-containing codons but do not appear to 
select against CpG-containing codons.  As seen previously, the RSCU of the ISFV-L 
viruses is also more similar to viruses infecting vertebrate hosts than it is to other ISFV. 
Within the pestiviruses, an extremely strong repression of codons with CpG is observed 
and this is particularly evident for the CpG-containing arginine and serine codons. 
Likewise, there is a strong compensatory selection for AGA (R) and AGG (R) among the 
pestiviruses. Pestiviruses also showed little repression of UpA dinucleotides and that is 
reflected here with several UpA-containing codons having O/E values >1.0. Strong biases 
against CpG-containing codons were also observed in the aedes-transmitted flaviviruses, 
particularly in the Dengue viruses. There is strong evidence to suggest that there is a 
common pattern of codon usage within the vertebrate-infecting flaviviruses in this analysis. 
All these viruses show strong biases against CpG- and UpA-containing codons. The RSCU 
observed in hepaciviruses and pegiviruses showed bias against UpA-containing codons but 
not against CpG-containing codons. The overall patterns observed within the hepaciviruses 
and pegiviruses were remarkably similar to those observed within the ISFV group. It is of 
interest to note that like hepaciviruses and pegiviruses, some ISFV have been documented 
to persist throughout the lifetime of their mosquito hosts (Sang et al., 2003). It is probable 
that in order to establish these chronic infections, all these viruses groups have evolved 
immune escape mechanisms to allow them to persist thus reducing the viruses’ reliance on 
mimicry of host codon usage to avoid detection.   
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6.6 Chapter conclusions 
In this chapter, the HCV genotypes have been shown to express CpG and UpA 
dinucleotides at a considerably higher level than is observed within the coding regions of 
the human genome. Lobo et al., (2009) have hypothesized that this relatively high 
expression of CpG and UpA may be linked to the viruses’ ability to modulate both the 
innate and the adaptive immune responses during infection (Lobo et al., 2009). Differences 
were also noted in the CpG and UpA expression between the different HCV genotypes, 
and there is an indication that these differences have evolved as a result of immune-
mediated pressure on the genotypes. Further work investigating the CpG and UpA 
expression within the Flaviviridae indicated that there is wide variation in the extent of 
CpG and UpA repression throughout the family with patterns generally being associated 
with phylogenetic groupings and common host tropisms. This suppression is also evident 
within the RSCU patterns observed within the viral family which, depending upon the viral 
host, often show marked preferences for codons not containing CpG and UpA.  
This study found evidence suggesting that gt3a viruses display an enhanced repression of 
CpG motifs in the E1-E2 region when involved in mixed genotype infections with gt1a. 
This observation was made using sequences from the data set presented in section 6.2 
(figure 6-1) and comparable results indicating a very low expression of CpG dinucleotides 
in gt3 strains involved in mixed infections were found after analysing published sequences 
from other studies (Herring et al., 2004; Smith et al., 2010). The reasons for this reduced 
CpG expression are unclear. Reductions in both the CpG and UpA motifs in RNA viruses 
have been shown to confer an increased replicative rate to the viruses studied (Atkinson et 
al., 2014). Previous work has also shown that low CpG and UpA poliovirus mutants can 
accumulate at greater titres in the brain (Lauring et al., 2012). These studies suggest that 
low CpG and/or UpA may confer a fitness advantage in RNA viruses. The low CpG 
observed in this study in gt3a viruses may confer a replicative advantage relative to the co-
infecting gt1 viruses and this correlates well with our earlier qPCR study demonstrating 
that gt3a viruses were most often the major viral genotype present in the mixed infections 
we analysed. Given that the E2 region of gt1 viruses has the unique property of protein 
kinase R (PKR) inhibition a key anti-viral protein (Atkinson et al., 2014), changes to this 
sequence may result in the loss of this function in this genotype, making the virus more 
interferon-sensitive (Lloyd et al., 2007). The gt3a E2 region is not constrained by such a 
function and this may explain the differences in the biases observed between the two 
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genotypes. It is also possible that the reduced gt3a CpG expression is a response to strong 
immune responses triggered by the gt1a viruses. Additionally, there is evidence to suggest 
that HCV viruses compartmentalise during infection with distinct viral populations 
detectable in the liver, serum and PBMCs among others (Navas et al., 1998; Di Liberto et 
al., 2006). It may be that reduced CpG enables gt3a viruses to compartmentalise into other 
tissues during mixed infections, enabling survival during mixed infection.  
This study was constrained by the limited availability of sequences from samples involved 
in mixed genotype infections. Studies in the field are often focused on the prevalence of 
mixed genotype infection and therefore sequences from identified samples are rarely 
published. In studies where sequences have been published, there is considerable variation 
in the region of the virus genome that was sampled with studies using the 5’UTR 
(Tsatsralt-Od et al., 2005), E1-E2 (Smith et al., 2010) and NS5B (van de Laar et al., 2009) 
regions to identify mixed genotype infections and in several studies, the sequences are 
poorly annotated making it difficult to decipher the sequences of interest. Coupled with the 
low number of studies, this variation in methodology makes it difficult to infer robust 
conclusions from the available data. In both the mixed infection samples from this research 
and the sequences from the literature, genotype 1a persistently co-infected with gt3a. In 
order to investigate if gt3a sequences also show a reduced CpG expression when in co-
infection with other genotypes, further work would be required to identify individuals with 
such rare infections. The majority of sequences analysed in this study were taken at a 
single time point and previous studies have shown fluctuating viral loads over the course of 
mixed infections (Pham et al., 2010; Grebely, Pham, et al., 2012). It would be interesting 
to analyse dinucleotide frequencies from samples at these different time points and 
investigate if there is any correlation with the changes in viral load. A recent breakthrough 
enabling the in-vitro culturing of clinical HCV isolates (Saeed et al., 2015) will also offer 
the opportunity to study mixed genotype infections  in-vitro for the first time. In addition to 
facilitating the culturing of isolates from patients with mixed genotype infections, this will 
also make the propagation of mock mixed infections, involving the co-culture of isolates 
from multiple patients possible. Whilst not providing an ideal model of the in-vivo 
infection process as many hepatoma cell lines lack key immune signalling pathways, these 
models will allow researchers to study how competition between the genotypes occurs. It 
would be interesting to take regular samples from these mixed isolate cultures and look for 
evidence of changes in the CpG levels of the virus over time as this may provide further 
evidence to support the observations made in this study.    
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A previous analysis of the codon usage of HCV by Zhou et al., (2013) demonstrated that 
HCV has a tendency to select against CpG- and UpA-containing codons (Zhou et al., 
2013).  Our study demonstrated a similar trend among the hepatitis C viruses and builds on 
the work of Zhou et al. (Zhou et al., 2013), by analysing a considerably larger dataset of 
viral sequences and analysing the different HCV genotypes separately. The study presented 
in this chapter found evidence of distinct differences in dinucleotide frequency and RSCU 
between the HCV genotypes. Previous work has suggested that the host immune system is 
a key driver of divergence among the HCV genotypes (Pang, Planet and Glenn, 2009). We 
found evidence supporting this with patterns in dinucleotide frequency and codon use 
among the HCV genotypes correlating negatively with interferon sensitivity. Genotype 2, 
which is the most sensitive to interferon-based therapies, expresses the lowest amount of 
CpG. The most interferon resistant genotype, gt1, and the other genotypes with 
intermediate interferon sensitivities express greater levels of CpG dinucleotides. Whilst 
these do suggest genotypic differences in interferon sensitivity, it is difficult to extrapolate 
if this variation in response to therapies indicates an accurate measure of in vivo 
endogenous interferon sensitivity. In vitro studies have suggested that CpG detection may 
be mediated by  PKR  and gt2 the is only HCV genotype whose NS5A is unable to inhibit 
PKR (Noguchi et al., 2001). PKR inhibition in genotype 1 viruses is uniquely mediated by 
both the E2 and NS5A proteins, resulting in a strong resistance to interferon (Noguchi et 
al., 2001; Lloyd et al., 2007). Studies have identified increased interferon induction in 
patients infected with gt1 (Robinson et al., 2015; Robinson et al., 2015). It is possible that 
the repression of CpG motifs in other genotypes may reduce the levels of interferon being 
activated which would be advantageous given they are more sensitive to its effects. The 
properties of these genotypes correlate well with dinucleotide biases observed in the 
genotypes in this study. In the dataset analysed, however, there was an over-representation 
of gt1 sequences (n=825) relative to the other genotypes (n=400). The number of studies 
contributing non-gt1 sequences was also low for some genotypes, meaning that the 
diversity of the isolates analysed was low in a number of cases. This bias within the 
sequences may have affected interpretation of the results and the dataset should be 
supplemented with full-genome sequences from other genotypes when they become 
available. A larger number of non-gt1 sequences within the dataset could provide more 
diversity for this analysis and increase the support for the observations made in this study.  
One of the major selective factors for dinucleotide frequency patterns among RNA viruses 
is thought to be the mimicry of host genomes (Greenbaum et al., 2008). Previous work by 
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Lobo et al. (2009), has examined this subject in detail and the data form this study supports 
the findings of the 2009 study (Lobo et al., 2009). The dinucleotide frequencies observed 
in the analysed viruses generally demonstrated a good correlation with the patterns 
observed in their host genomes. The majority of the studied viruses ultimately infect 
vertebrates in which the CpG residues are frequently methylated, increasing the risk of 
spontaneous deamination (Kow, 2002). Relative expression of CpG dinucleotides in 
vertebrates is low as a result and consequently, in order to avoid invoking immune 
responses against their genomes, many vertebrate-infecting RNA viruses mimic their hosts. 
UpA expression is also less in many of these viruses although generally to a lesser extent 
than CpG. Invertebrate genomes do not methylate their CpG residues and they have 
relatively high levels of CpG expression as a result (Bird, 1980). This is mirrored in the 
viruses infecting them, with flaviviruses that only infect insects (ISFV) exhibiting strong 
UpA suppression but little repression of CpG motifs. Interestingly, patterns of dinucleotide 
expression among the flaviviruses with unknown hosts (NK) were markedly different with 
greater suppression of CpG observed relative to the ISFV. These differences were also 
reflected in the RSCU of the NK viruses. A number of these viruses were isolated from 
mosquitoes and their hosts remain unknown (Takhampunya et al., 2014; Pauvolid-Correa 
et al., 2015). Work by Kapor et al. (2010) has suggested that dinucleotide composition 
analysis can be used to infer the most probable host for some virus species (Kapoor et al., 
2010). The conserved repression of CpG among the NK viruses suggests that these viruses 
are likely to infect as-yet unidentified vertebrate hosts. Viruses with ticks as intermediate 
vectors were also interesting, displaying a tendency to repress UpA to a greater extent than 
CpG. Ticks are known to have relatively long lifespans and may carry viruses for long 
periods of time, effectively acting as reservoirs as well as vectors. Viruses carried by them 
may as a result have increased adaptations to enable replication within insect hosts rather 
than vertebrates (Parola and Raoult, 2001). The pestiviruses also exhibited unusual trends, 
having a particularly low expression of CpG and a relatively high expression of UpA. 
Uniquely, pestiviruses have been shown to be able to inhibit the induction of type-1 IFN by 
dsRNA and subsequently inhibit the induction of RNAse L (Schweizer and Peterhans, 
2001; Matzener et al., 2009). RNAse L activation has also been shown to specifically 
target UpA and UpU motifs in viral genomes. As pestiviruses are able to inhibit activation 
of RNAse L regardless, there is a reduced selective pressure against UpA in these viruses. 
Whilst it is unclear why CpG suppression is so marked among this genus, it is possible that 
the suppression is associated with the host range of the viruses. The pestiviruses transmit 
directly between vertebrate hosts in herds via nasal secretions without an insect vector 
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(Lindenbach and Rice, 2007). Given that the pestiviruses are not reliant upon an insect 
vector for transmission, the viruses do not need to adapt to replication within insects and 
this may partly explain why the CpG expression is so low within the genus. 
This study adds to previous work by Lobo et al. (2009) (Lobo et al., 2009) by including an 
analysis of the dinucleotide frequencies and RSCU within the pegiviruses alongside the 
other three genera of the Flaviviridae. Both hepaciviruses and pegiviruses were shown to 
have higher levels of CpG and UpA in their genomes relative to other viruses within the 
Flaviviridae. All known hepaciviruses and pegiviruses infect vertebrate hosts and many 
have been shown to be capable of chronic infection in their relative hosts. A key 
requirement in the establishment of chronic infection is the modulation of both the innate 
and adaptive immune responses. It has been suggested that the ability of these viruses to 
repress immune function reduces the necessity to mimic host genomic patterns (Lobo et 
al., 2009). Among these viruses however, viruses infecting bats were found to have 
marked differences relative to other viruses, with relatively high CpG and low UpA 
expression. Bats are an ancient lineage of mammals, having evolved separately from other 
mammals over 50 million years ago (Simmons et al., 2008) and there are distinct 
differences in their immune systems relative to other mammals. In particular, bats lack the 
PYHIN gene family, many of which have key functions in DNA sensing and are known to 
encode the toll-like receptor group of proteins (Zhang et al., 2013). This suggests they are 
lacking a receptor capable of detecting unmethylated CpG motifs, therefore viruses 
infecting these species are not required to select against CpG to the same degree as viruses 
infecting other mammalian species.  
A study by Kapour et al. (2010) used nucleotide composition analysis to ascertain the 
likely hosts of three novel picorna-like viruses (Kapoor et al., 2010). This type of work is 
of particular interest as there remains considerable debate within the field on the 
evolutionary origins of HCV. The data presented in figure 6-9 indicate that the CpG and 
UpA profiles of the hepaciviruses and the pegiviruses are much more similar to the vector-
transmitted viruses than they are to other groups of viruses included in the analysis. 
Viruses utilising alternative routes of transmission including the pestiviruses, which are 
mucosally transmitted among mammals, and the insect-only flaviviruses, show markedly 
different UpA and CpG expression relative to the hepaciviruses and the pegiviruses. This 
compositional similarity to vector-transmitted viruses may indicate that the evolutionary 
history of both the hepaciviruses and the pegiviruses has at some point involved vector-
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borne transmission phases. Research by Pybus et al. (2007) (Pybus et al., 2007) has 
modelled the mechanical transmission of HCV by biting arthropods and demonstrated 
theoretically that it could contribute to the sustained endemic transmission of HCV. Pybus 
et al. also reason that in regions where HCV is endemic, such as West Africa and South 
East Asia, humans are subjected to relatively high biting rates by a wide range of 
arthropods, many of which are theoretically capable of facilitating the mechanistic 
transmission of HCV (Pybus et al., 2007). The findings of this study, showing the 
compositional similarity of HCV with vector-borne flaviviruses indicates that further 
research into the plausibility of arthropod transmission is warranted. The study by Kapoor 
et al. used a more rigorous discriminatory analysis to determine the most likely host 
incorporating information about mononucleotide and all 16 dinucleotide frequencies 
(Kapoor et al., 2010). It would be of interest to apply a similar analysis to a more extensive 
collection of Flaviviridae sequences and to determine if there is good discrimination 
between the different host ranges and transmission routes within the family. Our current 
knowledge of the hepaciviruses and the pegiviruses is expanding with numerous new 
species discovered in recent years (Pfaender et al., 2014). Our understanding of the 
evolutionary history of these viruses is likely to be further improved by the recent 
discovery of human hepegivirus 1 (HHpgV-1) (Kapoor et al., 2015). HHpgV-1 shares 
many features of both the hepaciviruses and pegiviruses and phylogenetic analysis has 
indicated that the virus clusters within a pegivirus clade that is distinct from other known 
human pegiviruses (Kapoor et al., 2015). Future work incorporating an analysis of the 
dinucleotide frequencies and RSCU of HHpgV-1 into this study may also be informative 
from an evolutionary perspective.     
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7 Chapter 7: Discussion 
 
7.1 Cohort characteristics 
In order to study the prevalence of mixed genotype HCV infections in Scotland, a cohort of 
patient-derived samples collected from the infected population in the region was 
successfully curated, comprising samples and anonymised clinical data from 512 patients, 
all of which underwent HCV genotyping during the period August 2013-March 2014. 
Clinical data was available for a further 620 patients who had a HCV genotyping test 
during the same period and of these 1132 records, detailed clinical information was 
available for a subset of 590 patients residing within the Glasgow and Paisley postcode 
districts. Whilst there was some bias within the cohort resulting in patients from Edinburgh 
being underrepresented and those interacting with clinical services being overrepresented, 
the cohort was considered illustrative of the current HCV-infected population in the region. 
Linked clinical data for the study was collected from the clinical portal system, which can 
includes details on patient contact with secondary care providers and can therefore be 
considered a relatively robust data set.   
An analysis of the cohort indicated that injecting drug use was the most common risk 
factor for infection, with 72.7% of subjects reporting a history of injecting drugs. 
Genotypes 1a and 3 were the most prevalent genotypes within the cohort, both infecting an 
estimated 45% of the population studied and almost 75% of the cohort was male. In line 
with a previous study by McDonald et al. (McDonald et al., 2011), the rates of co-
morbidities were high in our population. The most common co-morbidities experienced by 
patients within the cohort were similar to those reported in previous studies and included 
psychiatric disorders, trauma, stabbing or assaults, excessive alcohol intake, neurological 
disorders and gastrointestinal complications (McDonald et al., 2011). Further analysis 
revealed several previously unreported trends within our cohort. HCV viral load levels 
were noted to be significantly lower among female subjects infected with gt3 viruses when 
compared with male subjects infected with either gt1a or gt3 viruses. Previous research has 
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suggested that immune responses against HCV among females are more effective than in 
males, with improved responses to IFN-based therapy (Manns et al., 2001; Innes et al., 
2012) and higher rates of spontaneous clearance being reported in females (Wiese et al., 
2000; Barrett et al., 2001; Micallef, Kaldor and Dore, 2006). These associations are not 
apparent in postmenopausal females, suggesting that oestrogen may have a protective 
effect although the exact mechanisms involved remain to be elucidated (Baden, Rockstroh 
and Buti, 2014).  
Patients infected with gt3 viruses had a significantly higher prevalence of neurological 
disorders (13.0%) than subjects infected with gt1a viruses (7.2%). Few studies analysing 
HCV-associated co-morbidities have stratified their analysis by viral genotype and as a 
result, this finding has not previously been reported in the literature. A previous study 
identified increased rates of depression and anxiety in gt3 patients relative to those infected 
with other genotypes (Ashrafi et al., 2012) however, a patient history of psychiatric 
disorders was recorded separately in this study and, no difference was observed in the 
prevalence of psychiatric disorders between the genotypes in this study. Further 
information on the nature of the neurological disorders experienced by individuals in this 
study is required to confirm the significance of this finding as several factors may be 
confounding. Neurological disorders can be related to excessive alcohol intake and 
cirrhosis and, as both were frequently reported in patient histories within our cohort, they 
are likely confounding factors in the analysis. A repeat of the analysis, after exclusion of 
individuals with a history of excessive alcohol intake may be useful in establishing the 
significance of this finding. If the finding remains significant then the higher prevalence of 
neurological disorders among gt3 patients may indicate that there is either an aspect of the 
gt3 viral life cycle that results in increased neurotoxic activity or, that gt3 viruses are more 
likely to compartmentalise into the central nervous system. Intriguingly, studies have 
detected negative strand HCV genomes in the brain, suggesting that extra-hepatic viral 
replication can occur within the brain (Radkowski et al., 2002; Vargas et al., 2002). 
Radkowski et al. (2002) also identified two patients with different genotypes in serum- and 
brain-derived samples (Radkowski et al., 2005). The study detected gt1a in the brain-
derived sample of one patient and gt3 in the other with gt1b isolated from the serum of 
both patients, indicating that gt3 viruses are capable of compartmentalisation into the brain 
during multi-genotypic infection can occur (Radkowski et al., 2002). 
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It was intended that the clinical history of patients with mixed genotype infections would 
be compared with the history of those infected with a single genotype in order to 
investigate potential differences in clinical presentation and treatment outcomes. Partway 
through the study, it was realised that the specialist nature of the WWSSV meant that 
samples from across Scotland (excluding Lothian) were sent there and our ethical approval 
for the collection of anonymised clinical data only covered the Greater Glasgow and 
Paisley regions. Only 4/19 mixed infection positive samples were identified as belonging 
to patients from within the Greater Glasgow and Paisley regions therefore ultimately we 
were unable to draw any robust conclusions about the clinical impact of mixed genotype 
HCV infections. The difficulties encountered in forming cohorts of individuals infected 
with mixed genotype infection suitable for longitudinal studies have restricted the 
understanding of their prognosis. A well-planned cohort study comparing the health of 
those with mixed infections to those with a single genotype infection would be immensely 
valuable to the HCV field. Questions such as does liver disease progress faster during 
mixed infection, do viral loads fluctuate over time under these constraints, how responsive 
to DAA treatment are these patients and are there any sub-populations (aside from PWID) 
who are particularly prone to mixed genotype infection remain to answered.  
7.2 Mixed genotype infections 
Our research group has previously suggested that undiagnosed mixed genotype infections 
may respond poorly to some DAAs, possibly resulting in minor strain outgrowth and 
genotype switching (McNaughton et al., 2014). Within the UK, mixed genotype infections 
are rarely diagnosed and therefore little is known about their prevalence. A 2010 sentinel 
surveillance study of hepatitis testing encompassing data from 19 diagnostic laboratories in 
England found that mixed genotype infections were diagnosed in just 0.2% (Brant et al., 
2010). Using assays developed for mixed infection screening in gt1a and gt3 patients, an 
estimated prevalence rate for mixed gt1a/gta3 infection of 3.8% was observed within the 
study cohort. Despite only concentrating on g1a and gt3 strains, these results were 
comparable to those previously published in the literature (table 1-2). An evaluation of the 
study indicated that this was likely to be an underestimate of the true prevalence within the 
population (section 4.6). Given that none of the cohort samples had been previously 
identified by the clinic as having mixed infections prior to our study, this suggests the 
prevalence of mixed infection is grossly underestimated in the clinic and indicates that 
current methods used in diagnostic laboratories are inadequate for the diagnosis of mixed 
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genotype infections. A further analysis indicated there was a significant disparity in the 
prevalence of mixed genotype infections between the two genotypes tested and that within 
gt3 diagnosed patients, the prevalence of mixed infection was 6.7%. The prevalence of 
mixed genotype infection among gt1a diagnosed patients was significantly lower at 0.8%. 
This disparity was identified in the pilot study for this project (McNaughton et al., 2014) 
and remained evident after the project was scaled up. The reason for this difference is 
unclear and it has not been reported in previous studies. Further qPCR analysis supported 
this finding, indicating that gt3 was the major genotype in 80% (n=12) of the mixed 
genotype infections with results (n=15). In 66.6% of cases (n=10), the minor strain 
detected was calculated to contribute less than 1% of the total viral load. Previous studies 
have discussed viral competition in mixed genotype infections with many researchers 
concluding that usually the virus with the highest viral load eventually becomes dominant 
(Laskus et al., 2001; Pham et al., 2010; Ramirez et al., 2010). Studies in HIV-positive 
MSM have however shown that multiple HCV genotypes can be maintained over long 
periods of time (Culasso et al., 2014) and that super-infecting strains have the capacity to 
rapidly supplant pre-existing HCV strains (Chung et al., 2015), suggesting that viral 
dynamics during mixed infection are likely to be more complex than previously posited. 
Well documented studies of this nature in HIV-negative individuals are rare in the 
literature as many PWID have chaotic lifestyles and are considered a difficult to access 
population for healthcare professionals. Long-term studies of individuals with mixed 
genotype infections involving sequential sampling and the collection of linked clinical data 
are needed to evaluate the viral dynamics, the clinical prognosis of subjects and the 
consequences of treatment in the DAA era.  
Given that gt3 viruses are already considered relatively difficult to treat with the new DAA 
therapies (EASL, 2015), the additional impact of mixed genotype infection on treatment 
outcomes for this genotype should be evaluated, even if minor strains are present at low 
amounts. A study by Abdelrahman et al. (2015) looking at HCV  positive patients failing 
treatment with pegylated IFN-α and ribavirin has shown that minor strains can persist 
during treatment and supplant other drug-sensitive strains, even if they are present in very 
low amounts (Abdelrahman et al., 2015). Research by Bagaglio et al. (2015) has also 
indicated that infection with mixed genotype HCV infection can be an important 
prognostic indicator for treatment failure with pegylated IFN-α and ribavirin-based therapy 
(Bagaglio et al., 2015). Studies establishing response rates of mixed genotype infections to 
DAAs are lacking currently, largely because current diagnostic tests often lack the 
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sensitivity to detect them and individuals who are diagnosed with mixed genotype 
infections are also frequently excluded from clinic trials. Numerous treatment options for 
mixed genotype infections are available, including reputedly pan-genotypic treatments 
such as the sofosbuvir/ velpatasvir (marketed as Epclusa) (The Medical Letter, 2016) and 
combinations of other DAAs approved separately for the treatment of specific genotypes 
(AASLD-IDSA Guidance Panel, 2016). Studies on the effectiveness of DAAs for the 
treatment of mixed genotype infection should be undertaken to inform on clinical 
guidelines. Studies of this nature will also be of interest to public health bodies, some of 
whom have proposed treating injecting drug users with DAAs in order to reduce 
transmission within the population (Hellard et al., 2015). It should be considered however 
that the incidence of mixed genotype infection has been shown to be considerably higher in 
active drug users (van de Laar et al., 2009; Pham et al., 2010) and unless further studies 
are published showing these treatments are effective, such initiatives should proceed with 
caution to ensure resistance to DAAs is not selected for in these populations. The 
inappropriate treatment of mixed genotype HCV infections with DAAs may also lead to 
genotype switching, with DAA-resistant minor genotypes outgrowing and supplanting 
successfully treated major strains (McNaughton et al., 2014). Without repeated genotyping 
after non-responses to DAA treatment, genotype switching may be incorrectly interpreted 
as re-infection (McNaughton et al., 2014), and public health interventions treating people 
actively injecting drugs should be aware of this possibility.      
Informative in vivo studies on mixed genotype HCV infections are challenging as current 
diagnostic assays often lack the sensitivity to detect them and many subjects infected with 
mixed genotype infections are PWID. Subsequently, studies are often limited by small 
sample sizes, often in relatively specific populations, and incomplete longitudinal data 
(Cunningham et al., 2015). In the study of other viruses, the use of in vitro model systems 
has been highly informative however, the study of HCV within in vitro model systems has 
largely been constrained by the limited successes in culturing patient isolates in cells. The 
study of mixed HCV infection in in vitro systems has so far been challenging and studies 
in the field have relied heavily on the use of replicons and culture-adapted JFH-1 strains 
(Schaller et al., 2007; Tscherne et al., 2007; Webster, Ott and Greene, 2013). Recent work 
by Saeed et al., (2015) has shown that the addition of SEC14L2 to hepatoma cell lines can 
facilitate the culture of a wide range of HCV genotypes isolated from patients (Saeed et al., 
2015). This new method could provide a suitable in vitro model for the study of mixed 
genotype infections. Previous to this breakthrough, chimeric replicon and cell culture 
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studies based on JFH-1 have been the most widely available in vitro systems used to model 
mixed genotype infections. Studies in this system were a poor model for in vivo conditions, 
largely because high amounts of variability in the replicative rate of chimeric replicons and 
virions is observed (Imhof and Simmonds, 2010), therefore inter-genotypic comparisons 
were not possible. In addition to this, HCV viruses are not naturally chimeric and by using 
chimaeras, the action of many proteins is not studied, making these poor models for mixed 
genotype infections. Within the new SEC14L2 cell line model (Saeed et al., 2015), viruses 
of different genotypes can be co-cultured and the intrinsic replicative rates of different 
genotypes can be directly compared. An interesting study that this model system will 
enable is an analysis of the viral interactions observed during co-infection and super 
infection. Several clinical studies have observed that the strain with the highest viral load 
often eventually becomes dominant (Laskus et al., 2001; Pham et al., 2010; Ramirez et al., 
2010) and, using this model (Saeed et al., 2015), a robust in vitro study is now feasible. 
The replicative rates and sequences of the viruses can all be easily monitored and the 
importance of factors such as initial viral load and order of infection can be studied in 
detail.  The SEC14L2 cell line model (Saeed et al., 2015) also has considerable 
applications in the testing of DAA sensitivity for mixed genotype infections. The system 
could be used to observe viral dynamics under selective pressure from DAAs, suggesting 
which treatments are likely to be most effective in vivo. In individuals not responsive to 
treatment, isolates can also be cultured and numerous drugs can be tested against the 
viruses in order to find the most appropriate combination for the patient.  
 
7.3 The potential of deep sequencing for diagnostics 
Samples identified as having mixed genotype infections by traditional RT-PCR methods 
were further analysed by deep sequencing, utilising pan-genotypic PCR assays developed 
for this study targeting the E1-E2 and NS5B regions that were compatible with the 
Illumina MiSeq platform. Initial testing indicated that both assays were sensitive and the 
amplicons they generated proved to be highly discriminatory for HCV viral sub-typing, 
with the assays providing concordant results for 64/64 samples tested. An examination of 
the mixed infection samples yielded E1-E2 reads for both genotypes in 75% (n=15) of the 
samples tested. The data indicated that minor strains were more likely to be detected if they 
contributed a larger proportion of the total viral load and all minor strains contributing 
>0.3% of the viral load (as estimated by qPCR), were detected with the E1-E2 assay. The 
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NS5B assay was less sensitive than the E1-E2 assay, detecting just 30% of the minor 
strains in the mixed infection samples. This data indicated that the deep sequencing 
approach was less sensitive for the detection of mixed genotype infection than the nested 
PCR approach used in the initial screening process. Whilst sequence-based analysis of the 
NS5B region is generally considered the gold standard for HCV sub-typing (Hraber et al., 
2006; Smith et al., 2014), this study has highlighted the unexpected suitability of the E1-
E2 region for sequence-based typing analysis. Probit analysis indicated that the E1-E2 
assay was considerably more sensitive than the NS5B assay for gt1a strains. In the 
majority of mixed genotype infections detected, the minor strain was gt1a and the 
increased sensitivity of the E1-E2 assay for gt1a strains may be a contributing factor to the 
difference in detection rates. In addition, the NS5B region has extensive RNA secondary 
structure (Tuplin, Evans and Simmonds, 2004) and it may be that, after conversion into 
cDNA, secondary structure is still present, resulting in reduced primer binding and hence 
decreased sensitivity. Diversity analysis undertaken on the deep sequencing data also 
suggested that gt3a viral populations involved in mixed genotype infections were more 
diverse than those involved in single genotype infections. Increased viral diversity may 
have important clinical consequences in terms of the disease progression and treatment 
responses. Few studies have investigated the diversity of strains involved in mixed 
genotype infections and compared them to strains from single genotype infections. 
Findings from this analysis are in agreement with work by Toyoda et al., (1996) who used 
fluorescence single-strand conformation polymorphism analysis to show a greater 
quasispecies diversity among individuals with mixed genotype infection (Toyoda et al., 
1998). These findings are of interest as they provide insight into how HCV viruses adapt 
during mixed infection. To my knowledge this is the first study to compare viral diversity 
in mixed and mono-infected samples using deep sequencing methods and as a result, 
numerous issues were encountered in finding the most appropriate bioinformatics method 
for such an analysis. In particular, all methods tested were not able to confidently 
distinguish the presence of multiple strains of the same genotype from quasispecies 
diversity and this made it difficult to draw robust conclusions from the study. The number 
of reads generated by each sample was also found to be a confounding factor with more 
diversity generally observed in samples with larger numbers of reads. Future approaches 
should digitally normalise the numbers of reads in each sample, providing a similar of 
number of reads from each sample for downstream analysis. As the expansion in deep 
sequencing techniques continues to grow, improved bioinformatic tools for an analysis of 
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this nature will be developed and it may be worth re-analysing this data with new methods 
when they become available in the near future.  
HCV viral typing in diagnostic laboratories within the UK is usually classified at the 
genotype level with an additional test frequently used to sub-type gt1 infections into gt1a, 
gt1b and other gt1strains.  Other genotypes are not routinely sub-typed and there appears to 
be no studies examining the diversity of these non-gt1 subtypes in the region. Previous 
studies have shown gt3 infections in the region to be largely caused by gt3a strains 
(Mcnaughton et al., 2015) which have strong associations with transmission by injecting 
drug use. Data from this study supports this and no evidence of other gt3 sub-types present 
in the region was found throughout this study. The genotyping panel used to test the pan-
genotypic assays (chapter 5) was selected using samples from patients within the region 
with results from the diagnostic lab indicating that multiple gt2 and gt4 sub-types were 
present within the population sampled. Genotyping results with our pan-genotypic primers 
from the gt2 samples (n=9) identified both gt2a (n=5) and gt2b (n=4) strains and results 
from the gt4 samples (n=5) distinguished gt4a (n=3) and gt4d (n=2) in agreement with the 
diagnostic lab. Gt5 and gt6 strains are rare in the region and only a single gt6 strain was 
typed during the study. Non gt1 and non gt3 infections are estimated to contribute 6-11% 
of the total HCV infections within the UK depending upon the region (Public Health 
England, 2015). The epidemiology of these strains within the UK is not widely studied and 
the responses to DAA treatments for gt2 and gt4 sub-types are largely presumed to be 
consistent within a given genotype. The considerable differences observed in the genetic 
barriers to resistance against DAAs between gt1a and gt1b (Cento et al., 2012; Paolucci et 
al., 2013) strongly suggest that this is unlikely to be the case and, whilst studies have been 
published examining the sub-type specific responses to treatment in other genotypes (Al 
Ashgar et al., 2013; Chayama et al., 2015), it remains an understudied field.  Further 
evaluation of the pan-genotypic primers developed during this project with a wider range 
of HCV sub-types to assess their potential for genotyping in diagnostic laboratories would 
be useful.  It is also probable that resistance profiling by deep sequencing will become 
standard practice prior to DAA treatment in the near future. The regions of the HCV 
genome targeted by these assays should be evaluated for their potential to accurately sub-
type viruses and diagnose mixed genotype infections. The development of methods for the 
reliable detection of minor HCV strains has applications in DAA resistance testing and 
treatment monitoring, in addition to the diagnosis of mixed genotype infection. The pan-
genotypic primers developed for this study demonstrated that targeted primers can be 
  218 
 
developed that are capable of amplifying a broad range of different genotypes. Similar 
approaches could be developed for regions where DAA resistance associated variants can 
be detected and used to check for either pre-existence within the quasispecies or 
emergence during treatment.  
The major barrier to effective detection of minor strains remains the low viral loads of 
many resistance-associated and secondary infecting minor viruses. Recent work by 
Thomson et al. (2016) using a range of different deep sequencing library preparation 
methods found that viral loads below 1,000 IU/ml were difficult to sequence consistently 
(Thomson, Ip, Badhan, Christiansen, Ansari, et al., 2016) and other methods developed by 
Wei et al. (2016) were only able to consistently identify resistance-associated variants 
when they comprised greater than 5% of the total viral load (Wei et al., 2016). The method 
developed for this project has comparable sensitivities but qPCR results indicated that 
many of the minor strains detected in the mixed genotype infections were present at 
amounts considerably lower than 5% and consequently, the detection of mixed infections 
was poor relative to the Sanger-based genotype-specific approach used in chapter 4. These 
findings suggest that sensitivity is currently limited by the technology and that until 
improvements in the technology emerge, deep sequencing approaches will remain not 
competitive or cost-effective when compared with current Sanger-based approaches for the 
detection of mixed genotype infections. Recently Thomson et al. (2016) demonstrated that 
numerous library preparation methods were capable of detecting mixed genotype 
infections during whole genome sequencing and that the methods used could accurately 
quantify the ratios of each genotype present (Thomson et al., 2016). In addition to the 
limitations imposed by the low viral loads of the minor co-infecting genotypes, we were 
also limited in our options for this study as carrier RNA was used in the initial viral RNA 
extraction process and lack of additional sample prevented a second extraction from taking 
place. Carrier RNA is incompatible with many whole genome sequencing library 
preparation methods as detection of carrier RNA rather than viral RNA requires an 
increase in sequencing depth that is unattainable at worst or has serious cost implications. 
Numerous studies have had success extracting and sequencing low viral load samples by 
replacing carrier RNA with linear polyacrylamide during the extraction process (Malboeuf 
et al., 2013; Naccache et al., 2013). The incorporation of linear polyacrylamide into 
extraction protocols could provide a robust extraction method suitable for low-viral load 
samples without restricting downstream sequencing options. In this study, the use of carrier 
RNA meant we were limited to amplicon-based methods and substantial PCR bias was 
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observed in our controls, indicating that this method cannot be used to estimate the relative 
proportion of a minor strain present, making it unsuitable for resistant variant detection in 
its current form. A recent study comparing several methods of deep sequencing for HCV 
indicated that target-enrichment based methods could be both sensitive and affordable, and 
were capable of accurately detecting the ratios of mixed genotype HCV infections 
(Thomson et al., 2016). This suggests that target-enrichment may have been a useful 
alternative approach for our study although the relatively high error thresholds used are 
likely to reduce the sensitivity of the approach. Methods involving the incorporation of 
target-enrichment or linear amplification strategies should be trialled and compared 
directly with the approach developed for this study to determine if they improve upon 
current sensitivity. Linear amplification strategies may improve upon current diagnostic 
sensitivity by increasing the number of templates but maintaining the proportion of each 
strain present (Hashimshony et al., 2012).  
 
7.4 Dinucleotides biases of HCV and other Flaviviridae 
Previous studies have suggested that low CpG (and/or UpA) levels in RNA viruses may 
confer increased replicative rates (Atkinson et al., 2014) and enable viruses to accumulate 
at greater rates within the brain (Lauring et al., 2012). A study analysing the dinucleotide 
frequency expression in HCV found that gt3 viruses involved in mixed genotype (gt1a/gt3) 
infections expressed fewer CpG dinucleotides in their E1-E2 region than gt3 strains in 
single genotype infections (chapter 6). No significant differences were observed in UpA 
expression. The qPCR analysis of our mixed infections found that gt3a viruses were the 
major viral genotype present in the majority of mixed infections we analysed, supporting 
the possibility that the low CpG expression is conferring a replicative or immune escape 
advantage to the gt3 viruses over the gt1a strains. The previously mentioned SEC14L2 cell 
line model (Saeed et al., 2015) may be a useful tool for studying this phenomenon as 
mixed genotype infections could be generated in vitro and isolates of each genotype 
sampled and sequenced at regular intervals. A key experiment would be to investigate 
competition between gt1 and gt3viruses after artificially reducing the CpG expression in 
gt1a viruses to see if the competitive advantage of the gt3 viruses is diminished. If the 
viruses replicate at similar rates after decreasing the CpG levels in gt1a viruses, it would 
add further weight to the findings of the in vivo study in this project, and support the 
hypothesis that reduced CpG expression is a key factor in viral competition during mixed 
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genotype infections. It would be interesting to investigate if there are specific regions 
within E1-E2 where CpG dinucleotides are selected against during mixed infections and to 
understand how rapidly this occurs. Whilst differences in CpG expression were detected in 
the E1-E2 sequences analysed in this study, no differences in expression were observed in 
the NS5B sequences from the same samples, implying that some regions of the HCV 
genome may be constrained in their ability to repress CpG. Using the SEC14L2 cell line 
model (Saeed et al., 2015), it  would also be possible to evaluate the full-length of the 
HCV genome for altered CpG expression  and investigate if other regions of the virus 
repress CpG during mixed infection.  A recent publication by Witteveldt et al. (2016) has 
shown that reducing the CpG and UpA dinucleotides in HCV replicons and the luciferase 
or neomycin genes encoded within them can drastically enhance replication (Witteveldt, 
Martin-Gans and Simmonds, 2016). Intriguingly and contrary to what was observed during 
this study, genotypic differences in the response to modifications were observed, with gt3 
and gt4 replicons displaying a reduced replication enhancement relative to the gt1b and 
gt2a replicons (Witteveldt, Martin-Gans and Simmonds, 2016). Our study identified 
genotypic differences in the expression of CpG dinucleotides with gt2 viruses, and 
particularly gt2b strains, having the lowest expression of CpG. A recent study has 
implicated protein kinase R (PKR) as a key mediator of CpG detection (Atkinson et al., 
2014) and it is notable that gt2 the is only HCV genotype whose NS5A is unable to inhibit 
PKR (Noguchi et al., 2001).  The study by Witteveldt et al. (2016) (Witteveldt, Martin-
Gans and Simmonds, 2016) and the findings of our study suggest that the differences 
observed in the dinucleotide expression between the genotypes may have functional 
implications for the different genotypes but what they are remains unclear.  
Previous research by Lobo et al. (2009) (Lobo et al., 2009), was expanded on during this 
project and a study of the dinucleotide expression and RSCU of a wide range of 
Flaviviridae was undertaken, including several pegivirus strains. Throughout the family, 
the evidence of viral adaptation to replication within their hosts could be observed within 
their genomes. The pegiviruses were shown to be remarkably similar to the hepaciviruses 
in this analysis and both genera exhibited compositional similarity to vector-transmitted 
viruses. This suggests that at some point in the evolutionary history of both the 
hepaciviruses and the pegiviruses, vector-borne transmission was feasible, raising 
interesting questions about the ancestral origins of the two genera. In addition to this, a 
wide range of mammalian-infecting hepaciviruses and pegiviruses have been identified 
through increased sampling and sequencing studies (Kapoor et al., 2013, 2015; Pfaender et 
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al., 2014), increasing the plausibility of a zoonotic origin for HCV. Gaps in our knowledge 
of the factors contributing to the sustained endemic transmission of HCV in regions such 
as West Africa and South East Asia still exist, with a considerable number of transmission 
events remaining unexplained. The mechanistic transmission of HCV by vector has been 
shown to be theoretically plausible (Pybus et al., 2007) and the findings of this study 
suggest that further research should be undertaken. The increased sampling of a wide range 
of biting arthropods from HCV- endemic regions and screening using sensitive sequencing 
methodologies may be of value in exploring this theory.     
The Flaviviridae are responsible for considerable morbidity and mortality worldwide and, 
in addition to HCV and ongoing endemic Dengue transmission, there has recently been 
outbreaks of Zika virus in South America and Yellow Fever in Africa. Other viruses in the 
family, and particularly the pestiviruses, are important veterinary pathogens and have a 
considerable economic impact in the agricultural industry.  Understanding what restricts 
the transmission range of the Flaviviridae and drives immune reactions against them is 
therefore of particular importance for reducing the medical and veterinary burdens caused 
by these viruses. An improved knowledge of the immunological pathways activated by 
CpG dinucleotides may be of use in the development of vaccines against the viruses. 
Artificially increasing the levels of CpG and UpA in Polio virus has been shown to be 
detrimental to the viral infectivity and authors of the manuscript postulated that it could 
provide an innovative approach to vaccine design for a range of viruses (Burns et al., 
2009) and an alternative to the live and attenuated vaccines that are currently available. In 
this study, hepaciviruses and pegiviruses of bats were found to express relatively high 
amount of CpG compared to viruses infecting other mammals. Other research indicated 
that bats lack the PYHIN gene family, which is known to encode the toll-like receptor 
group of proteins (Zhang et al., 2013). This adds weight to the hypothesis that the TLR 
proteins (particularly TLR-9) are involved in the detection of RNA with high levels of 
CpG motifs (Ohto et al., 2015). Intriguingly research has also been published showing that 
PKR, which was implicated in the characteristic low level of CpG expression of HCV gt2 
strains, can be activated by TLRs (Hsu et al., 2004). Further dissection of the immune 
pathways underlying the dinucleotide expression observed within the family may be of use 
for vaccine development and could be particularly useful for the improvement of 
veterinary vaccines for the pestiviruses, which have extremely low CpG expression.      
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7.5 Summary 
Previous to the development of DAA therapies, the standard of care therapy for HCV was 
a non-specific treatment consisting of pegylated IFN-α and ribavirin, regardless of 
genotype. The introduction of DAAs, many of which are more efficacious in certain 
genotypes, has initiated a need to invest more research into understanding the differences 
between the genotypes. Over recent years studies have emerged showing different 
pathologies and distinct transcriptional upregulation patterns induced by gt1a and gt3 
strains (Robinson et al., 2015; Robinson et al., 2015). Gt3 viruses have also been 
associated with an accelerated progression to fibrosis (Bochud et al., 2009; Larsen et al., 
2010) and higher rates of HCC relative to other genotypes (Nkontchou et al., 2011). These 
findings suggest that gt3 viruses are causing more damage when infecting hepatocytes 
relative to other genotypes. This raises the intriguing consideration that perhaps gt3 viruses 
are less well adapted to replication within the liver than other HCV genotypes. Gray et al. 
(2012) have previously stated that the complex viral population structures observed within 
HCV-infected individuals most likely arise from multiple sub-populations of HCV, 
including populations from both hepatic and extra-hepatic sites of replication, as other 
models are not sufficient to explain the diversity observed (Gray et al., 2012). The data 
from this project indicated that during mixed genotype infection, gt3 was the most often 
the dominant population within the serum. Samples from other sites, including PBMCs and 
the liver, were not available to us for testing and it would have been interesting to 
investigate if the proportions of the genotypes were similar at each site. A study by 
Radkowski et al. (2002) has published evidence of the compartmentalisation of HCV 
genotypes into discrete sites during multi-genotypic infection (Radkowski et al., 2002),. 
Our study also identified significantly more neurological disorders occurring in gt3 
infected individuals. A recent publication has shown that distinct HCV lineages can be 
isolated from the CNS of individuals with cognitive impairment (Tully et al., 2016).Whilst 
a larger study is required to confirm the association of neurological disorders and gt3, it is 
interesting to consider if this is evidence that gt3 viruses are more adept at replication 
within the CNS than gt1a viruses. Little was known about the nature of the neurological 
disorders experienced by individuals in this study and it would be advantageous to gain 
more insight into this topic.  
The 2015 Public Health England Report has also documented that UK hospital admissions 
and mortality from HCV -associated end-stage liver disease and HCC within the UK have 
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increased dramatically over the past decade (Public Health England, 2015). The effective 
treatment of HCV, in addition to clearing the virus, has been shown to reduce mortality 
from all causes, reduce the co-morbidity burden and improve the overall quality of life in 
those achieving an SVR (Spiegel et al., 2005; Backus et al., 2011; Simmons et al., 2015). 
Increased availability and access to the DAAs targeting HCV has resulted in the treatment 
of HCV with these drugs becoming increasingly feasible although clearance rates for 
individuals infected with non-gt1 (and particularly gt3) viruses remain unsatisfactory, 
especially when the prohibitive financial cost of the new DAAs is considered.  In the UK, 
and particularly in Scotland, where gt3 is responsible for an estimated 45% of infections, 
this poses a significant challenge to clinicians trying to treat patients infected with HCV. 
From previously being considered the genotype with the most favourable treatment 
responses to PEG-IFN-α and Ribavirin, gt3 viruses are now considered the hardest to treat 
with the new regimens available (Goossens and Negro, 2014). Understanding contra-
indications to treatment, improving the stratification of patient groups and developing our 
knowledge of subtle differences between the genotypes and sub-types will all be key 
factors in improving our capacity to successfully treat non-gt1 HCV infections.  Current 
genotyping methods used within diagnostic laboratories often discriminate between gt1a, 
gt1b and other gt1 isolates but the characterisation of other genotypes remains limited to 
the genotypic level. Sub-type discrepancies in treatment efficacy have also been 
documented with a phase II trial of Ombitasvir/Paritaprevir/Ritonavir in gt2 patients noting 
an SVR24 rate of just 27% among gt2b patients compared to an SVR24 rate of 90% in gt2a 
patients (Chayama et al., 2015), indicating this an area that warrants further research. 
Additionally, the efficacy of DAA regimens for the treatment of mixed genotype infections 
also remains poorly studied. There is concern in the field that ineffective treatment of 
undiagnosed mixed genotype infections may result in genotype switching (McNaughton et 
al., 2014). The increased prevalence of mixed gt1a/gt3 infections observed in gt3 patients 
suggests that gt3-diagnosed individuals are likely to be disproportionately affected by 
genotype switching during DAA treatment, further complicating the treatment of 
individuals diagnosed with gt3 viruses. Ensuring the accurate diagnosis of mixed genotype 
infections,  and developing more discriminatory methods HCV genotyping and sub-typing 
will aid the identification of groups that may be difficult to treat or are likely to fail 
treatment is therefore increasingly important. Sequencing-based diagnostic methods are 
increasing feasible in clinical virology and investment in such methods should be 
encouraged.   
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8 Chapter 8: Appendices 
 
Table 8-1; Viral sequences 
 Viral sequences used for analysis throughout the project and the study they were used for. 
Study used for Figure Accession numbers 
CpG and UpA 
analysis, codon 
bias analysis 
(Flaviviridae) 
 
Figure 1-1 
Figure 6-8 
Figure 6-9 
Figure 6-12 
NC_023439.1, NC_023424.1, NC_027998.1, NC_001474.2, 
NC_002640.1, NC_001563.2, NC_001477.1, NC_001475.2, 
NC_009942.1, NC_012812.1, NC_012671.1, NC_012532.1, 
NC_012533.1, NC_012534.1, NC_012735.1, NC_026797.1, 
NC_026624.1, NC_021154.1, NC_021153.1, NC_004102.1, 
NC_003996.1, NC_003678.1, NC_003675.1, NC_003676.1, 
NC_003679.1, NC_002657.1, NC_000943.1, NC_001837.1, 
NC_002032.1, NC_001809.1, NC_001655.1, NC_002031.1, 
NC_001672.1, NC_001564.1, NC_001461.1, NC_001437.1, 
NC_024889.1, NC_012932.1, NC_025679.1, NC_025677.1, 
NC_025673.1, NC_025672.1, NC_024017.1, NC_024018.2, 
NC_024806.1, NC_024805.1, NC_024377.1, NC_024299.1, 
NC_021069.1, NC_023176.1, NC_018705.3, NC_009029.2, 
NC_015843.2, NC_020902.1, NC_018713.1, NC_009028.2, 
NC_009026.2, NC_008604.2, NC_009824.1, NC_009827.1, 
NC_009823.1, NC_009826.1, NC_007580.2, NC_008718.1, 
NC_008719.1, NC_016997.1, NC_006947.1, NC_006551.1, 
NC_005064.1, NC_005062.1, NC_005039.1, NC_004355.1, 
NC_004119.1, NC_003690.1, NC_003687.1, NC_003635.1, 
NC_001710.1, NC_017086.1 
CpG and UpA 
analysis 
(hepaciviruses and 
pegiviruses) 
Figure 6-10 NC_020902.1, KC410872.1, NC_024377.1, NC_021154.1, 
KC815311.1, KF234530.1, KF234529.1, KF234528.1, 
KF234527.1, KF234526.1, KF234525.1, KF234524.1, 
F234523.1, KF234522.1, KF234521.1, KF234520.1, 
KF234519.1, KF234518.1, KF234517.1, KF234516.1, 
KF234515.1, KF234514.1, KF234513.1, KF234512.1, 
KF234511.1, KF234510.1, KF234509.1, KF234508.1, 
KF234507.1, KF234506.1, KF234505.1, KF234504.1, 
KF234503.1, KF234502.1, KF234501.1, KF234500.1, 
KF234499.1, KC796073.1, KC796093.1, KC796089.1, 
KC796088.1, KC796087.1, KC796086.1, KC796085.1, 
KC796084.1, KC796083.1, KC796082.1, KC796081.1, 
KC796080.1, KC796079.1, KC796076.1, KC618401.1, 
KC618400.1, KC618399.1, KC618398.1, NC_001837.1, 
U94421.1, NC_001710.1, JN127373.1, HQ331235.1, 
HQ331234.1, HQ331233.1, GU566734.1, U22303.1, 
AF023425.1, AF023424.1, AY196904.1, AF309966.1, 
AF104403.1, U94695.1, AY949771.1, D87255.1, D90601.1, 
D90600.1, U75356.1, U63715.1, AF121950.1, AF070476.1, 
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AF081782.1, AF031829.1, AF031828.1, AF031827.1, 
AF006500.1, AB008336.1, AB008342.1, AB003293.1, 
AB003292.1, AB003289.1, D87263.1, D87262.1, AB013501.1, 
AB013500.1,  AB018667.1, AB021287.1, AB003291.1, 
AB008335.1, D87715.1, D87714.1, D87713.1, D87712.1, 
D87711.1, D87710.1, D87709.1, D87708.1, AB003290.1, 
AB003288.1 
CpG and UpA 
analysis (complete 
HCV genomes) 
Figure 6-6 
Figure 6-7 
Figure 6-11 
 
EU256028, EU256029, JX463525, JX463555, JX463556, 
JX463569, DQ889268, DQ889269, DQ889270, DQ889271, 
DQ889272, DQ889273, DQ889274, DQ889275, DQ889276, 
DQ889277, DQ889278, DQ889279, EU781751, EU781800, 
EU781787, EU781794, EU781795, EU781786, EU781782, 
EU781804, EU781789, AY956468, AY956464, AY956469, 
AY956466, AY956463, AY956465, EU255999, GQ149768, 
EU155288, EU155291, EU155294, EU482876, EU155295, 
EU155296, EU155297, EU155298, EU482834, EU155319, 
EU482835, EU155323, EU239716, EU155276, EU256008, 
EU256010, EU482836, EU256016, EU256018, EU482887, 
EU482868, EU482869, EU155241, EU529679, EU482871, 
EU256025, EU529680, EU256095, EU256026, EU256030, 
DQ430812, DQ430811, JX463526, JX463527, JX463528, 
JX463529, JX463534, JX463535, JX463557, JX463559, 
JX463560, JX463538, JX463539, JX463540, JX463541, 
JX463546, JX463571, DQ889283, DQ889284, DQ889286, 
DQ889287, DQ889288, DQ889289, DQ889290, EU781803, 
EU781752, EU781783, EU781750, EF032883, EU781768, 
EU781777, EU781774, DQ889280, EU781790, DQ889281, 
EU781760, DQ889282, EU781780, EU255996, EU255931, 
EU255997, EU256086, EU255933, EU155299, EU155309, 
EU862840, EU155311, EU155313, EU239715, EU155277, 
EU482865, EU862841, EU256020, EU256021, EU256022, 
EU256023, EU256056, EU660387, EU256027, EU255938, 
EU155245, EU256032, EU155246, DQ430814, DQ430813, 
JX463530, JX463536, JX463537, JX463558, JX463561, 
JX463562, JX463563, JX463564, JX463565, JX463566, 
JX463567, JX463568, JX463542, JX463543, JX463544, 
JX463547, JX463548, JX463549, JX463570, JX463572, 
JX463573, JX463574, JX463575, JX463576, JX463551, 
JX463552, JX463582, JX463583, JX463584, JX463553, 
JX463554, EF032884, DQ889291, EU660383, EU155213, 
EU255993, EU155215, EU255995, EU260396, EU862828, 
EU256039, EU482837, EU256040, EU482878, EU155310, 
EU482884, EU482840, EU482841, EU529676, EU155314, 
EU256009, EU482847, EU256011, EU256013, EU155239, 
EU256014, EU256015, EU155240, EU155242, EU256094, 
EU482870, EU256035, EU256036, EU256037, EU256038, 
JX463531, JX463532, JX463533, JX463585, JX463613, 
JX463614, JX463545, JX463550, JX463577, JX463578, 
JX463579, JX463580, JX463581, JX463624, EF032885, 
EU155247, EU260395, EU255994, EU155214, EU255932, 
EU569723, EU862829, FJ024282, EU256041, EU256042, 
EU256043, EU155265, EU256051, EU256104, EU482843, 
EU256004, EU660384, EU256017, EU529678, EU256058, 
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EU155243, EU482848, EU155244, EU256033, JX463586, 
JX463587, JX463588, JX463615, JX463616, JX463596, 
JX463597, JX463598, JX463599, JX463600, JX463625, 
JX463626, JX463627, JX463607, JX463608, FJ205869, 
EU862830, EU155248, EU155249, EU155250, EU155251, 
EU256060, EU482838, EU155252, EU482842, EU155266, 
EU155267, EU256046, EU256047, EU256048, EU256049, 
EU155268, EU256050, EU155269, EU155270, EU862831, 
EU155271, EU256067, EU256052, EU155272, EU256068, 
EU155273, EU155274, EU255939, EU155275, EU256002, 
EU482882, EU255940, EU482844, EU155278, EU482845, 
EU256003, EU155233, EU482861, EU155236, EU256005, 
EU256006, EU255934, EU482862, EU482863, EU155237, 
EU482864, EU482866, EU482867, EU256007, EU255936, 
EU256012, EU529677, EU155282, EU255941, EU155283, 
EU255937, EU256057, EU256024, EU256031, EU256034, 
JQ061779, JQ061780, JQ061781, JQ061782, JQ061783, 
JQ061784, JQ061785, JQ061786, JQ061787, JX463589, 
JX463590, JX463591, JX463617, JX463619, JX463594, 
JX463620, JX463601, JX463602, JX463603, JX463604, 
JX463628, JX463629, JX463630, JX463631, JX463632, 
JX463633, JX463634, JX463635, JX463636, JX463637, 
JX463609, JX463610, JX463638, JX463611, JX463612, 
FJ024087, FJ181999, FJ024274, FJ024275, FJ205867, 
FJ024276, FJ182000, FJ024278, FJ205868, FJ182001, 
FJ024280, FJ024281, FJ390399, EU255935, EU155238, 
EU255942, JX463592, JX463595, JX463621, JX463622, 
JX463623, JX463605, JX463606, JX463639, JX463640, 
FJ390394, FJ410172, FJ390395, AY651061, EU781829, 
EU781832, AB691953, EU781830, FN435993, AF054250, , 
D85516, AF356827, D45172, D30613, M96362, EU781827, 
EU781826, EU781825, AB779679, AB779562, AB080299, 
AF054251, AF054259, AF054252, AF054248, AF054253, 
AF054254, AF054249, AF054255, AF054247, AF054256, 
AF054257, AF054258, AF313916, EU781828, D13558, D10750, 
EU781831, , AJ000009, EF032892, EF032893, EF032894, 
EU155368, EU155359, EU529682, EU256080, EU256081, 
EU155366, EU155367, EU155369, EU482859, EU155356, 
EU155357, EU155360, EU482860, EU256084, EU256085, 
EU155358, EU256075, EU256076, EU155361, EU155362, 
EU862837, EU155372, EU256077, EU256078, EU155363, 
EU256079, EU482874, EU256082, EU256083, EU155370, 
EU155371, EU155373, EU155374, EU482875, EU155364, 
EU155365, EU155375, EU155376, EU255960, EU155377, 
AY587016, D10934, AY460204, L02836, EF638081, HQ639940, 
HQ639937, HQ639946, HQ639947, EU857431, KC844052, 
KC844051, GU451218, GU451221, GU451222, GU451219, 
GU451223, HQ912956, HQ912957, HQ912958, GU451220, 
HQ912959, GU451224, AJ238799, AJ132996, AJ132997, 
U45476, AJ238800, EU482833, EU155382, EU155381, 
JN120912, AB154185, AB154186, AB154187, AB154188, 
AB154189, AB154190, AB154191, AB154192, AB154193, 
AB154194, AB154177, AB154195, AB154196, AB154197, 
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AB154198, AB154199, AB154200, AB154201, AB154202, 
AB154203, AB154204, AB154178, AB154205, AB154206, 
AB154179, AB154180, AB154181, AB154182, AB154183, 
AB154184, AB442219, AB442222, AB016785, AY045702, 
M58335, D90208, D50480, D50481, D50482, D50483, D50485, 
D50484, AB426117, AB435162, AB119282, AF139594, D63857, 
S62220, AB191333, AB049087, AB049088, AB049089, 
AB049090, AB049091, AB049092, AB049093, AB049094, 
AB049095, AB049096, AB049097, AB049098, AB049099, 
AB049100, AB049101, D14484, X61596, D11168, D11355, 
AB442221, AB442220, DQ244140, DQ244141, AF165045, 
AF165063, AF165064, AF207752, AF207753, AF207754, 
AF207755, AF207756, AF207757, AF207758, AF207759, 
AF207760, AF165046, AF165047, AF207761, AF207762, 
AF207763, AF207764, AF207765, AF165048, AF207766, 
AF207767, AF207768, AF207769, AF207770, AF165049, 
AF207771, AF207772, AF207773, AF207774, AF208024, 
AF165050, AF165051, AF165052, AF165053, AF165054, 
AF165055, AF165056, AF165057, AF165058, AF165059, 
AF165060, AF165061, AF165062, D89872, D89815, AB429050, 
AB249644, U16362, U01214, AF176573, AY587844, AF483269, 
U89019, M84754, DQ071885, EF407459, EF407473, EF407481, 
EF407467, EF407458, EF407495, EF407500, EF407502, 
EF407491, EF407474, EF407475, EF407476, EF407493, 
EF407478, EF407480, EF407468, EF407496, EF407498, 
EF407466, EF407469, EF407486, EF407472, EF407479, 
EF407483, EF407470, EF407497, EF407461, EF407471, 
EF407463, EF407484, EF407503, EF407465, EF407462, 
EF407482, EF407487, EF407490, EF407499, EF407489, 
EF407492, EF407485, EF407501, EF407494, EF407460, 
EF407488, EF407477, EF407464, EF407504, GU133617, 
EU155333, EU482849, EU155331, EU155334, EU155337, 
EU155325, EU234061, EU255961, EU255962, EU155324, 
EU482888, EU155326, EU155327, EU155328, EU155329, 
EU234062, EU155335, EU155336, EU155330, KC439507, 
KC439508, KC439515, KC439527, EU155332, HQ110091, 
KC439503, KC439504, KC439505, KC439506, KC439509, 
KC439510, KC439511, KC439512, KC439513, KC439514, 
FJ478453, EU660388, EU482877, EU155301, EU155302, 
EU155303, EU155262, EU256102, EU155315, EU239714, 
EU256103, EU155279, EU155280, EU256054, EU862835, 
KC439516, KC439517, KC439518, KC439519, EU256001, 
EU155219, EU155223, EU155230, EU256089, EU256090, 
EU155231, EU155232, EU256098, EU256099, EU256100, 
EU155305, EU256101, EU155306, EU155307, EU155316, 
EU155317, KC439488, KC439499, KC439481, KC439482, 
EU256000, EU256088, EU155224, EU155225, EU155227, 
EU155228, EU155300, EU155304, EU155308, EU256045, 
EU256066, EU482881, KC439487, KC439500, KC439501, 
KC439483, KC439484, KC439485, EU155217, EU155220, 
EU155221, EU155222, EU155226, EU155229, KC439486, 
EU155218, EU482883, EU256059, EU155261, EU155263, 
EU155318, EU155281, KC439489, KC439490, KC439491, 
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KC439492, KC439502, EU660386, EU155253, EU256061, 
EU155254, EU155255, EU155256, EU256062, EU155257, 
EU482839, EU155258, EU482879, EU482880, EU155259, 
EU155260, EU256064, EU256065, EU155264, EU155234, 
EU482885, EU155235, EU256091, EU482886, EU256092, 
KC439493, KC439494, KC439495, KC439496, KC439497, 
KC439498, FJ024086, FJ024277, FJ024279, FJ390396, 
FJ390397, FJ390398, KC439520, KC439521, KC439522, 
KC439523, KC439524, KC439525, KC439526, AB622121, 
HQ537005, HQ537006, AY587845, KC844047, D14853, 
AY051292, KC248194, AM910652, JF735110, JF735112, 
JF735116, JF735117, JF735118, JF735119, KC197238, 
KC197236, KC197237, KC197239, AM408911, EF026073, 
AF169003, AF169004, NC_009823, JX014307, AF238481, 
AF238482, AF238483, AF238484, AF238485, AF169002, 
AF169005, AF177036, KF676351, KF676352, HQ639943, 
HQ639944, HQ639945, HQ639938, HQ639939, KC844043, 
KC967476, AY746460, D00944, AB047640, AB047641, 
AB047642, AB047643, AB047644, AB047645, AB047639, 
AB690460, AB690461, KF700370, AB030907, AF238486, 
KC844048, KC967478, KC967477, JQ745651, KC197226, 
AB661373, AB661374, AB661375, AB661376, AB661377, 
AB661378, AB661379, AB661380, AB661381, AB661382, 
AB661383, AB661384, AB661385, AB661386, AB661387, 
AB661388, AB661389, AB661390, AB661391, AB661392, 
AB661393, AB661394, AB661395, AB661396, AB661397, 
AB661398, AB661399, AB661400, AB661401, AB661402, 
AB661403, AB661404, AB661405, AB661406, AB661407, 
AB661408, AB661409, AB661410, AB661411, AB661412, 
AB661413, AB661414, AB661415, AB661416, AB661417, 
AB661418, AB661419, AB661420, AB661421, AB661422, 
AB661423, AB661424, AB661425, AB661426, AB661427, 
AB661428, AB661429, AB661430, AB661431, AB661432, 
AB559564, D10988, AY232748, AY232749, AY232730, 
AY232731, AY232732, AY232733, AY232734, AY232735, 
AY232736, AY232737, AY232738, AY232739, AY232740, 
AY232741, AY232742, AY232743, AY232744, AY232745, 
AY232746, AY232747, DQ430815, DQ430817, DQ364460, 
EU643835, D50409, KC967479, KC197228, KC197227, 
JX227949, JX227950, JX227951, JX227965, JX227966, 
JF735114, JF735120, KC844050, KC844042, KC197229, 
KC197231, KC197230, DQ155561, DQ155560, JF735113, 
KC197232, KC197233, HM777359, HM777358, KC197234, 
JX227953.1, JX227953, AB031663, KC197235, KC197240, 
JX227967, JX227968, JX227974, JF735111, FN666429, 
FN666428, JF735115, JF735124, GU294484, AB691595, 
AB691596, AF046866, D28917, D17763, NC_009824, 
AB792683, DQ437509, HQ639941, HQ639942, HQ912953, 
KC844041, X76918, GQ356217, GQ356216, GQ356214, 
GQ356212, GQ356211, GQ356210, GQ356209, GQ356208, 
GQ356207, GQ356206, GQ356205, GQ356204, GQ356203, 
GQ356202, GQ356201, GQ356200, HQ738645, GQ275355, 
JQ717260, JQ717259, JQ717254, JQ717255, JQ717257, 
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JQ717258, JN714194, JQ717256, KF035125, KF035123, 
KF035124, KF035126, KF035127, GU814263, DQ430819, 
AY956467, DQ430820, JQ065709, KC844044, D49374, 
JF735123, JX227954, JF735121, JF735126, JX227969, 
JF735125, JX227955, JX227956, FJ407092, JF735122, D63821, , 
DQ418785, GU814265, NC_009825, Y11604, DQ988078, 
DQ988079, DQ988073, DQ988074, DQ988075, DQ988076, 
DQ988077, DQ516084, AB795432, DQ418782, DQ418783, 
DQ418784, DQ418788, DQ418787, DQ418789, FJ462435, 
FJ025854, FJ025855, FJ025856, FJ462436, EU392172, 
FJ462437, KC844045, DQ516083, DQ418786, EU392169, 
EU392170, EU392174, EU392175, EF589160, EF589161, 
FJ462432, JX227971.1, JX227963.1, EU392171, EU392173, 
FJ462438, FJ839870, JX227958.1, JX227957.1, FJ462433, 
JX227972.1, JX227961.1, FJ462441, JX227973.1, JX227970.1, 
FJ462440, JX227979.1, JX227978.1, JX227977.1, FJ462431, 
FJ462434, FJ462439, JX227976.1, JX227975.1, JX227962.1, 
FJ839869, HQ537008, HQ537009, KF373567, KC844046, 
NC_009826, Y13184, AF064490, KC767831, KC76783, 
KC76783, KC76783, KC76783, KC76782, DQ278892, KC191671, 
HQ639936, HQ91295, HQ912954, KC84403, KC84403, 
AY859526, DQ480513, DQ480516, DQ480523, DQ480514, 
DQ480515, DQ480518, DQ480519, DQ480520, DQ480521, 
DQ480522, DQ480517, DQ480524, DQ480512, Y12083, 
EU246930, NC_009827, D84262, EF424629, D84263, 
DQ314805, EU408326, EU246931, EU246932, DQ835760, 
DQ835764, EU246936, DQ314806, D63822, D84265, 
DQ835762, EU246935, DQ835770, DQ835761, DQ835769, 
AY878651, DQ278893, AY878650, DQ278891, D84264, 
EF424628, EU246933, JX183555, JX183556, DQ835767, 
DQ835765, DQ835766, DQ835763, AY878652, DQ278894, 
DQ835768, EU246937, EU246938, EF424627, EU408327, 
EU246934, EF424626, EF424625, EU408328, EU408329, 
EU246939, EF632069, EF632070, EF632071, EU408330, 
EU408331, EU408332, EU246940, EU798761, FJ435090, 
EU798760, EU158186, EU643836, EU643835, EF108306.2 
Los Alamos HCV 
genotype 
reference 
sequences (2012) 
(Kuiken et al., 
2005) 
Figure 1-4 
 
NC_004102, M67463, EF407419, AF511950, EF032892, 
AY587016, D11355, D14853, AY051292, AM910652, 
AY746460, D00944, AB047639, D10988, AB030907, AF238486, 
D50409, DQ155561, HM777359, HM777358, AB031663, 
FN666429, FN666428, X76918, AF046866, NC_009824, 
D49374, FJ407092, D63821, Y11604, DQ418788, FJ462435, 
FJ025854, FJ025855, FJ025856, FJ462436, FJ462437, 
DQ516083, DQ418786, EU392172, EF589160, EF589161, 
EU392169, EU392170, EU392174, EU392175, FJ462432, 
FJ462438, EU392171, EU392173, FJ839870, FJ462433, 
FJ462441, FJ462440, FJ462431, FJ462434, FJ462439, 
FJ839869, HQ537008, HQ537009, NC_009826, AF064490, 
DQ278892, AY859526, DQ480513, Y12083, NC_009827, 
EF424629, D84263, EU408326, EU246932, DQ835764, 
DQ314806, D84265, EU246935, DQ835761, DQ278893, 
D84264, EU246933, DQ835766, AY878652, EU246938, 
EU408327, EU246934, EF424626, EF424625, EU408328, 
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EU408329, EU246939, EF632069, EF632070, EF632071, 
EU408330, EU408331, EU408332, EU246940, EU158186, 
EU798761, FJ435090, EU798760, EU643834, EU643836, 
EF108306 
Mixed genotype 
infection CpG 
analysis (gt1a 
sequences) 
Figure 6-1 
Figure 6-11 
AB520610, AF009606, AF271632, AF290978, AF511948, 
AF511949, AF511950, AF529293, AJ278830, AJ557444, 
AY388455, AY615798, AY695436, AY885238, AY956463, 
AY956464, AY956466, AY956468, AY958045, D10749, 
DQ061300, DQ061304, DQ061308, DQ061313, DQ061319, 
DQ061323, DQ061327, DQ430811, DQ838739, EF032883, 
EF032886, EF032887, EF032891, EF032895, EF032896, 
EU370586, EU370616, EU370636, EU370656, EU482831, 
EU482832, EU482834, EU482835, EU482836, EU482837, 
EU482838, EU482840, EU482841, EU482842, EU482843, 
EU482844, EU482845, EU482846, EU482847, EU482848, 
EU482850, EU482852, EU482853, EU482854, EU482855, 
EU482856, EU482872, EU482873, EU677247, EU677252, 
EU687193, EU687194, EU687195, EU781823 
Mixed genotype 
infection CpG 
analysis (gt3a 
sequences) 
Figure 6-1 
Figure 6-11 
AB691595, AB691596, AB792683, AF046866, AM423055, 
AM423056, AM423057, AM423058, AM423059, AM423060, 
AM423061, AM423062, AY956467, AY957985, AY958044, 
D17763, D28917, DQ430819, DQ430820, DQ437509, 
GQ275355, GQ356200, GQ356201, GQ356202, GQ356203, 
GQ356204, GQ356205, GQ356206, GQ356207, GQ356208, 
GQ356209, GQ356210, GQ356211, GQ356212, GQ356213, 
GQ356214, GQ356215, GQ356216, GQ356217, GQ379231, 
GU172375, GU570704, GU814263, HQ108092, HQ108096, 
HQ108100, HQ108104, HQ639941, HQ639942, HQ738645, 
HQ912953, JN714194, JQ664687, JQ717254, JQ717255, 
JQ717256, JQ717257, JQ717258, JQ717259, JQ717260, 
JQ802144, JQ802145, KC844041, KF035123, KF035124, 
KF035125, KF035126,  
KF035127 
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Table 8-2; Univariable and multivariable analysis of co-morbidities by age 
Results of a univariable and a multivariable analysis of the co-morbidities affecting individuals infected with HCV analysed by age. P values ≤0.05 were considered statistically 
significant and have been highlighted. Values tending towards significance (between p>0.05 and p ≤0.1) have been underlined.
 
Co-morbidity
 <45yrs 
(n=360)
%
>= 45yrs 
(n=227)
% p
 <45yrs 
(n=360)
%
>= 45yrs 
(n=227)
% p
No recorded co-morbidities 76 21.11 37 16.30 0.36 76 21.11 37 16.30 0.21
High alcohol consumption 111 30.83 65 28.63 0.38 111 30.83 65 28.63 0.30
Obesity 10 2.78 6 2.64 0.24 10 2.78 6 2.64 0.80
Truama, stabbing or assault 62 17.22 28 12.33 0.21 62 17.22 28 12.33 0.26
Cancer 3 0.83 10 4.41 0.02 3 0.83 10 4.41 <0.01
Cardiovascular disease or stroke 18 5.00 25 11.01 0.06 18 5.00 25 11.01 0.02
Diabetes 7 1.94 10 4.41 0.09 16 4.44 8 3.52 0.90
Dermatology 16 4.44 8 3.52 0.85 7 1.94 10 4.41 0.10
Endocrine 5 1.39 6 2.64 0.93 5 1.39 6 2.64 0.83
Gastrointestinal disorders 37 10.28 43 18.94 0.03 37 10.28 43 18.94 0.01
Gynecological disorders 15 4.17 5 2.20 0.04 15 4.17 5 2.20 0.06
Haematological 4 1.11 7 3.08 0.06 4 1.11 2 0.88 0.30
Hemochromatosis 4 1.11 2 0.88 0.81 4 1.11 7 3.08 0.01
Liver transplant 0 0.00 1 0.44 0.62 0 0.00 1 0.44 0.19
Neurological disorders 38 10.56 22 9.69 0.61 38 10.56 22 9.69 0.45
Orthopaedic 15 4.17 17 7.49 0.06 15 4.17 17 7.49 0.12
Psychiatric disorders 160 44.44 98 43.17 1.00 160 44.44 98 43.17 0.63
Respiratory 36 10.00 20 8.81 0.24 36 10.00 20 8.81 0.60
Rheumatological 1 0.28 4 1.76 0.15 1 0.28 4 1.76 0.04
Urological or renal disorders 14 3.89 14 6.17 0.63 14 3.89 14 6.17 0.11
Vascular 23 6.39 12 5.29 0.48 23 6.39 12 5.29 0.82
HBV 4 1.11 0 0.00 0.31 4 1.11 0 0.00 0.13
HIV 8 2.22 1 0.44 0.06 8 2.22 1 0.44 0.15
TB 3 0.83 0 0.00 0.22 3 0.83 0 0.00 0.28
Age (Univariable analysis) Age (Multivariable analysis)
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Table 8-3; Finney’s table 
Finney’s table, used for the conversion of results into probit during Probit analysis
  
 
 
 
 
 
233 
 
 
 
Figure 8-1; Selection of the gt3a control strain  
Maximum likelihood phylogenetic tree of complete gt3a sequences with gt1 sequence used as an outgroup 
(not shown). The control selected (3a.GB.2005.Patient) can be seen to cluster closely to the Glasgow 3a 
sequence in the tree. Bootstrap support of >70% after 1000 replicates is indicated on the tree. 
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Figure 8-2; Calculation of viral load 
Explanation of how the calculation to convert qPCR 
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Figure 8-3; WWSVC HCV genotyping SOP 
Extract from North Glasgow Microbiology BBV-SOP-109 v2, used within the WSSVC clinical testing 
laboratory for HCV genotyping at the time of sample collection. Data provided by Dr Tamer Abdelrahman, 
Clinical Lecturer at the University of Glasgow. 
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Table 8-4; Raw data from CD-Hit analysis of Run 1  
Raw data from CD-Hit analysis of Run 1 (using 0.9 similarity threshold) with gt2 and H77 contamination 
excluded.*denotes the number of distinct clusters identified with >500 or >1000 reads within the cluster. 
 
RUN 1
Sample
HCV 
genotype
>500* >1000* >500* >1000*
g3-36 3a 9 4 17 10
g3-41 3a 14 8 5 3
g3-44 3a 16 8 11 7
g3-51 3a 11 5 17 5
g3-67 3a 13 3 16 5
g3-73 3a 27 14 16 10
1a 0 0 3 3
g3-80 3a 4 4 3 2
1a 0 0 1 0
g3-125 3a 11 6 12 8
1a 4 2 0 0
g3-128 3a 16 9 13 7
g3-155 3a 26 17 10 6
g3-166 3a 15 11 9 4
g3-176 3a 21 11 4 4
g-27 3a 9 5 11 2
g-30 3a 12 6 13 7
g-45 3a 10 7 16 11
e-15 3a 0 0 1 0
1a 6 5 9 8
e49 3a 9 5 13 5
3-1 3a 13 9 7 4
3-2 3a 9 5 4 3
3-3 3a 29 14 31 19
3-4 3a 8 4 7 4
3-5 3a 7 5 4 3
3-6 3a 14 9 6 3
3-7 ND n/a n/a n/a n/a
3-8 3a 26 15 5 3
3-9 3a 17 10 2 2
3-10 3a 12 8 4 2
3-11 3a 7 7 4 2
3-12 3a 7 5 4 2
3-13 3a 5 4 20 7
3-14 3a 9 4 2 2
3-15 3a 20 13 2 0
3-16 3a 14 9 2 2
3-17 3a 10 6 0 0
3-18 3a 19 11 2 2
3-19 3a 18 11 2 2
3-20 3a 8 7 0 0
3a-transcript1 3a 9 5 9 4
3a-transcript2 3a 5 4 7 3
3a-transcript3 3a 9 7 10 4
0.1% 1a-major3a 3a 6 6 2 2
1a 0 0 0 0
1% 1a-major3a 3a 7 4 4 2
1a 2 2 2 0
10% 1a-major3a 3a 62 33 0 0
1a 49 24 3 3
neg-serum-2 ND n/a n/a n/a n/a
neg-h2o ND n/a n/a n/a n/a
G
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 s
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p
le
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Table 8-5; Raw data from CD-Hit analysis of Run 2 
Raw data from CD-Hit analysis of Run 2 (using 0.9 similarity threshold) with gt2 and H77 contamination 
excluded.*denotes the number of distinct clusters identified with >500 or >1000 reads within the cluster. 
 
RUN 2
Sample
HCV 
genotype
>500* >1000* >500* >1000*
g3-85 1a 38 22 18 13
g3-92 1a 20 11 42 21
1a-128 1a 14 6 0 0
1a-1 1a 1 0 22 14
1a-2 1a ND ND 10 5
1a-3 1a ND ND 12 5
1a-4 1a ND ND 25 15
1a-5 1a 12 8 7 4
1a-6 1a 2 1 46 25
1a-7 1a 2 0 36 16
1a-8 1a ND ND 31 14
1a-9 1a 15 10 27 14
1a-10 1a 2 2 2 0
1a-11 1a ND ND 27 13
1a-12 1a ND ND 16 9
1a-13 1a 1 1 32 17
1a-14 1a ND ND 17 8
1a-15 1a ND ND 43 22
1a-16 1a 16 11 45 19
1a-17 1a ND ND 13 7
1a-18 1a ND ND 16 10
1a-19 1a 3 3 17 5
1a-20 1a ND ND 43 22
E1a-1 1a 21 13 n/a n/a
E1a-2 1a 21 12 n/a n/a
E1a-3 1a 16 12 n/a n/a
E1a-4 1a 29 14 n/a n/a
E1a-5 1a 45 32 n/a n/a
E1a-6 1a 21 13 n/a n/a
E1a-7 1a 26 19 n/a n/a
E1a-8 1a 21 9 n/a n/a
E1a-9 1a 43 28 n/a n/a
E1a-10 1a 30 10 n/a n/a
E1a-11 1a 25 12 n/a n/a
E1a-12 1a 9 7 n/a n/a
E1a-13 1a 20 14 n/a n/a
E1a-14 1a 19 13 n/a n/a
E1a-15 1a 26 19 n/a n/a
E1a-16 1a 45 28 n/a n/a
E1a-17 1a 35 18 n/a n/a
E1a-18 1a 70 31 n/a n/a
E1a-20 1a 20 10 n/a n/a
1a-transcript1 1a 30 13 26 16
1a-transcript2 1a 24 11 30 13
1a-transcript3 1a 21 8 30 13
0.1% 1a-major3a 1a 5 5 7 5
3a 0 0 2 2
1% 1a-major3a 1a 3 2 7 5
3a 0 0 3 3
10% 1a-major3a 1a 4 3 8 4
3a 0 0 4 2
neg-serum-2 ND n/a n/a n/a n/a
neg-h2o ND n/a n/a n/a n/a
C
o
n
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ls
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ix
ed
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